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Summary 
The National Bowel Cancer Screening Program (NBCSP) aims to reduce the morbidity and 
mortality from bowel cancer by actively recruiting and screening the target population for 
early detection or prevention of the disease. 
The NBCSP has been running since August 2006, and this report focuses on measures of 
program performance for people invited to screen from July 2012 to June 2013 (those turning 
50, 55 or 65).  
How many 2012–13 invitees participated in the NBCSP? 
About 33.5% of the 964,000 people invited from July 2012 to June 2013 returned a completed 
bowel cancer screening kit for analysis. This overall participation rate was slightly lower 
than that of the previous monitoring report (Table 1), and small decreases were evident in all 
3 target age groups.  
How many positive screening results were there? 
About 23,500 participants (7.5%) who returned a valid screening test had a positive screening 
result. These people were encouraged to follow up this result by visiting their primary 
health-care practitioner (PHCP) for referral to further investigative testing (colonoscopy). 
Seventy per cent of those with a positive screening result were recorded as having a 
colonoscopy at the time of this report. 
How many bowel cancers and adenomas were detected? 
One participant in every 32 who underwent a colonoscopy to follow up a positive screening 
result was diagnosed with a confirmed (52 participants) or suspected (352 participants) 
cancer, while advanced adenomas were found in a further 728 participants (1 in 17 
colonoscopies) assessed. Adenomas are benign growths that have the potential to become 
cancerous, and their removal is likely to lower the risk of future bowel cancers in these 
patients.  
Were there differences between subgroups participating in the 
NBCSP? 
As in previous years, women were more likely to screen than men; conversely, men had 
higher rates of screen-detected bowel cancers, and overall bowel cancer incidence and 
mortality. 
Aboriginal and Torres Strait Islander participants, participants who lived in Regional and 
Remote regions, and participants who lived in areas of lower socioeconomic status, had 
higher rates of positive screening results, yet lower rates of follow-up colonoscopies than 
other participants. 
  vii 
2012–13 NBCSP data at a glance 
Table 1 compares 2012–13 key performance measures for the NBCSP for the target ages of 50, 
55 and 65 with those from the previous monitoring report (2011–12 invitees). 
Table 1: Performance measures for the NBCSP, people aged 50, 55 and 65, 2011–12 and 2012–13  
 2011–12(a)  2012–13  
Performance measure Per cent 
Participation rate 35.0  33.4 
 50 years 29.2  27.4 
 55 years 34.1  33.2 
 65 years 44.0  41.6 
Faecal occult blood test (FOBT) positivity rate 7.0  7.5 
Primary health-care practitioner (PHCP) follow-up rate 63.4  58.0 
Colonoscopy follow-up rate 72.0  70.4 
Colonoscopy outcomes    
 Suspected/confirmed cancers 3.1  3.2 
 Advanced adenomas 6.7  5.7 
 Polyps awaiting histopathology 39.6  41.2 
 No abnormality 46.3  46.0 
(a) 2011–12 data relate to those presented in the previous monitoring report for those eligible for invitation from 1 July 2011 to 
30 June 2012 (AIHW 2013). See Table A6.1 in Appendix A for final data for those invited in 2011–12. 
Note: Definitions for these performance measures are in Section 2. 
Source: National Bowel Cancer Screening Program Register. 
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Section 1 Introduction 
Structure of this report 
This report provides the most up-to-date national data available for the National Bowel 
Cancer Screening Program (NBCSP). 
The first section presents an overview of bowel cancer in Australia, outlines the process of 
bowel cancer screening, and describes the development and management of the NBCSP. It 
also provides a brief overview of technical issues that should be considered when 
interpreting the information in this report. 
The second section presents national data for the NBCSP from 1 July 2012 to 30 June 2013. 
Data are presented against a series of performance measures. A summary of each 
performance measure, including definition, rationale, information on data quality and a 
guide for interpretation, form the start of each chapter. This is followed by measure-specific 
background information and detailed analyses. 
Additional data tables for some sections of this report are presented on the Australian 
Institute of Health and Welfare (AIHW) webpage for National Bowel Cancer Screening Program 
monitoring report: 2012–13 supplementary tables. 
Overview of bowel cancer and bowel screening 
What is bowel cancer? 
Cancer is a group of several hundred diseases in which abnormal cells are not destroyed by 
normal processes within the body, but multiply and spread out of control. Cancers are 
distinguished from each other by the specific type of cell involved and the place in the body 
in which the disease began.  
Bowel cancer refers specifically to cancer of the large intestine (that is, the colon or rectum). 
It is often referred to as colorectal cancer.  
Generally, bowel cancer 
involves a multistage process 
in which a series of cellular 
mutations occur in epithelial 
cells (the protective layer of 
surface tissue on exposed 
bodily surfaces, which also 
forms the lining of some 
internal cavities, such as the 
large intestine) over time. Early 
stages of these mutations result 
in benign polyps that are 
relatively common in old age. 
However, a polyp may then undergo additional mutations and become a benign adenoma 
and, ultimately, a malignant bowel cancer that can invade into deeper layers of bowel tissue 
and then spread to other sites in the body (Figure S1.1).  
 
 
©  Cancer Council Victoria  2013.  
Source: Cancer Council Victoria (2013). 
Reproduced with permission of the copyright owner. 
Figure S1.1: The beginnings of bowel cancer 
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These mutations occur relatively slowly, making early detection and removal of small 
cancers—and adenomas and polyps that may become cancerous—effective in preventing ill 
health (morbidity) or death from bowel cancer.  
How common is bowel cancer? 
Bowel cancer is a disease predominantly 
seen in developed and affluent countries, 
with the highest rates occurring in Australia, 
New Zealand and Western Europe. It has 
been estimated that there were about 
1.4 million new cases of bowel cancer 
diagnosed worldwide in 2008 (10% of 
worldwide cancer diagnoses), and 608,000 
deaths attributed (8% of all worldwide 
cancer deaths). Worldwide, males have 
bowel cancer incidence rates that are 1.4 times higher than females (Jemal et al. 2011).  
In Australia, the incidence of bowel cancer has been increasing slightly each year since 1982 
(the year national cancer data were first collected), with 14,860 new cases diagnosed in 2010. 
The risk of being diagnosed by the age of 85 was 1 in 10 for males and 1 in 15 for females in 
2010, with the risk increasing sharply from the age of 45. Bowel cancer accounts for over 9% 
of all deaths from invasive cancers in Australia, with 3,980 deaths in 2012, making it the 
second most common cause of cancer-related death after lung cancer (ABS 2014; 
AIHW 2014). 
What causes bowel cancer? 
A proportion of bowel cancers (about 20%) are thought to be due to a hereditary component 
(Weitz et al. 2005). However, a larger proportion can be attributed to known and unknown 
environmental and lifestyle factors (WCRF & AICR 2011).  
An evaluation of the evidence by the World Cancer Research Fund found there was 
sufficient evidence that tobacco smoking, obesity and the consumption of alcohol and red 
and processed meats were risk factors for colorectal cancer, while consumption of foods 
containing dietary fibre and higher levels of physical activity provided a protective effect 
from bowel cancer (WCRF & AICR 2011).  
The incidence rate of bowel cancer is also known to increase with age—about 93% of people 
diagnosed in Australia in 2010 were 50 or older (see ‘Chapter 6 Incidence of bowel cancer’, 
Section 2). This is likely to be due to the accumulation of cellular mutations with increasing 
age. 
How is bowel cancer treated? 
Treatment for bowel cancer commonly involves surgery to remove the cancer, with or 
without additional chemotherapy or radiation therapy. Prognosis depends mainly on what 
stage of development the cancer had reached, with smaller, less developed cancers having 
much better prognoses than advanced cancers (Table S1.1). Bowel cancer stages are generally 
defined using the Australian clinicopathological stage (ACPS) classification system shown in 
Table S1.1 (ACN 2005). 
Terminology 
Incidence: the number of new cases of bowel 
cancer diagnosed in a year. 
Morbidity: illness. 
Mortality: the number of deaths from bowel 
cancer in a year. 
Prognosis: the likely outcome of an illness. 
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Table S1.1: Defined Australian clinicopathological stages of bowel cancer 
Australian 
clinicopathological 
stage Description Survival estimates(a) 
A Submucosa or into but not through muscularis 
propria 
  (cancer contained within superficial layers of bowel) 
Bowel cancers diagnosed at this stage 
showed a 93% 5-year survival rate 
B Through muscularis propria 
  (deep invasion into bowel tissue) 
Bowel cancers diagnosed at this stage 
showed an 82% 5-year survival rate 
C Spread of cancer to lymph nodes 
  (invasion through bowel tissue, and cancer found in  
  lymph nodes) 
Bowel cancers diagnosed at this stage 
showed a 59% 5-year survival rate 
D Metastatic disease 
  (cancer also discovered at other sites in the body) 
Bowel cancers diagnosed at this stage 
showed an 8% 5-year survival rate. Palliative 
care is commonly used at this stage 
(a) Survival estimates were sourced from an American study by O’Connell et al. (2004) which used a comparable classification system. Similar 
rates have been shown in Australia (Morris et al. 2007). 
Improving treatment outcomes 
Early diagnosis of bowel cancer can improve treatment outcomes and survival. Removal of 
non-benign polyps (polypectomy) and adenomas during a colonoscopy reduces the risk of 
them developing into bowel cancer. Studies have shown that 14% of patients who refuse 
polypectomy for adenomas will develop bowel cancer within 10 years (Stryker et al. 1987). 
The excision of adenomatous polyps, and regular surveillance thereafter, has been found to 
reduce bowel cancer risk by about 76–90% (Winawer et al. 1993).  
A bowel cancer screening program that can highlight individuals with signs of a potential 
bowel abnormality, allowing earlier investigation by colonoscopy, can therefore reduce 
bowel cancer morbidity and mortality. 
How do we screen for bowel cancer? 
Bowel cancer may be present for many years before showing symptoms such as visible rectal 
bleeding, change in bowel habits, bowel obstruction or anaemia. Often, symptoms such as 
these are not exhibited until the cancer has reached a relatively advanced stage. However, 
non-visible bleeding of the bowel may have been occurring in the precancerous stages for 
some time. The relatively slow development of bowel cancer makes it a valid candidate for 
population screening (APHDPCSS 2008). 
Screening tools and target populations for screening for bowel cancer vary around the world 
(Table S1.2). Evidence from clinical trials has shown that regular (biennial) screening using 
faecal occult blood testing—which can detect evidence of blood in the stool (faeces) not 
visible to the naked eye—can reduce mortality from bowel cancer by 15–33% (DoHA 2005).  
A faecal occult blood test (FOBT) is a non-invasive test that detects microscopic amounts of 
blood in the bowel motion—a common sign of a bowel abnormality such as an adenoma or 
cancer. FOBTs are accepted as the primary screening tool for bowel cancer by a large number 
of countries, and some supplement the FOBT with flexible sigmoidoscopy (a thin flexible 
tube that is inserted into the rectum and guided around the lower part of the bowel where 
most bowel cancers develop) or colonoscopy (a thin flexible tube that is inserted into the 
rectum and guided around the entire length of the bowel). Table S1.2 summarises the 
screening tools and target populations of screening programs for a number of countries. 
 4 National Bowel Cancer Screening Program monitoring report: 2012–13 
Table S1.2: Selected international bowel cancer screening programs—tools and target populations 
Country 
Primary 
screening tool Frequency Start year 
Target population 
(age in years) Notes 
Australia FOBT 5-yearly, 
see notes 
2006 50–65 People turning the target ages are 
sent an FOBT kit. As noted in 
Table S1.3, the NBCSP is being 
expanded from 2015 to implement a 
biennial screening interval for those 
aged 50–74 by 2020. 
Canada FOBT Varies 
between 
provinces 
See notes 50–74 Ten provinces had started programs 
or pilots by 2010. FOBT is the 
primary screening tool; however, 
provinces are free to adopt other 
primary screening tools. 
England FOBT Biennial 2006 60–69 FOBTs are supplemented by one-off 
flexible sigmoidoscopy in individuals 
aged 55–64. 
Finland(a) FOBT Biennial 2004 60–67 Currently in a RCT ‘implementation’ 
phase, with screening and control 
arms. The control group will be 
offered screening when the 
implementation phase is complete 
(once target ages 50–69). 
France FOBT Biennial 2002 50–74  
Germany FOBT Annual 1971 50–54  Followed by 
FOBT Biennial  55 and over or 
Colonoscopy 10-yearly  55 and over  
Italy FOBT Biennial See notes 50–69, see notes Regionally based programs began 
between 1982 and 2006 (65 
programs in total). The target age 
ranges from 44 to 75, with all 
programs screening those aged 50 
to 69. 
Ireland(b) FOBT Biennial 2012 60–69  The program is being expanded over 
time until the full 55–74 age group is 
reached.  
Israel FOBT Annual 1993 50–74  
Japan FOBT Annual 1992 40 and over   
New 
Zealand(c) 
FOBT Biennial 2011 50–74  Four-year pilot program scheduled to 
start in late 2011 for residents of the 
Waitemata District. 
Poland Endoscopy 120 months 2000 40–46  
Scotland FOBT Biennial 2006 50–74   
South Korea(a) FOBT Annual 2004 50 and over  
United 
States 
FOBT, 
sigmoidoscopy 
and 
colonoscopy 
See notes  50–75  While no national organised program 
exists, screening with FOBT 
(annual), sigmoidoscopy (5-yearly) 
and colonoscopy (10-yearly) 
depending on individual risk factors 
is promoted through guideline 
dissemination and media campaigns. 
(a) Bulliard et al. (2014). 
(b) National Cancer Screening Service (2013). 
(c) New Zealand Ministry of Health (2013). 
Source: Benson et al. (2012) except where otherwise noted. 
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How is bowel cancer screening managed in Australia? 
Population-based bowel cancer screening involves testing for signs of bowel cancer in people 
who do not have any obvious symptoms of the disease. People who do have symptoms, or a 
significant family history, are encouraged to discuss these with their primary health-care 
practitioner (PHCP). In accordance with the Clinical practice guidelines for the prevention, early 
detection and management of colorectal cancer, approved by the National Health and Medical 
Research Council (ACN 2005), these people should be referred directly for diagnostic 
assessment (generally colonoscopy). However, it is recognised that some people at increased 
risk may not seek the assistance of a medical professional (for example, those who are 
symptomatic but reluctant to act on their symptoms). As a result, all people of the target ages 
are currently invited to screen, regardless of evidence of previous symptoms or significant 
family history.  
The guidelines (ACN 2005) recommend organised screening with an FOBT, performed at 
least once every 2 years, for the Australian population aged 50 or over.  
A variety of FOBT kits to aid the early detection of bowel cancer are available in Australia 
over the counter from pharmacies, through medical practitioners and through the following 
programs: 
• BowelScreen AustraliaTM—this is a pharmacy-based bowel cancer awareness, education 
and screening initiative for the Australian community advocating annual screening for 
all non-symptomatic Australians aged 50 and over 
(see <www.bowelscreenaustralia.org>). 
• BowelScan—this is a community service project of various Rotary clubs and districts in 
Australia. It has been operating since 1982, advocating annual screening for men and 
women over the age of 40. It seeks to increase community knowledge of bowel cancer 
and its symptoms, and distributes subsidised FOBT kits to facilitate early diagnosis. 
About 150,000 kits are distributed annually across Australia 
(see <www.nationalbowelscan.org.au>).  
The NBCSP is the national screening program implemented in 2006 by the Australian 
Government in partnership with the state and territory governments (see 
<www.cancerscreening.gov.au>). This report is based on data collected through the NBCSP.  
The National Bowel Cancer Screening Program 
Initial pilot 
In 1996, the Australian Health Technology Advisory Committee systematically reviewed the 
literature on screening for bowel cancer against the World Health Organization principles for 
the assessment of a screening program. The committee concluded that, if pilot testing was 
encouraging, the Australian Government should develop a bowel cancer screening program 
for the at-risk population—the ‘well population aged over 50’ (AHTAC 1997). The Bowel 
Cancer Screening Pilot Program was conducted from November 2002 to June 2004 to test the 
feasibility, acceptability and cost-effectiveness of bowel cancer screening in the Australian 
community.  
Start of the National Bowel Cancer Screening Program 
After the success of this pilot, the Australian Government implemented Phase 1 of the 
NBCSP in late 2006 (Table S1.3). In July 2008, Phase 2 of the NBCSP began. Phase 2 was 
originally scheduled to end on 30 June 2011 (with most invitations ceasing on 
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31 December 2010); however, Phase 2 was continued from July 2011. The program was 
expanded from July 2013 to also invite Australians turning 60. The rollout of biennial 
screening for those 50–74 will begin in 2015.  
Table S1.3: NBCSP phases and target populations 
Phase Start date End date Target ages 
1 7 August 2006 30 June 2008 55 and 65 
2 1 July 2008 30 June 2011(a) 50, 55 and 65 
2(b) 1 July 2011 30 June 2013 50, 55 and 65 
3 1 July 2013 Ongoing 50, 55, 60 and 65 
3 1 July 2015  50, 55, 60, 65, 70 and 74 
3 1 July 2016  50, 55, 60, 64, 65, 70, 72 and 74 
3 1 July 2017  50, 54, 55, 58, 60, 64, 68, 70, 72 and 74 
3 1 July 2018  50, 54, 58, 60, 62, 64, 66, 68, 70, 72 and 74 
3 1 July 2019  50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72 and 74 
(a) Eligible birthdates, and thus invitations, ended on 31 December 2010. 
(b) Ongoing NBCSP funding began. 
Note: The eligible population for all Phase 2 and 3 start dates incorporates all those turning the target ages from 1 January of  
that year, onwards. 
The goal of the NBCSP is to reduce the morbidity and mortality from bowel cancer by 
actively recruiting and screening the target population for early detection or prevention of 
the disease. 
The NBCSP has been phased in gradually to help ensure that health services, such as 
colonoscopy and treatment options, are able to meet any increased demand. This is 
consistent with the introduction of other screening programs, such as the National Cervical 
Screening Program, which was also phased in over several years.  
The National Bowel Cancer Screening Program Register, currently maintained by the 
Department of Human Services (DHS, formerly Medicare Australia), is responsible for 
inviting people to participate in screening using an FOBT supplied with the invitation pack. 
To avoid the possibility of samples deteriorating due to exposure to heat and delays in 
processing (Grazzini et al. 2010; van Rossum et al. 2009), participants living in ‘hot zone’ 
postcodes are not sent kits during months where the average temperature has historically 
been greater than 30.5 degrees Celsius. They are sent their kit either before or after those 
hotter months. 
Once an eligible person has been sent and completed their FOBT, they are asked to post it to 
a central pathology laboratory for analysis. Results are sent to the participant, the 
participant’s nominated PHCP and the NBCSP Register. Participants with a positive result, 
indicating blood in their stool, are advised to consult their PHCP to discuss further 
diagnostic testing—in most cases, this will be a colonoscopy.  
Responses to invitations, and the outcomes for participants who complete the screening test, 
are monitored to the point of definite diagnosis for those who are found to have bowel 
cancer (DoHA 2013a). Refer to Appendix B, Figure B.1 for a complete representation of the 
current screening pathway from invitation to diagnosis. 
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How is the National Bowel Cancer Screening Program monitored? 
The AIHW produces these NBCSP monitoring reports for the Australian Government 
Department of Health. These reports analyse data extracted from the NBCSP Register and 
provide an overview of screening participation and outcomes.  
This current report presents statistics on the progression of eligible participants invited, from 
1 July 2012 to 30 June 2013, through the screening pathway. It covers measures of 
participation, FOBT results, and follow-up investigations and outcomes. Analyses are 
presented by age, sex, state and territory, geographical region, socioeconomic status, 
Aboriginal and Torres Strait Islander status, language spoken at home and disability status. 
In addition, the most recent incidence and mortality data for bowel cancer are presented as 
an indication of the current status of bowel cancer in Australia. As the NBCSP began only in 
late 2006 and currently targets a relatively small population, any influence NBCSP screening 
has on incidence and mortality rates may not be apparent for several years. 
Terminology and concepts used in this report 
Eligible population 
The eligible population list is compiled from those registered as an Australian citizen or 
migrant in the Medicare enrolment file, or registered with a Department of Veterans’ Affairs 
(DVA) gold card. Due to some variability between actual NBCSP invitation dates and invitee 
target-age birthdays, those who were the following ages when invited (from 1 January 2012 
to 30 June 2013) were included in the target-age cohorts in this report: 
• 50 year olds: those aged 49–52 when invited 
• 55 year olds: those aged 54–57 when invited 
• 65 year olds: those aged 64–67 when invited 
While all kits returned are analysed and processed by the NBCSP, invitees who were outside 
the target ages or did not live in Australia at the time of invitation were excluded from 
analyses in this report. There were 1,856 invitees excluded from the eligible population in 
2012–13 (see Table A1.1). These people were mainly participants outside the target ages who 
independently requested a kit, or were involved in jurisdictional pilot projects (such as those 
aimed at improving Aboriginal and Torres Strait Islander participation). 
Those people in the eligible population who had opted off the NBCSP (due to reasons such 
as already having regular colonoscopies) or suspended their participation as at 
31 December 2013 were included in analyses, as many had progressed through the screening 
pathway before opting off or suspending their participation.  
Participation 
The term participation is used to refer to participation in the screening test. Hence, the 
participation rate is the proportion of the eligible population invited who returned a 
completed FOBT.  
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FOBT positivity rate 
The FOBT positivity rate refers to the proportion of participants with positive FOBT results 
out of all participants who returned a valid FOBT kit; participants that returned inconclusive 
kits were excluded from this rate. 
Primary health-care practitioner and colonoscopy follow-up rates 
The proportion of participants with a positive FOBT result who subsequently visited a PHCP 
is referred to as the primary health-care practitioner follow-up rate. PHCPs are classified by 
DHS as a general practitioner or other primary health-care provider. This may include 
remote health clinics or specialists providing general practitioner services. 
The proportion of participants with a positive FOBT who subsequently had a colonoscopy is 
referred to as the colonoscopy follow-up rate.  
Crude versus estimated rates 
Due to inherent time lag between invitation and completion of an FOBT, calculation of a 
crude participation rate for a period can result in an underestimate of the true (final) 
participation rate, especially if sufficient time to allow all invitees to participate has not 
passed when calculating the crude rate. To adjust for the time lag in participation, this report 
includes data up to 6 months after the invitation period being reported.  
However, for later stages in the NBCSP pathway, such as PHCP and colonoscopy follow-up, 
modelled rates based on the time it took each individual with a positive FOBT result to 
respond were also calculated. The modelled response rates were calculated using the 
Kaplan–Meier method and provide a rate that adjusts for time lag in those who were invited 
later in the reported period and may not have yet had sufficient time to have a follow-up 
colonoscopy, for example. This method can only minimise the effect of the time lag—it 
cannot account for non-return of NBCSP forms (see ‘NBCSP data collection’ below). Details 
of the Kaplan–Meier method can be found in Appendix D.  
Data considerations 
The analyses in this report are based on data recorded in the NBCSP Register for the eligible 
population invited from 1 July 2012 to 30 June 2013, and includes participation and 
follow-up activity until 31 December 2013.  
NBCSP data collection 
Data are collected about participants and their screening outcomes from a variety of sources 
throughout the screening pathway. The data are collected on forms completed by 
participants, PHCPs, colonoscopists, pathologists, nurses, medical administrative staff 
and/or other specialists, and are ultimately returned and stored in the NBCSP Register. 
Completion of NBCSP forms by practitioners is not mandatory, and there is the possibility 
of inconsistent reporting. For example, assessment, colonoscopy and histopathology report 
forms are received from different sources and may be entered into the register in any 
sequence; however, each must have a positive FOBT result to be included. This means that 
there may be data for colonoscopies without an associated PHCP assessment form, and data 
for histopathology results without a completed colonoscopy report form. When 
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inconsistencies occur, these are noted to provide an indication of the reliability of the data. 
Additionally, specific histopathology data collection projects have been undertaken in some 
states and territories that may distort comparisons of histopathologically confirmed 
outcomes between jurisdictions. 
Because of time lags in reporting and under-reporting by clinicians, data on PHCP 
consultations, colonoscopies and histopathological outcomes in this report may understate 
the true performance of the NBCSP in this period and should be interpreted with caution. 
Self-reported population subgroup identification 
Information on the Aboriginal or Torres Strait Islander status of invitees may have been 
populated in the NBCSP Register through other Medicare programs for which the invitee 
has provided this information; however, in practice, this information for invitees overall is 
considered low quality. Therefore, identification of participants as Aboriginal or Torres Strait 
Islander, having a disability, or speaking a language other than English at home is by 
self-identification through return of a completed participant details form along with their 
FOBT for analysis. As membership of these subgroups is only known for invitees who 
participate, it is not possible to accurately determine NBCSP participation rates for these 
subgroups. Instead, the percentage of participants who identified as members of these 
subgroups is shown, and compared with the corresponding percentage of the population 
aged 50, 55 and 65 who identified themselves as members of these subgroups in the 2011 
Australian Census of Population and Housing. This allows an estimation of under-reporting 
or under-participation for these subgroups to be made.  
Postcode-based subgroup identification 
Subgroup analyses based on remoteness area and socioeconomic status (Index of Relative 
Socioeconomic Disadvantage) area are based on an invitee’s postcode at the time of 
invitation. The correspondences (previously known as concordances) used in this report are 
based on 2011 postal area boundaries and classifications, which are defined only in census 
years. See Appendix C for further details. 
The need to apply correspondences to determine subgroup identification introduces an 
unavoidable level of inaccuracy. For example, many postcodes may not have valid 
socioeconomic status or remoteness correspondence data available (such as for 
non-residential postcodes, or newly created postcodes), and some areas may have changed 
classification group since the time of the last census, either due to boundaries being 
redefined by Australia Post, or subsequent population changes. The Australian Bureau of 
Statistics advises that caution should always be taken when analysing the results of data that 
have been converted using correspondences, and the potential limitations of the data taken 
into account. 
Colonoscopy follow-up 
Theoretically, the denominator for the colonoscopy follow-up rate should be all positive 
FOBTs that were referred for colonoscopy by a PHCP. However, due to the time lag in 
visiting PHCPs and the low rate of PHCP assessment form return, this cannot be accurately 
estimated. Instead, the total number of positive FOBTs recorded in the NBCSP Register was 
used as the denominator.  
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As not all participants with a positive FOBT will be referred for a colonoscopy (for examples, 
see tables A3.9 and A3.11), this method may result in an underestimation of the true 
colonoscopy follow-up rate. The use of positive FOBTs as the denominator may also 
influence the rates shown in unexpected ways. For example, differences in age and sex 
population subgroups may be masked by differing referral rates; tables A2.2 and A3.9 show 
that the rate of positive FOBTs (used as the denominator for colonoscopy follow-up) 
increases with age, yet referrals for colonoscopy generally do not. 
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Section 2 Performance measures 
Structure of this section 
The Population based screening framework (APHDPCSS 2008) uses 5 incremental stages to 
describe a screening pathway. Figure S2.1 shows these stages and details how the NBCSP 
performance measures shown in the following chapters relate. The 2 remaining chapters in 
this section (‘Chapter 6 Incidence of bowel cancer’, and ‘Chapter 7 Mortality from bowel 
cancer’) provide additional context about bowel cancer in Australia. 
 
Recruitment
Targeted population encouraged 
to participate in screening
(Chapter 1)
Screening
Targeted population who participate in 
screening
(Chapter 1)
Assessment
Screened population who 
require further assessment
(Chapter 2)
Diagnosis
(Chapter 3)
Outcomes
(Chapters 4 and 5)
 
Source: APHDPCSS (2008). 
Figure S2.1: The 5 population-based screening framework stages 
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1 Participation 
What do we mean by participation? 
Definition: The proportion of the eligible population invited who returned a completed 
FOBT kit for analysis.  
Rationale: Through increased participation in bowel cancer screening, abnormalities that 
could otherwise develop into bowel cancer can be detected and treated. High participation 
is required for the NBCSP to achieve its major objectives of reducing bowel cancer 
incidence, morbidity and mortality. 
Data source: National Bowel Cancer Screening Program Register. 
Data quality: As the number of invitations issued and FOBT kits returned is known, there 
are limited data quality issues. See ‘Data considerations’, Section 1, for further details. 
Guide to interpretation: Participation data are based on the eligible population invited to 
screen from 1 July 2012 to 30 June 2013, as recorded in the register. Persons are counted 
only once in the reporting period, even if they were invited or screened more than once. 
See ‘Eligible population’, Section 1 for further information. 
Participation rate calculations should, in principle, exclude people from the denominator 
who are unlikely to require screening, such as those who have a previous diagnosis of 
bowel cancer, those who have had a colonoscopy in the past 5 years, or those who have 
completed any FOBT kit within the past 2 years. In practice, none of these groups can be 
reliably identified, and so all invitees are included in the denominator, and the numerator 
if applicable. Similarly, those who had opted off or suspended their participation are 
included in this chapter; this may cause a slight underestimation of participation, but 
increases outcome data for later chapters. 
Kaplan–Meier rates (see Box 1.1) are presented to visually depict participation rates from 
time (in weeks) of invitation. 
Key results 
• Of the 963,518 eligible people invited into the NBCSP in 2012–13, 321,413 (33.4%) had 
participated by 31 December 2013.  
• Kaplan–Meier curves showed that participation rates tended to plateau about 16 weeks 
after original invitation. 
• Participation rates differed between the 3 target ages. The highest rate of participation 
was by people aged 65 (41.6%), followed by those aged 55 (33.2%). Those aged 50 had 
the lowest participation (27.4%). 
• There was also a difference in participation between the sexes; the participation rate for 
women (35.7%) was higher than that for men (31.1%). 
• Those people invited in Remote and (particularly) Very Remote regions had lower levels of 
participation than people invited from all other regions. 
• People living in areas with the lowest socioeconomic status had the lowest level of 
participation. 
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Detailed analyses of 2012–13 invitee response 
From 1 July 2012 to 30 June 2013, a total of 965,374 FOBT invitations were sent out (Table 
A1.1). Of these, 1,856 were sent to people outside the target ages, or to addresses that were 
not in Australia, and were therefore not part of the eligible NBCSP population. To confirm 
the NBCSP Register provided adequate invitation coverage of the target ages, the Australian 
Bureau of Statistics Estimated Resident Populations for those aged 50, 55 and 65 in 2012 was 
compared with invitations where the eligible birthday occurred in 2012. Based on this 
comparison, invitation coverage for the eligible population was considered to be complete 
(data not shown). 
Of the 963,518 invitation kits issued to the eligible population, 321,413 people participated by 
returning a completed FOBT for analysis. This gave an overall Australia-wide crude 
participation rate of 33.4% (Table A1.2). A further 39,525 people did not return a kit but 
responded by opting off or suspending participation. This meant 360,938 people (37.5% of 
eligible invitations) responded in some form.  
The 33.4% participation rate recorded in this report was lower than that reported in the 
previous monitoring report (35.0%), with all jurisdictions (except the Northern Territory), all 
ages, both sexes, and all remoteness and socioeconomic status areas recording a decrease. 
Reasons for these decreases are not known. 
This report allowed a 6-month window between the period being reported and the cut-off 
for data analysis to allow sufficient time for almost all invitees who are likely to participate 
to do so. Previous monitoring reports have determined that 6 months is sufficient for crude 
participation rates to be valid (AIHW 2013). However, Kaplan–Meier estimates are provided 
in addition to visually show the response time between invitation and participation. 
The effect of invitation reminders 8 weeks after the original invitation can be seen (figures 
A1.1, A1.2 and A1.3) as a second steep rise in participation between weeks 10 and 14. 
Participation rates generally plateaued 16 weeks after invitation. 
Box 1.1: What are Kaplan–Meier estimates? 
Kaplan–Meier estimates are statistical methods that calculate a modelled rate based on the 
time it takes each individual invited for screening to move between points on the screening 
pathway. For example, participation is calculated by following each invited person and, for 
those who respond (by returning a completed FOBT kit), recording the time (in weeks) it 
took them to do so. This allows the calculation of an overall response rate over time from 
the date of invitation, calculated as if all invitations sent throughout the particular period 
reported were sent on the same date. 
Participation by population subgroups 
The eligible population was analysed by a number of population subgroups, as any 
subgroup with low participation rates may benefit from additional initiatives to increase 
participation. 
Kaplan–Meier estimates are provided for some subgroup analyses to show differences in 
participation over time since invitation.  
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Participation by state and territory 
Participation rates varied by state and territory. Northern Territory (24.8% crude 
participation), New South Wales (31.2%) and Queensland (32.2%) had lower participation 
rates than other jurisdictions (Table A1.2). For all other jurisdictions, participation rates were 
higher than the overall Australian rate. These jurisdictional participation results were in the 
same pattern as results in the previous annual monitoring report.  
Reasons why invitees in particular jurisdictions participate more or less than the national 
average are unknown; however, further analysis of jurisdictional participation by 
socioeconomic status and remoteness areas showed that participation in New South Wales 
and Queensland was generally lower across all subgroups (including Major cities, and Inner 
and outer regional areas) than the other jurisdictions. There appears to be an overall trend 
towards lower participation from invitees in these jurisdictions, instead of smaller 
population subgroups affecting their overall participation rates. As New South Wales and 
Queensland are two of the larger jurisdictions, their rates have a greater effect on the 
Australian participation rate.  
Participation by age and sex 
Participation rates were higher for women than men and increased with increasing age 
(figures 1.1, A1.2 and A1.3). These trends appeared across all population subgroups, and 
were similar to previous NBCSP monitoring reports. 
Those aged 55 (33.2% participation) were 1.2 times more likely to have participated than 
those aged 50 (27.4%). Those aged 65 (41.6%) were 1.5 times more likely to have participated 
than 50 year olds (Table A1.2 and Figure A1.2).  
Women were 1.1 times more likely than men to participate in bowel screening (35.7% for 
women compared with 31.1% for men) (Table A1.2 and Figure A1.3).  
 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure 1.1: Crude participation, by age and sex, 2012–13 
Participation by remoteness area and socioeconomic status area 
While more than 65% of all participants came from Major cities (with a 32.8% crude 
participation rate), participation was higher in Inner regional (35.5%) and Outer regional 
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(34.1%) areas than all other geographical areas (Table A1.3 and Figure 1.2). Similar results 
were found for participation by remoteness area and jurisdiction, with participation higher 
in Inner regional and Outer regional areas and lower in Remote and Very remote areas (Figure 
1.3). Jurisdiction-specific figures (figures A1.4a–A1.4h) are provided in Appendix A. 
Analysis of invitees grouped into population-based socioeconomic status quintiles showed 
invitees from within the lowest socioeconomic areas (the areas with the most disadvantage) 
had lower participation than for those living in all other socioeconomic areas (Table A1.4 and 
Figure 1.2). Only the 2 highest socioeconomic status quintiles had average participation 
above the national average. 
 
 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure 1.2: Crude participation, by remoteness area and by socioeconomic status area, 2012–13 
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Notes 
1. Rate per remoteness area is an average of participation across that remoteness area. 
2. Participation rates rounded to integers. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure 1.3: Crude participation, by remoteness area, 2012–13 
Participation by Aboriginal and Torres Strait Islander status, language spoken at home 
and disability subgroups 
As discussed in Section 1 (see ‘Data considerations’), identification of invitees by these 3 
subgroups is not reliably known at the time of invitation; this information is only obtained 
once an invitee completes the relevant section of their participant details form when they 
participate. Therefore, it is not possible to accurately determine participation rates for these 
subgroups. 
Instead, the proportion of participants who reported their status within these subgroups is 
shown, along with the corresponding population proportions derived from the 2011 
Australian Bureau of Statistics (ABS) Census of Population and Housing (tables A1.5–A1.7). 
While these are not ideal comparisons, they do allow some understanding of people in these 
3 subgroups, and if they are participating in the NBCSP in similar proportions to their levels 
within the Australian population (as recorded at the 2011 Census). For example, if 1.5% of 
the Australian population in the target ages identified as Indigenous at the 2011 Census, did 
the same proportion of people who participated in the NBCSP identify as Indigenous? If the 
proportion participating is below 1.5%, it may indicate under-participation by this 
population subgroup. 
The following comparisons should be interpreted with caution as the eligible NBCSP 
population (which includes only those in the target ages, living in Australia, who are 
registered as Australian citizens or migrants in the Medicare enrolment file, or are registered 
with a DVA gold card) may differ somewhat from the population recorded in those target 
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ages at the 2011 Census (which did not have the same eligibility criteria, such as Medicare or 
DVA gold card registration). Further, there were slight differences in the proportion of 
people who did not identify (did not answer these questions) between the NBCSP and 2011 
Census data (tables A1.5 and A1.7); this may affect comparisons shown below.  
The proportion of participants who identified as Indigenous in the NBCSP was consistently 
lower across all age and sex groups than the comparable proportion who identified as 
Indigenous in the 2011 Census (Table A1.5). This may have been due to the eligible 
population who were Indigenous having participated at a lower rate than would be expected 
(that is, 0.6% of the eligible population who participated identified as Indigenous, compared 
with 1.5% of the target ages identifying as Indigenous at the time of the 2011 Census). 
As the NBCSP Register assumes all people who do not answer the question about language 
spoken at home speak English, it was not possible to determine the ‘Not stated’ percentage 
for comparison with the percentage from the 2011 Census (Table A1.6). Therefore, no 
interpretation about participation rates by people who speak a language other than English 
at home should be made, though Table A1.6 is provided for completeness.  
As the proportion of participants who identified as having a severe or profound activity 
limitation (4.8%) was slightly greater than the proportion identified in the 2011 Census 
(4.6%), it is likely that participation among invitees in this subgroup was no lower than for 
those invitees without a severe or profound activity limitation (Table A1.7).  
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2 Faecal occult blood test outcomes 
What do we mean by FOBT outcomes? 
Definition: The proportion of the eligible population invited who returned a positive 
(abnormal) result from a correctly completed FOBT kit. 
Rationale: Monitoring of FOBT outcomes, including for various subgroups, is important to 
ensure the quality of the screening test results and participant safety. 
Data source: National Bowel Cancer Screening Program Register. 
Data quality: All FOBT kits returned are analysed for outcome, with the result reliably 
stored in the register. There are no quality issues with this measure. See ‘Data 
considerations’, Section 1, for further details. 
Guide to interpretation: FOBT result data are based on data recorded in the register to 
31 December 2013 for persons invited from 1 July 2012 to 30 June 2013. 
Persons are counted only once in the reporting period, even if they completed more than 
1 FOBT during this period. For participants who returned more than 1 FOBT kit, the results 
were analysed according to the following order of precedence: a positive result was selected 
over any other result, and a negative result was selected over an inconclusive result. 
Key results 
• Of the 321,413 participants who had completed an FOBT kit, 316,572 (98.5%) had done so 
correctly, allowing for analysis by the pathology laboratory. However, 154 were 
inconclusive when analysed and those participants were still to complete and return a 
replacement FOBT. 
• Out of the 316,418 valid FOBT kits analysed, 23,671 returned a positive result, giving an 
overall positivity rate of 7.5%.  
• The positivity rate for men (8.3%) was 1.2 times that for women (6.8%). 
• The FOBT positivity rates for both sexes increased with older age, consistent with the 
known rise in polyp, adenoma and bowel cancer incidence rates with increasing age. 
• Positivity rates increased with increasing geographical remoteness. Rates for participants 
in Very remote (9.1%), Remote (8.0%) and Outer regional (7.9%) areas were higher than 
those in Inner regional (7.6%) areas and Major cities (7.4%). 
• Positivity rates were higher for participants living in areas with higher socioeconomic 
disadvantage—from 6.3% for participants living in areas with the least disadvantage to 
8.6% for participants living in areas with the most disadvantage. 
• Participants who self-identified as Aboriginal and Torres Strait Islander had a higher 
positivity rate (10.6%) than those who reported as non-Indigenous (7.4%) or those who 
did not state their Indigenous status (9.5%). 
• The positivity rate of participants with a severe or profound activity limitation (11.8%) 
was higher than participants without those limitations (7.3%). 
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Background information 
Each invitee in the NBCSP is initially sent 1 FOBT kit containing 2 sample tubes to be 
completed, from 2 separate bowel motions, and returned to the pathology laboratory 
together for analysis.  
Completed and returned kits are categorised by pathologists into 3 groups: correctly 
completed, incorrectly completed or unsatisfactory. A kit may be incorrectly completed or 
unsatisfactory (and thus ineligible for analysis) due to: 
• the participant not completing the test correctly 
• the completed kit having expired 
• the kit having taken more than 14 days between the date of the first sample and analysis 
by the pathology laboratory. 
Participants who return FOBTs that were incorrectly completed are asked to complete 
another FOBT. See Figure B.1, Appendix B, for details of the screening pathway. 
Results of correctly completed FOBT kits are classified by pathologists as either positive 
(abnormal—blood was detected in either sample), negative (blood was not detected in either 
sample) or inconclusive (only 1 sample was taken, and it was negative). Valid kits are 
considered to be those from which it is possible to determine a positive or negative outcome. 
Participants with a positive FOBT are encouraged to visit their PHCP to follow up this 
finding. Those with an inconclusive kit are requested to complete another FOBT kit, while 
those with a negative result are reminded that it is recommended they rescreen every 2 years 
with an FOBT. Participants are advised to discuss continuing screening options with their 
PHCP.  
Detailed faecal occult blood test outcome analyses 
From 1 July 2012 to 30 June 2013, 963,518 eligible people were invited to screen, and by 
31 December 2013, 321,413 participants had returned at least 1 completed FOBT kit. Of these, 
316,572 (98.5%) had a correctly completed FOBT kit tested by the pathology laboratory 
(Table A2.1); the remaining kits had been incorrectly completed. Of the correctly completed 
kits, some were deemed inconclusive when tested. Those participants who returned an 
incorrectly completed or inconclusive FOBT kit were requested to complete another FOBT; 
however, by 31 December 2013, 4,841 participants had not returned a replacement kit, and 
154 had returned kits with an inconclusive result. These were excluded from the positivity 
analyses. 
Of the 316,418 valid FOBT kits analysed, 23,671 (7.5%) returned a positive FOBT result 
(Table A2.2). These participants were advised to consult their PHCP to discuss this result 
and seek further diagnostic testing (see ‘Chapter 3 Follow-up of positive FOBT results’, 
Section 2).  
Faecal occult blood test outcomes by population subgroups 
Faecal occult blood test outcomes by state and territory 
The positivity rates for the Northern Territory (8.6%), South Australia (7.9%) and Victoria 
(7.6%) were higher than the overall Australian rate of 7.5% (Table A2.3). 
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Faecal occult blood test outcomes by age and sex 
The FOBT positivity rate increased with increasing age. This was true for both men and 
women (Figure 2.1 and Table A2.2). These findings are consistent with the increase in 
prevalence of polyps and adenomas with age (Winawer et al. 1997). 
The men’s positivity rate (8.3%) was 1.2 times the rate for women (6.8%), indicating both age 
and sex affect the FOBT positivity rate (Table A2.2). 
 
 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013 
Figure 2.1: FOBT positivity, by age and sex, 2012–13 
Faecal occult blood test outcomes by remoteness area and socioeconomic status area 
Analysis of the positivity rate by area (Table A2.4) showed increasing positivity with 
increasing remoteness. Outer regional, Remote and Very remote areas had positivity rates 1.1, 
1.1 and 1.2 times the positivity rate of Major cities, respectively. This was a similar result to 
previous reports. Positivity rates by remoteness area and jurisdiction are shown in Figure 
2.2. Jurisdiction-specific figures (figures A2.1a–A2.1h) are provided in Appendix A. 
FOBT positivity rates also increased for people living in areas of increasing disadvantage 
(Table A2.5). The positivity rate for participants living in areas with the lowest 
socioeconomic status (8.6%) was 1.4 times that of participants living in areas with the highest 
socioeconomic status (6.3%). Socioeconomic status analyses for the participation measure 
(see ‘Chapter 1 Participation’, Section 2) and the FOBT analyses in this chapter show that 
those living in areas with lower socioeconomic status participate less in the NBCSP 
(Table A1.4); yet those who do participate return a higher proportion of positive FOBT 
results (Table A2.5). 
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Notes 
1. Remoteness areas left unshaded contain data that are not publishable due to small numbers, confidentiality or other concerns.  
2. Rate per remoteness area is an average of positivity across that remoteness area. 
3. Positivity rates rounded to 1 decimal place. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure 2.2: FOBT positivity, by remoteness area, 2012–13 
Faecal occult blood test outcomes by Aboriginal and Torres Strait Islander status, 
language spoken at home and disability subgroups 
Aboriginal and Torres Strait Islander participants had a higher positivity rate (10.6%) than 
non-Indigenous participants (7.4%) (Table A2.6).  
The positivity rate of those who spoke a language other than English at home (7.9%) was 
higher than participants who spoke English at home (7.4%) (Table A2.7); however, as those 
who do not report their language spoken at home are assumed to speak English, the 
interpretability of this result is limited. 
People with a severe or profound activity limitation recorded a higher positivity rate (11.8%) 
than people without such limitations (7.3%) (Table A2.8). Reasons for this difference are 
speculative, but may include a lower level of physical activity (Wolin et al. 2011), or 
comorbidities and medications that increase the likelihood of a positive FOBT screening 
result in people with a severe or profound activity limitation.  
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3 Follow-up of positive FOBT results 
What do we mean by FOBT follow-up? 
Definition: The proportion of the eligible population invited who returned a positive 
(abnormal) result from a correctly completed FOBT kit who received follow-up care by a 
PHCP and colonoscopist. 
Rationale: People who complete a screening test and receive a positive result are likely to 
be concerned; however, not all positive screening results are ‘true’ positives for bowel 
cancer. Monitoring of follow-up care for participants with a positive FOBT is important to 
ensure those participants follow up their screening result with medical specialists. 
Data source: National Bowel Cancer Screening Program Register. 
Data quality: All positive FOBT results are recorded in the register; however, reporting of 
follow-up care by PHCPs, colonoscopists, surgeons and pathologists is not mandatory, so 
follow-up rates may be underestimated. See ‘Data considerations’, Section 1, for further 
details. 
Guide to interpretation: This chapter discusses the follow-up procedures, including PHCP 
visits, colonoscopy procedures and histopathology diagnoses for those participants who 
were invited from 1 July 2012 to 30 June 2013. Persons are counted only once in the 
reporting period, even if they attended more than 1 follow-up consultation during this 
period. For participants who attended more than 1 follow-up consultation, the first 
consultation after the positive result was used to establish time to follow-up, while the 
most serious follow-up result was used for outcomes. 
Kaplan–Meier rates (see ‘Crude versus estimated rates’, Section 1) are used to take into 
account potential time lag between a positive FOBT result and both PHCP and 
colonoscopy follow-up dates. 
The rates of colonoscopy follow-up are discussed in this chapter, while the actual 
outcomes of colonoscopic investigation are discussed in ‘Chapter 4 Bowel abnormality 
detection’, Section 2. 
Key results 
• Using Kaplan–Meier estimates, of the 23,671 participants who had a positive FOBT, 
58.7% had a follow-up PHCP visit and 72.1% had a follow-up colonoscopy within 1 year 
of their screening result; PHCP visits appear to be under-reported (see Box 3.1). 
• PHCP follow-up was highest for participants living in Inner regional and Outer regional 
areas. 
• Of the 13,721 participants who had reported a PHCP consultation, 82.5% reported 
experiencing no symptoms before their positive FOBT result and 91.7% were referred for 
a colonoscopy. 
• Aboriginal and Torres Strait Islander participants, participants who spoke a language 
other than English at home, and those with a severe or profound activity limitation had a 
lower rate of colonoscopy follow-up than other participants. 
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Background information 
The NBCSP uses an FOBT as the screening tool to screen for microscopic blood loss from the 
bowel—a sign of potential bowel problems that require further investigation, including 
bowel cancer and adenomas. A procedure such as a colonoscopy is required to actually 
diagnose a bowel condition after a positive screening test.  
Participants who receive a positive FOBT result are encouraged to follow up this outcome 
with their PHCP. In accordance with the Clinical practice guidelines for the prevention, early 
detection and management of colorectal cancer (ACN 2005), PHCPs are encouraged to refer all 
participants with a positive FOBT for a colonoscopy, unless other information gained at the 
consultation suggests an alternative course of action.  
Colonoscopy is currently considered the most accurate method of investigation to assess the 
colon and rectum, as it enables biopsy and subsequent histopathological diagnosis. 
Colonoscopy also allows identification and endoscopic removal of polyps and adenomas.  
As most bowel cancers are known to initiate from polyps (Cappell 2005), their removal at 
colonoscopy provides a preventive measure to lower the risk of future bowel cancers. A 
study by Stryker and colleagues (1987) estimated the cumulative risk of bowel cancer at the 
site of an untreated polyp was 2.5% at 5 years, 8% at 10 years and 24% at 20 years 
post-discovery.  
This is one of the advantages of the NBCSP; while bowel cancer screening aims to find 
cancers at an earlier and treatable stage, follow-up colonoscopy after a positive screen may 
also identify and remove precancerous lesions. This should result in lower bowel cancer 
incidence rates in future years. However, the effect may not be apparent until about 10 years 
from the start the program. 
Detailed primary health-care practitioner follow-up analyses  
Of the 23,671 participants invited who returned a positive FOBT result, 13,721 (58.0%) had a 
PHCP visit registered by 31 December 2013 (Table A3.1). Using Kaplan–Meier estimates to 
minimise any effect of time lag, an estimated 58.7% of participants had consulted a PHCP 
within 1 year of their positive FOBT result (Table A3.2). The reminder letter sent to 
participants and their PHCP 8 weeks after a positive FOBT clearly had a positive effect, with 
an increase in the follow-up rate seen between 10 and 14 weeks (figures A3.1a–c).  
Box 3.1: Interpretation of follow-up results 
Assessment form return has recently improved over that recorded in earlier monitoring 
reports. Some of this improvement is due to the time increase between the invitation and 
final data cut-offs used in the last 3 reports, which allowed sufficient time for the majority 
of participants with a positive FOBT result to attend their PHCP, thus reducing the effect of 
time lag. This is apparent as the similar crude and Kaplan–Meier rates.  
However, there is still room for more improvement in assessment form return as there were 
more recorded colonoscopies than recorded PHCP visits (tables A3.1 and A3.12), and PHCP 
referral is generally required to progress to colonoscopy. 
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Of the participants who had a reported PHCP consultation: 
• 82.5% reported having no symptoms before the positive FOBT result (Table A3.8) 
• 91.7% were referred for colonoscopy (Table A3.9)  
• for those not referred for colonoscopy (1,142), the main reasons were having had a 
colonoscopy in the previous 18 months (47.9%), other medical condition(s) (29.9%) or the 
participant declining a colonoscopy (26.0%) (Table A3.11) 
• of the 297 participants who declined colonoscopy (Table A3.11), 170 were not referred 
for any other assessment (data not shown). 
As the invitation strategy at the time of this report sent invitations to all people who turned 
the target ages regardless of recent screening or surveillance—or current bowel cancer 
status—it is possible that some participants move through the screening pathway before 
these reasons potentially negate the need for further follow-up. However, without complete 
PHCP form return (as well as participant opt-off form return), it is not possible to accurately 
quantify the number of people that should be excluded from asymptomatic 
population-based bowel screening.  
Primary health-care practitioner follow-up by population subgroups 
Primary health-care practitioner follow-up by state and territory 
NBCSP implementation is the responsibility of each jurisdiction, and states and territories 
may have different follow-up policies and procedures. There were large differences recorded 
in PHCP follow-up between the jurisdictions, with the Northern Territory, Victoria and the 
Australian Capital Territory recording the lowest levels of PHCP follow-up (Table A3.1). The 
Kaplan–Meier PHCP follow-up rates up to 52 weeks from a positive FOBT result showed a 
similar pattern to the crude data regarding state and territory differences (Table A3.2 and 
figures A3.1b and A3.1c). For clarity, Kaplan–Meier curves for the states and territories were 
divided between figures A3.1b and A3.1c. With the exception of those living in the Northern 
Territory and Victoria, at least 40% of all people with a positive FOBT had recorded a 
follow-up with their PHCP within 4 weeks. 
Primary health-care practitioner follow-up by age and sex 
PHCP follow-up rates increased with age (Figure 3.1 and Table A3.1). As it is unlikely that 
PCHPs would return assessment forms differently for different-aged participants, this 
suggests that older participants are more likely to follow up their positive result. 
More women (60.1%) than men (56.0%) had an assessment form recorded, suggesting that 
women are more likely to follow up a positive FOBT with their PHCP. This was a common 
finding when comparing sexes across all PHCP subgroup tables.  
From the PHCP visits recorded, women had a slightly higher rate of reported symptoms 
(Table A3.8), and a slightly lower rate of referral for colonoscopy (Table A3.9), possibly due 
to a higher percentage of women (27.6%) declining colonoscopy than men (24.2%) 
(Table A3.11). Women also had a higher rate of non-colonoscopy follow-up procedures. 
 
  National Bowel Cancer Screening Program monitoring report: 2012–13 25 
 
 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure 3.1: Primary health-care practitioner follow-up, by age and sex, 2012–13 
Primary health-care practitioner follow-up by remoteness area and socioeconomic status 
area 
Participants in Inner regional (60.0%) and Outer regional areas (59.9%) had the highest rates of 
PHCP consultations (Table A3.3). Participants in Remote and Very remote areas had the lowest 
rates of PHCP follow-up recorded. Follow-up to a PHCP varied by remoteness area and 
jurisdiction (Figure 3.2). However, this could reflect differences in the return of assessment 
forms rather than a true difference in follow-up. Jurisdiction-specific figures (figures A3.2a–
A3.2h) are provided in Appendix A. Referral for colonoscopy was similar across remoteness 
areas (Table A3.10).  
PHCP follow-up between participants from different socioeconomic status areas was also 
similar (Table A3.4).  
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Notes 
1. Remoteness areas left unshaded contain data that are not publishable due to small numbers, confidentiality or other concerns.  
2. Rate per remoteness area is an average of PHCP follow-up reported across that remoteness area. 
3. PHCP follow-up rates rounded to integers. 
4. Differences in PHCP follow-up rates across remoteness areas may involve differences in assessment form return and not a real difference 
in follow-up. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure 3.2: Follow-up by primary health-care practitioners after a positive FOBT result, by 
remoteness area, 2012–13 
Primary health-care practitioner follow-up by Aboriginal and Torres Strait Islander status, 
language spoken at home and disability subgroups 
All 3 population subgroups had low numbers of participants with returned assessment 
forms. Care must be taken when interpreting results in these tables. 
There were no major differences in the rates of PHCP visits when comparing participants by 
Aboriginal and Torres Strait Islander status, language spoken at home or disability status 
(tables A3.5–A3.7, respectively). 
Detailed colonoscopy follow-up  
Background 
This section presents the rate at which participants with a positive FOBT had follow-up 
assessment by colonoscopy. Due to the recommendation that all referrals be for colonoscopy, 
it is not possible to analyse follow-up by other assessment methods (for example, 
sigmoidoscopy) as data are not available. 
Following a positive FOBT result, PHCPs should refer a participant for colonoscopy, and the 
results should be returned to the NBCSP Register on a colonoscopy report form (Figure B.1, 
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Appendix B). Some of these colonoscopies would also have sent pathology samples for 
analysis, and these additional results should be returned to the register on histopathology 
report forms. Lastly, each participant may choose to have their colonoscopy through the 
private or public health-care system (depending on their individual circumstances and 
choice), and those who had a private colonoscopy may then make a Medicare claim for that 
procedure. The register records claims from NBCSP-related private colonoscopies.  
As not all colonoscopy forms are returned to the register, a count of colonoscopy report 
forms only will not be a complete count of all colonoscopies performed as part of NBCSP 
follow-up. Therefore, in an effort to obtain the most comprehensive picture of true NBCSP 
colonoscopy follow-up, colonoscopy procedures up until 31 December 2013 were identified 
through 3 sources: 
1. colonoscopy report forms (colonoscopy outcomes can be analysed using data on these 
forms)  
2. additional histopathology report forms (from the subset of colonoscopies that, although 
not directly reported on a colonoscopy report form, must have sent samples to 
histopathology—which were reported on histopathology report forms)  
3. claims for Medicare benefits for NBCSP-related private colonoscopies that were not 
reported through a colonoscopy report form (from the subset of NBCSP colonoscopies 
that were undertaken through the private healthcare system, as identified by DHS).  
Figure 3.3 visually presents the number of colonoscopies counted, and from which source (or 
sources) they were identified. If all colonoscopy forms were returned and recorded, it would 
be expected that no extra colonoscopies would be counted from outside the colonoscopy 
report forms box. However, 3,932 NBCSP-related colonoscopies were identified by a private 
colonoscopy Medicare claim only, and a further 197 were identified through a 
histopathology report form only. Details such as colonoscopic findings could not be obtained 
for these colonoscopies; however, they are still counted in the total number of colonoscopies 
performed as part of NBCSP follow-up activities. Even though using these 3 sources allows 
the count of NBCSP colonoscopies to be as complete as possible, further investigation has 
previously shown a number of additional colonoscopies are likely to be unaccounted for, so 
colonoscopy follow-up rates are underestimated. 
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NBCSP colonoscopies recorded for participants invited July 2012–June 2013 (n = 16,670)
Colonoscopy report forms (12,541)(a)+(b)
Medicare claims onlyHistopathology report forms (1,562)(b)+(c)
11,176(a)
3,932(d)
197(c)
1,365(b)
 
People invited in 2012–13 with: 
(a) colonoscopy report forms recorded in the NBCSP Register for which no histopathology report form has been received 
(b) colonoscopies performed as part of the NBCSP where a colonoscopy and histopathology report form were recorded on which confirmed 
outcomes can be calculated. The total number of colonoscopy report forms is given by (a)+(b) 
(c) colonoscopies performed as part of the NBCSP where only a histopathology report form was recorded 
(d) colonoscopies performed as part of the NBCSP where only a Medicare claim was recorded. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure 3.3: Sources of colonoscopy follow-up data, 2012–13 
2012–13 colonoscopy follow-up 
Of the 23,671 positive FOBT results from participants invited, 16,670 had a colonoscopy 
registered by 31 December 2013, giving a crude colonoscopy follow-up rate of 70.4% 
(Table A3.12). Of these, 3,932 colonoscopies were known to have taken place only due to a 
Medicare claim for the procedure; no colonoscopy or histopathology report forms were 
recorded for those colonoscopies.  
Reasons for this non-complete rate of follow-up are likely to be similar to reasons for the low 
rate of PHCP follow-up: not all participants may follow up a positive FOBT result (and the 
positive FOBT count was used as the denominator for colonoscopy follow-up instead of all 
PHCP colonoscopy referrals), there is a time lag between booking and having a colonoscopy, 
and there is some delay in returning colonoscopy report forms. See ‘Data considerations’ and 
‘Colonoscopy follow-up’, Section 1, for further details. 
To adjust for the effect of time lag on the follow-up rate, an analysis using Kaplan–Meier 
estimates was performed. The Kaplan–Meier analysis of colonoscopy follow-up estimated 
72.1% of participants with a positive FOBT had a colonoscopy within 52 weeks of notification 
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of their positive result (Table A3.13 and Figure A3.3a). As these Kaplan–Meier rates were 
similar to the crude rate reported, the time lag waiting for a colonoscopy procedure was not 
a major factor in this report.  
Colonoscopy follow-up by population subgroups 
Colonoscopy follow-up by state and territory 
There were differences in colonoscopy follow-up rates between states and territories 
(tables A3.12 and A3.13). Queensland (82.0%), Tasmania (77.3%) and South Australia (73.5%) 
had the highest rates of crude colonoscopy follow-up. Much like the PHCP follow-up 
differences by jurisdiction (Table A3.1), these colonoscopy follow-up differences 
(tables A3.12 and A3.13 and figures A3.3b and A3.3c) may also be affected by NBCSP 
implementation procedures specific to each jurisdiction. Overall, 53% of those with a positive 
FOBT had undergone a colonoscopy within 12 weeks of their positive screen. 
Colonoscopy follow-up by age and sex 
The crude rate of colonoscopy follow-up for people aged 65 (72.1%) was higher than for 
those aged 50 and 55 (68.8% and 69.7%, respectively) (Figure 3.4 and Table A3.12).  
The difference in crude colonoscopy follow-up between men and women was smaller (69.8% 
and 71.1%, respectively) (Table A3.12). 
 
 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013 
Figure 3.4: Colonoscopy follow-up, by age and sex, 2012–13 
Colonoscopy follow-up by remoteness area and socioeconomic status area 
Colonoscopy follow-up for participants living in Major cities was higher than in all other 
regions (Table A3.14), yet PHCP follow-up in Major cities was lower than the overall 
Australian PHCP follow-up rate (Table A3.3). As time lag is not considered a contributing 
factor towards PHCP or colonoscopy rates in this report, there may be differences in form 
return between PHCPs and colonoscopists between regions.  
Colonoscopy follow-up rates varied by remoteness area and jurisdiction (Figure 3.5). 
Queensland had a high percentage of colonoscopy follow-up for most remoteness areas. 
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However, these differences may be affected by colonoscopy and histopathology form return 
differences within medical facilities across remoteness areas and jurisdictions. 
Jurisdiction-specific figures (figures A3.4a–A3.4h) are provided in Appendix A. 
There were also differences in colonoscopy follow-up between participants living in areas of 
differing socioeconomic status (Table A3.15); those living in areas with greater 
socioeconomic disadvantage had lower rates of colonoscopy follow-up than those living in 
areas with less socioeconomic disadvantage.  
 
 
Notes 
1. Remoteness areas left unshaded contain data that are not publishable due to small numbers, confidentiality or other concerns.  
2. Rate per remoteness area is an average of colonoscopy follow-up reported across that remoteness area. 
3. Colonoscopy follow-up rates rounded to integers. 
4. Differences in colonoscopy follow-up rates across remoteness areas may involve differences in form return and not a real difference in 
follow-up. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure 3.5: Colonoscopy follow-up after a positive FOBT result, by remoteness area, 2012–13 
Colonoscopy follow-up by Aboriginal and Torres Strait Islander status, language spoken 
at home and disability subgroups 
All 3 population subgroups had low numbers of participants with returned colonoscopy 
report forms. Care must be taken when interpreting results in these tables. 
Although Aboriginal and Torres Strait Islander participants had a lower rate of colonoscopy 
follow-up (58.7%) than non-Indigenous participants (71.4%), this difference should be 
interpreted with caution due to the low number of Aboriginal and Torres Strait Islander 
participants (121) who were recorded as having a colonoscopy (Table A3.16). 
Participants who spoke English at home had a higher rate of colonoscopy follow-up (70.9%) 
than participants who spoke a language other than English (67.2%) (Table A3.17).  
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Participants with a severe or profound activity limitation had a lower rate of colonoscopy 
follow-up (61.5%) than participants without such limitations (72.6%) (Table A3.18). This is a 
different finding from the PHCP follow-up result, where participants with a severe or 
profound activity limitation had a similar rate of PHCP follow-up (60.2% versus 60.6%) 
(Table A3.7). Further analysis of referral and reason for non-referral data showed 12.1% of 
participants with a severe or profound activity limitation were not referred to colonoscopy, 
compared with 7.9% of participants without such limitations (data not shown). Participants 
with a severe or profound activity limitation were more likely to cite limited life expectancy, 
a significant comorbidity or other medical condition as the reason for non-referral. They 
were less likely to report having had a recent colonoscopy as the reason for non-referral. 
Detailed histopathology follow-up  
Background 
If a NBCSP colonoscopy procedure removed specimens (such as polyps or adenomas) for 
analysis by histopathology, this is noted on the colonoscopy report form and the result of the 
histopathology analysis should then be returned to the NBCSP Register on a completed 
histopathology report form. However, there was a high rate of non-return of histopathology 
report forms, which may be due to the time lag in processing of samples, or poor form return 
from pathology laboratories. 
In recent years, several jurisdictions have started projects to improve histopathology data 
return, and this may have resulted in some jurisdictions having a higher proportion of 
confirmed colonoscopy outcomes than other jurisdictions.  
As final diagnosis of cancers suspected at colonoscopy requires confirmation by 
histopathology, the suspected number of missing histopathology report forms means the 
confirmed cancer numbers in ‘Chapter 4 Bowel abnormality detection’, Section 2 are likely to 
be under-reported, and by different degrees for different jurisdictions. 
2012–13 histopathology follow-up 
Data recorded on the 12,541 colonoscopy report forms returned indicated samples were sent 
to histopathology for 6,735 participants (53.7%, data not shown). However, as at 
31 December 2013, only 1,562 histopathology report forms (23.2%) had been returned. 
Outcomes of these are discussed in ‘Chapter 4 Bowel abnormality detection’, Section 2. 
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4 Bowel abnormality detection 
What do we mean by bowel abnormality detection? 
Definition: The proportion of the eligible population invited who returned a positive result 
from a correctly completed FOBT kit who then had an abnormality detected at follow-up. 
Rationale: Monitoring of abnormalities detected through the NBCSP by various 
stratifications is important to determine the effectiveness of the program, and to help 
determine the rate of false positive screening results. 
Data source: National Bowel Cancer Screening Program Register. 
Data quality: Reporting of follow-up care by colonoscopists, surgeons and pathologists is 
not mandatory, so outcomes may be underestimated. See ‘Data considerations’, Section 1, for 
further details. 
Guide to interpretation: Follow-up data are based on data recorded in the register to 
31 December 2013 for persons invited from 1 July 2012 to 30 June 2013. Due to the time delay 
between notification of a positive FOBT result and progression to colonoscopy and 
histopathological confirmation of results, outcome data are incomplete. 
Only outcomes from colonoscopies that returned colonoscopy report forms are included in 
Table A4.1; additional data from histopathology report forms are then included in Figure 4.1 
and tables A4.2–A4.4. While additional colonoscopies are known to have taken place (due to 
the return of Medicare claim forms, see ‘Chapter 3 Follow-up of positive FOBT results’, 
Section 2) they do not have outcome data available.  
Persons are counted only once in the reporting period, even if they have more than 1 
abnormality detected during this period. Histopathologically confirmed results are reported 
over (colonoscopist-)suspected results. 
The abnormalities analysed in this chapter include polyps, adenomas and cancers diagnosed, 
and these are reported firstly using colonoscopy findings only, then with the addition of 
available histopathology confirmation data. The stage of confirmed cancer spread is not 
reported as sufficient staging data were not available.  
Some jurisdictions have started specific data collection projects to improve the quantity and 
quality of the outcome data reported to the register in recent years. 
Key results 
• Of the 23,671 participants with a positive FOBT, 12,738 (54%) had a valid colonoscopy or 
histopathology report form recorded (Figure 3.3). A further 5,074 (21%) had other 
recorded outcomes (Table A3.9). Recorded outcomes for 5,859 (25%) people with a 
positive FOBT were unknown as at 31 December 2013. 
• There were 52 confirmed and 352 suspected cancers found in those with outcome data 
available, equating to 1 suspected or confirmed cancer being found for every 32 
participants undergoing colonoscopy after a positive FOBT.  
• A further 728 participants had an advanced adenoma detected during colonoscopy. 
• The proportion of people for whom abnormalities were detected at colonoscopy 
increased with age and was higher for men than women. 
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Background information 
This chapter presents outcomes from the NBCSP as at 31 December 2013 based on those 
people invited who returned a positive FOBT and proceeded to colonoscopy. Program 
outcomes at key pathway points are summarised in Figure 4.1. 
Data for colonoscopy outcomes were derived from information recorded on the colonoscopy 
and histopathology report forms. From 2011, a new combined colonoscopy/histopathology 
form has been implemented, with the aim to improve the level of outcome data returned to 
the NBCSP Register. A new surgical resection form that will collect staging data is also to be 
implemented. 
Outcome information comes from the last points in the NBCSP pathway, and by 
31 December 2013 there were still colonoscopy and histopathology report forms yet to be 
returned. Ultimately, for cancers and adenomas detected at colonoscopy, the final diagnosis 
must be returned by histopathology. However, as reporting by clinicians to the NBCSP is not 
mandatory, a participant may have colonoscopy details, histopathology details or both 
recorded in the register. As a result, outcomes were classified in the following order: 
• Confirmed cancers included suspected cancers at colonoscopy where a biopsy sample 
was taken that was confirmed as cancer by histopathology. Confirmed cancers also 
included any tissue samples from surgical resection or colonoscopic excisions that were 
confirmed to be cancerous, and subsequently reported by histopathology report form. 
Confirmed cancers were given a higher priority than suspected cancers.  
• Suspected cancers were abnormalities detected at colonoscopy that the colonoscopist 
suspected to be cancer, but did not have histopathology outcomes available. Final 
diagnoses cannot be confirmed until histopathology results are returned, though bowel 
cancer is highly likely if the colonoscopist has suspected a cancerous lesion.  
• Adenomas confirmed by histopathology were categorised into 3 risk levels—advanced, 
small and diminutive. These risk levels are described in Appendix B.  
• Polyps awaiting histopathology were polyps detected at colonoscopy that had not had 
an associated histopathology report form returned. There is the potential that a number 
of these may be reclassified as adenomas by histopathology, so the number of adenomas 
counted may be under-reported. 
• Participants recorded as having no cancer or adenoma were those who had no polyps or 
suspected cancers detected at colonoscopy, or had polyps detected at colonoscopy that 
were confirmed as non-adenomatous by histopathology. 
Detailed analyses 
Three separate analyses regarding abnormality detection are presented here. As it is 
important to understand what results the colonoscopists are reporting initially, the first 
analysis (Table A4.1) reports findings when only analysing colonoscopy report forms. The 
second analysis (Figure 4.1 and tables A4.2 and A4.3) reports updated colonoscopy 
outcomes, when including histopathology results recorded as part of the colonoscopy 
procedures.  
Bowel abnormality detection at colonoscopy 
Of the 321,413 people invited into the NBCSP from 1 July 2012 to 30 June 2013 who returned 
FOBT kits, 23,671 were found to have blood in their samples (Figure 4.1), giving a positive 
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result that should be followed up by colonoscopy. However, only 12,541 (53.0%) of these had 
colonoscopy report form details recorded from which colonoscopy outcome data could be 
reported (Figure 3.3).  
Results from the 12,541 colonoscopies with a completed colonoscopy report form showed 
there were 427 (3.4%) participants with a suspected cancer and 1,710 (13.6%) with 1 or more 
polyps greater than 10 millimetres in size (Table A4.1). The cumulative risk of polyps 
(mainly adenomas) greater than 10 millimetres developing into bowel cancer within 10 years 
is considered to be 8% (Stryker et al. 1987). The removal of these polyps alone could be 
estimated to have stopped a future bowel cancer from developing in about 136 participants 
screened in 2012–13.  
There were a further 5,004 (39.9%) participants with polyps less than or equal to 
10 millimetres, and 3,035 (24.2%) other diagnoses such as diverticular disease or 
haemorrhoids (Table A4.1). About 1 in 5 participants with a positive FOBT who had a 
colonoscopy report form returned were found to have no abnormality.  
Specimen samples were sent to histopathology for most polyps and suspected cancers found 
(data not shown).  
Bowel abnormality detection, including histopathology 
After including the 1,562 histopathology report forms—many of which updated the original 
‘suspected’ colonoscopy diagnosis—the outcomes available for the 12,738 who had a 
colonoscopy or histopathology report form were: 
• 52 participants had bowel cancer detected and confirmed by histopathology 
• 352 participants had suspected bowel cancers that were still awaiting histopathological 
diagnosis 
• 1,231 participants had an adenoma diagnosed by histopathology 
• 5,857 participants were found to have no abnormality (Table A4.2). 
Results for another 5,246 participants awaiting histopathology outcomes for excised polyps 
were not available by 31 December 2013.  
In summary, of the 23,671 people with a positive FOBT: 
• 12,738 had diagnostic outcome information available (above) 
• 3,932 had a colonoscopy that was identified only through a NBCSP-related Medicare 
claim and therefore had no diagnostic outcome data (Figure 3.3) 
• 1,142 were not referred to colonoscopy (Table A3.9).  
Therefore, there were 5,859 (24.8%) people remaining who had received a positive FOBT but 
had no follow-up information recorded.  
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Recruitment
963,518 eligible invitations sent
Screening
321,413 participants returned an 
FOBT for screening
(33.4%)
Assessment
23,671 positive FOBTs
(7.5%)(a)
Diagnosis(b)
12,738 recorded 
colonoscopies
(53.8%)
Recorded colonoscopy outcomes
No cancer or adenoma 5,857 (46.0%)
Polyp awaiting histopathology 5,246  (41.2%)
Diminutive adenoma 303 (2.4%)
Small adenoma 200 (1.6%)
Advanced adenoma 728 (5.7%)
Suspected cancer 352 (2.8%)
Confirmed cancer 52 (0.4%)
 
(a) Based on the 316,418 participants who returned a valid FOBT. 
(b) Additionally, 3,932 participants underwent colonoscopic diagnostic assessment as identified through a Medicare claim. However, these 
were not included as there were no associated outcome data available for analysis. 
Notes 
1. Adenoma classifications are described in Appendix B. 
2. Figure is not to scale. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure 4.1: NBCSP participant outcomes, 2012–13 
Bowel abnormality detection, including histopathology, by population subgroups 
Bowel abnormality detection by state and territory 
As mentioned in the previous chapter, a number of jurisdictions have undertaken projects to 
improve their level of returned histopathology data. For example, Queensland had much 
higher proportions of histopathology-confirmed abnormalities (adenomas and cancers) 
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compared with the other jurisdictions (Table A4.2). However, this is mainly due to having 
more complete data for participant outcomes, rather than a geographical link to higher 
bowel cancer incidence. Therefore, outcome data completeness between jurisdictions needs 
to be taken into account when analysing Table A4.2. 
Considering a number of jurisdictions had run projects to improve histopathology data 
collection, at the national level the percentage of histology-confirmed outcomes (and the 
percentage of polyps awaiting histopathology) was not greatly different from the percentage 
in previous reports (AIHW 2009; AIHW 2010; AIHW 2012b; AIHW 2013). 
Bowel abnormality detection by age and sex 
Table A4.1 presents the recorded colonoscopy diagnoses for people invited into the NBCSP 
in 2012–13; these numbers do not take into account histopathology results that may have 
updated these diagnoses. Conversely, colonoscopist-suspected cancers shown in tables A4.2 
and A4.3 include only those that have not been updated by histopathology to their final 
diagnosis; therefore, Table A4.1 and the later tables show different numbers of suspected 
cancers.  
As would be expected from the known increase in bowel cancer incidence with age 
(see ’Chapter 6 Incidence of bowel cancer’, Section 2), the incidence of abnormalities detected 
at colonoscopy increased with age; 1.9% of people aged 50 who had a colonoscopy returned 
a suspected or confirmed cancer outcome compared with 4.3% for those aged 65 
(Table A4.3).  
Similarly, men (3.7%) showed an incidence of suspected or confirmed cancers that was 
1.4 times that of women (2.6%) (Table A4.3). This was also consistent with known bowel 
cancer incidence in the Australian population. 
Cancer spread status 
While the scope of the NBCSP is to monitor participants up to the point of ‘definite 
diagnosis’ (DoHA 2013a), staging data for confirmed cancers are useful to determine the 
effectiveness of the NBCSP at detecting bowel cancers at a more treatable stage than for those 
diagnosed with symptomatic bowel cancers. Cancers diagnosed at earlier stages are 
generally associated with improved patient prognosis (Morris et al. 2007). 
A biopsy of a suspected cancer taken at colonoscopy is adequate to confirm a cancerous 
growth, but is not usually sufficient to obtain information on the stage and potential 
metastatic spread of the cancer. To gain these data, a sample from a surgical resection (or 
colonoscopic local excision) plus additional biopsies (for example, lymph node) are required. 
If available, these additional data can be recorded on the histopathology report form. 
However, these data cannot be presented in this report due to limited cancer spread 
information returned for the 52 participants with confirmed cancers. 
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5 Adverse events 
What is the adverse event rate within the NBCSP? 
Definition: The proportion of eligible people invited from 1 July 2012 to 30 June 2013 who 
had an adverse event (such as bleeding or perforation) reported after having a 
colonoscopy as part of NBCSP follow-up. 
Rationale: As with any invasive procedure, there is the risk of an adverse event occurring 
with a colonoscopy. Monitoring of adverse events through the NBCSP is important to 
ensure participant safety in the program.  
Data source: National Bowel Cancer Screening Program Register. 
Data quality: Reporting of adverse events after a NBCSP colonoscopy is not mandatory. 
There is a risk an adverse event that occurs days or weeks after the colonoscopy (for 
example, unplanned hospital admission within 30 days of procedure) will not be 
associated with the NBCSP procedure, thus not be recorded in the register using the 
relevant NBCSP adverse event form. These issues would be expected to cause an 
underestimation of adverse events. See ‘Data considerations’, Section 1, for further details. 
Guide to interpretation: This chapter discusses the recorded adverse events for 
participants invited into the NBCSP who had a colonoscopy as a result of a positive FOBT. 
Adverse event data are based on data recorded in the register to 31 December 2013 for 
persons invited from 1 July 2012 to 30 June 2013. Due to the time delay between 
notification of a positive FOBT result and progression to colonoscopy or surgery, data may 
be incomplete. 
While the NBCSP records the number of people referred by PHCPs for various procedures 
(for example, sigmoidoscopy, barium enema, colonoscopy), only outcomes (including 
adverse) of colonoscopy are analysed in this report. 
Persons are counted only once in the reporting period, even if they have more than 1 
adverse event reported during this period. 
As per the adverse event form, unplanned hospital admissions after a colonoscopy are 
recorded only if they occurred within 30 days of the procedure. 
Key results 
• For participants invited in 2012–13, 48 out of 16,670 who underwent colonoscopy (about 
1 in every 347 participants undergoing colonoscopy) recorded an adverse event. 
• Bleeding was the most commonly recorded adverse event, with more recorded for men 
than women. 
• About 1 in every 416 participants undergoing colonoscopy required an unplanned 
hospital admission within 30 days of the colonoscopy. 
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Background information 
Colonoscopy is an invasive procedure performed after preparation of the bowel. The 
procedure is performed under sedation and is considered safe and relatively pain free. 
However, several complications and adverse events are associated with colonoscopy, 
including:  
• intolerance of the bowel preparation—some people develop dizziness, headaches or 
vomiting  
• reaction to the sedatives or anaesthetic—this is very uncommon but is of concern in 
people who have severe heart disease or lung disease  
• perforation (making a hole in the bowel wall) 
• major bleeding from the bowel—this can occur as a result of polyps being removed. 
The draft report of the Quality Working Group to the NBCSP noted that the 2 main 
complications arising were perforation and post-colonoscopic bleeding. A literature review 
by the Quality Working Group showed the risk of death associated with colonoscopy to be 
low, with incidence rates 0.03% or lower. The incidence rate of perforation was 0.07–0.30%, 
and bleeding was found to have an incidence rate of 0.03–2.00% (NBCSP-QWG 2009).  
Overall adverse events  
Table A5.1 shows adverse events recorded up to 31 December 2013 for people invited to 
participate in the NBCSP from 1 July 2012 to 30 June 2013. Of participants with a positive 
FOBT, 16,670 were known to have had a colonoscopy, with 48 (0.3%) having an adverse 
outcome recorded (data not shown). Men recorded more adverse events, with bleeding being 
the most common. The most frequent additional service required because of an adverse 
event was unplanned hospital admission within 30 days of colonoscopy.  
Overall, the recorded incidence rate of a bleeding event related to colonoscopy was 0.2%. 
Smaller numbers were recorded for all other types of adverse event. 
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6 Incidence of bowel cancer 
What do we mean by bowel cancer incidence? 
Definition: The number of people diagnosed with bowel cancer, reported for various 
population subgroups.  
Rationale: Monitoring of bowel cancer incidence statistics alongside the implementation of 
the NBCSP allows an understanding of the potential effect of screening on incidence. 
Data source: Australian Cancer Database (ACD). 
Data quality: Each Australian state and territory has legislation that makes the reporting 
of cancers (excluding basal cell and squamous cell carcinomas of the skin) mandatory. The 
AIHW compiles and maintains the ACD, in partnership with the Australasian Association 
of Cancer Registries, whose member registries provide data to the AIHW annually. This 
began with cases first diagnosed in 1982, and the ACD currently has data on cancers 
diagnosed up to and including 2010, though the 2010 incidence counts for New South 
Wales and the Australian Capital Territory are estimates, as their 2010 incidence data were 
not available. 
Guide to interpretation: Bowel cancer comprises cancer of the colon and cancer of the 
rectum, collectively known as colorectal cancer. An objective of the NBCSP is to reduce the 
incidence of bowel cancer in Australia. Positive FOBTs and subsequent colonoscopies 
identify and remove polyps and adenomas that might develop into cancer, thereby 
reducing future incidence. However, it is expected that during the first few years of the 
NBCSP, incidence rates may increase, as pre-existing, developed cancers (in addition to 
polyps and adenomas) that had not resulted in symptoms are found earlier through 
screening. This should stabilise over time as retesting of participants occurs (for example, 
50-year-olds who are reinvited when they turn 55).  
This chapter provides bowel cancer incidence data, grouped by age, sex and population 
subgroups. See the AIHW National Bowel Cancer Screening Program monitoring report:  
2012–13 supplementary tables webpage for additional tables. 
Detailed numbers and rates for bowel cancer in Australia over time are in the AIHW 
Australian Cancer Incidence and Mortality workbook for colorectal cancer—an interactive 
workbook that currently includes incidence data from 1982 to 2010 and mortality data 
from 1968 to 2011. It is available at <www.aihw.gov.au/acim-books>.  
Key results 
In 2010: 
• 14,860 people were diagnosed with bowel cancer (8,258 males; 6,602 females). 
• Bowel cancer accounted for 13% of all invasive cancers diagnosed, making it the second 
most commonly diagnosed cancer in Australia, after prostate cancer. 
• The age-standardised incidence rate for bowel cancer was 74 per 100,000 males, 51 per 
100,000 females and 62 per 100,000 persons. 
• The risk of being diagnosed by the age of 85 was 1 in 10 for males and 1 in 15 for females.  
• The average age of diagnosis was 68 for males and 70 for females. 
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Detailed bowel cancer incidence analyses 
Bowel cancer incidence by state and territory 
The incidence of bowel cancer varied between jurisdictions in the period 2006 to 2010 
(supplementary tables S1.3a–S1.4c). Tasmania (76 cases per 100,000 persons) and Queensland 
(65) had the highest age-standardised incidence rates, and the Northern Territory and 
Western Australia (each 57) had the lowest.  
Bowel cancer incidence by age and sex 
In 2010, and similar to previous years, newly diagnosed cases of bowel cancer were relatively 
rare in people under 45; however, the incidence rate increased sharply for older age groups 
(Figure 6.1). The highest incidence rates were in people aged 80 and over (more than 400 
cases per 100,000 population). 
 
Source: AIHW Australian Cancer Database. 
Figure 6.1: Age-specific incidence rates of bowel cancer, Australia, 2010 
Trends 
The number of new cases of bowel cancer for males increased between 1996 and 2010 by 
37%, with incidence in females showing a similar increase (36%). While the age-standardised 
rates have decreased gradually between 1996 and 2010 for males (0.4% per year) and for 
females (0.2% per year), the increase in the number of cases due to the ageing population in 
Australia means the burden bowel cancer places on the health-care system is still increasing 
(Figure 6.2 and supplementary tables S1.1a–S1.2c).  
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Note: Rates age-standardised to the Australian 2001 population. 
Source: AIHW Australian Cancer Database. 
Figure 6.2: Incidence and age-standardised incidence rates of bowel cancer, Australia, 1996–2010  
Analysis of NBCSP data shows 606 suspected cancers were detected within the NBCSP in 
2010. Due to limitations in histopathology report form return, it is not possible to accurately 
determine how many of these were actually confirmed and thus registered in the ACD as 
bowel cancers (the NBCSP data for 2010 show 214 of these were confirmed by NBCSP 
histopathology report form).  
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7 Mortality from bowel cancer 
What do we mean by bowel cancer mortality? 
Definition: The number of people who have died from bowel cancer (as the underlying 
cause of death), by various stratifications.  
Rationale: Changes in the number and rate of bowel cancer deaths are monitored to help 
understand the effect of interventions (such as screening and improved treatments). 
Data source: National Mortality Database (NMD). 
Data quality: See Appendix C for further information on mortality data.  
Guide to interpretation: Bowel cancer mortality data from the NMD includes deaths up to 
2011. The denominator is based on ABS estimated resident populations up to 2011. As 
these data are for years prior to the screening data in this report, these outcomes are not 
currently related in any way to the screening activities presented in this report. However, 
they provide a baseline against which to monitor future outcomes. 
A major objective of the NBCSP is to reduce mortality from bowel cancer in Australia 
through early detection and treatment of bowel cancers, and through identifying and 
treating polyps and adenomas that might develop into cancer. It is hoped these outcomes 
will eventually result in a reduction in the number of people who die from bowel cancer; 
however, it may take many years for this effect to become apparent, as polyps and 
adenomas detected at screening now may not have become cancers resulting in death for 
many years. However, even then it is not possible to provide a causal link between any 
changes in mortality rates in relation to the NBCSP. 
See the AIHW National Bowel Cancer Screening Program monitoring report: 2012–13 
supplementary tables webpage for additional tables. As mortality data are enumerated by 
age at death, not age at diagnosis, it is not accurate to analyse NBCSP performance by 
looking at mortality rates of people aged 50, 55 and 65; the NBCSP target ages were 
included for illustrative purposes only. 
Key results 
In 2011: 
• There were 3,999 deaths from bowel cancer in Australia (2,219 males; 1,780 females). 
Bowel cancer accounted for 9% of all deaths from invasive cancers, second only to lung 
cancer. 
• The age-standardised death rate was 20 per 100,000 males and 13 per 100,000 females.  
• The risk of dying from bowel cancer by the age of 85 was 1 in 36 for males, 1 in 59 for 
females and 1 in 46 overall. 
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Detailed bowel cancer mortality analyses 
Bowel cancer mortality by state and territory 
In 2007–2011, Tasmania experienced the highest age-standardised rate of deaths from bowel 
cancer (21 deaths per 100,000 population) followed by the Northern Territory (19). Western 
Australia experienced the lowest age-standardised rate of deaths from bowel cancer (15) 
(supplementary tables S2.3a–S2.4c). 
Bowel cancer mortality by age and sex 
Death from bowel cancer is relatively rare before 50 years of age, with 95% of deaths for 
those aged 50 or over (Figure 7.1). In 2011, the highest age-specific death rates were in the 
oldest age groups—people aged 80–84 (148 per 100,000 population) and 85 and over (210 per 
100,000). There were 1,173 deaths in the 50–69 year age group, 29% of all bowel cancer 
deaths. This age group is currently targeted by the NBCSP; however, the outcomes of 
screening participation may also affect mortality rates in older ages. 
 
Notes 
1. Rates age-standardised to the Australian 2001 population and are expressed per 100,000 population. 
2. Deaths registered in 2011 are based on preliminary versions of cause of death data and are subject to further revision by the ABS. 
Source: AIHW National Mortality Database. 
Figure 7.1: Age-specific mortality rates for bowel cancer (ICD-10 C18–C20), Australia, 2011 
Trends 
Between 1997 and 2011, the age-standardised death rate from bowel cancer fell by an average 
of 2.7% per year for males, 2.8% per year for females, and 2.7% per year overall (Figure 7.2 
and supplementary tables S3.1a–S3.2c). It is expected the NBCSP will, in time, continue to 
contribute to this decline in the death rate.  
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Notes 
1. Rates age-standardised to the Australian 2001 population and are expressed per 100,000 population. 
2. Deaths registered in 1997–2009 are based on the final version of cause of death data; deaths registered in 2010 and 2011 are based on 
revised and preliminary versions, respectively and are subject to further revision by the ABS. 
Source: AIHW National Mortality Database. 
Figure 7.2: Age-standardised mortality rates for bowel cancer, Australia, 1997–2011  
Bowel cancer mortality by region 
In 2007–2011, age-standardised deaths from bowel cancer were higher in Inner regional and 
Outer regional areas of Australia (each with 18 deaths per 100,000) (supplementary tables 
S3.5a–S3.6c). Age-standardised death rates were lowest in Very remote areas (13 deaths 
per 100,000). 
Bowel cancer mortality of Aboriginal and Torres Strait Islander peoples 
Information in the NMD on Aboriginal and Torres Strait Islander status is considered of 
sufficient quality for reporting for New South Wales, Queensland, Western Australia, South 
Australia and the Northern Territory only. 
In 2007–2011 in these jurisdictions, the age-standardised rate of deaths from bowel cancer 
was lower for Aboriginal and Torres Strait Islander people (13 deaths per 100,000) than for 
non-Indigenous people (16 deaths per 100,000) (supplementary tables S3.7a and S3.7b).  
Bowel cancer mortality-to-incidence ratio 
The trends in bowel cancer mortality-to-incidence ratios have been steadily falling for many 
years (Figure 7.3). Any change in these rates due to the NBCSP would depend on the 
number of people screened, the number of precancerous polyps removed and the stage of 
growth at which cancers were detected. However, it would be expected that, at least until 
biennial screening is fully implemented, the NBCSP would assist in ongoing reductions in 
these ratios. 
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Notes 
1. Ratios calculated from rates, age-standardised to the Australian 2001 population. 
2. Deaths registered in 1997–2009 are based on the final version of cause of death data; deaths registered in 2010 are based on revised 
version and are subject to further revision by the ABS. 
Source: AIHW Australian Cancer Database and AIHW National Mortality Database. 
Figure 7.3: Trends in mortality-to-incidence ratios for bowel cancer, Australia, 1997–2010  
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Appendix A Additional data 
A1 Participation tables and figures 
Table A1.1: Screening invitation, by state and territory, 2012–13 
 NSW Vic Qld WA SA Tas ACT NT Australia 
Invitations issued to the eligible population(a)(b) 
50 years 100,166 79,360 68,186 37,908 25,305 8,042 5,108 5,033 329,108 
55 years 124,368 94,515 78,526 41,778 30,521 9,934 6,051 4,292 389,985 
65 years 76,208 58,564 49,760 26,563 20,152 6,861 3,681 2,636 244,425 
Total 300,742 232,439 196,472 106,249 75,978 24,837 14,840 11,961 963,518 
Persons suspended(c) 
50 years 1,041 837 641 329 295 91 68 41 3,343 
55 years 1,510 1,215 1,074 515 502 133 100 43 5,092 
65 years 1,706 1,299 1,194 559 516 164 90 39 5,567 
Total 4,257 3,351 2,909 1,403 1,313 388 258 123 14,002 
Persons opting off(d) 
50 years 1,603 1,305 1,062 548 408 137 91 40 5,194 
55 years 2,519 1,940 1,671 786 717 229 115 72 8,049 
65 years 3,761 2,928 2,610 1,311 1,043 368 166 93 12,280 
Total 7,883 6,173 5,343 2,645 2,168 734 372 205 25,523 
Persons participating(e) 
50 years 25,687 22,738 17,562 11,374 7,873 2,391 1,553 1,083 90,261 
55 years 38,597 32,326 24,975 15,254 11,353 3,662 2,249 1,063 129,479 
65 years 29,670 23,951 20,716 11,854 9,732 3,244 1,682 824 101,673 
Total 93,954 79,015 63,253 38,482 28,958 9,297 5,484 2,970 321,413 
Total respondents(f) 
50 years 28,331 24,880 19,265 12,251 8,576 2,619 1,712 1,164 98,798 
55 years 42,626 35,481 27,720 16,555 12,572 4,024 2,464 1,178 142,620 
65 years 35,137 28,178 24,520 13,724 11,291 3,776 1,938 956 119,520 
Total 106,094 88,539 71,505 42,530 32,439 10,419 6,114 3,298 360,938 
(a) Invitations to screen were issued from 1 July 2012 to 30 June 2013 to members of the Australian population (registered as Australian 
citizens or migrants in the Medicare enrolment file, or who are registered with a Department of Veterans’ Affairs gold card) who turned 50, 55 
or 65 from 1 January 2012 to 30 June 2013. Some invitations were sent to non-target ages on request, or due to various pilot projects. 
(b) There were 1,856 invitations sent to those not of the 3 target ages at the time of invitation, or to addresses overseas (making 965,374 
invitations in total). These were excluded from the eligible population and further analysis. 
(c) ‘Persons suspended’ refers to the eligible population invited who did not return a faecal occult blood test (FOBT) kit, but elected to suspend 
participation until a later date.  
(d) ‘Persons opting off’ refers to the eligible population invited who did not return an FOBT kit, but elected to opt off. 
(e) ‘Persons participating’ refers to the eligible population invited who returned an FOBT kit for analysis, regardless of whether it was correctly 
completed or if they later suspended or opted off. 
(f) ‘Total respondents’ refers to the eligible population invited who returned a response (returned an FOBT kit, or suspension/opt-off request). 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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Table A1.2: Crude participation, by state and territory, 2012–13 
 NSW Vic Qld WA SA Tas ACT NT Australia 
Males 
50 years Number 12,166 10,479 8,240 5,411 3,701 1,044 755 528 42,324 
 Per cent 24.0 26.3 24.0 28.1 29.1 26.2 29.3 20.1 25.5 
55 years Number 17,681 14,688 11,430 7,096 5,088 1,661 1,031 533 59,208 
 Per cent 28.5 31.4 29.1 33.6 33.5 33.5 35.0 23.8 30.5 
65 years Number 14,170 11,228 9,904 5,802 4,541 1,569 791 449 48,454 
 Per cent 36.9 39.0 39.2 42.8 45.9 45.3 43.8 29.8 39.5 
Total Number 44,017 36,395 29,574 18,309 13,330 4,274 2,577 1,510 149,986 
 Per cent 29.2 31.5 29.9 33.9 35.3 34.5 35.1 23.7 31.1 
Females 
50 years Number 13,521 12,259 9,322 5,963 4,172 1,347 798 555 47,937 
 Per cent 27.3 31.0 27.5 32.0 33.2 33.2 31.6 23.1 29.4 
55 years Number 20,916 17,638 13,545 8,158 6,265 2,001 1,218 530 70,271 
 Per cent 33.5 37.0 34.5 39.5 40.8 40.2 39.2 25.8 35.9 
65 years Number 15,500 12,723 10,812 6,052 5,191 1,675 891 375 53,219 
 Per cent 41.0 42.7 44.1 46.6 50.6 49.3 47.5 33.2 43.7 
Total Number 49,937 42,620 33,679 20,173 15,628 5,023 2,907 1,460 171,427 
 Per cent 33.3 36.4 34.5 38.6 40.9 40.4 38.7 26.1 35.7 
Persons 
50 years Number 25,687 22,738 17,562 11,374 7,873 2,391 1,553 1,083 90,261 
 Per cent 25.6 28.7 25.8 30.0 31.1 29.7 30.4 21.5 27.4 
55 years Number 38,597 32,326 24,975 15,254 11,353 3,662 2,249 1,063 129,479 
 Per cent 31.0 34.2 31.8 36.5 37.2 36.9 37.2 24.8 33.2 
65 years Number 29,670 23,951 20,716 11,854 9,732 3,244 1,682 824 101,673 
 Per cent 38.9 40.9 41.6 44.6 48.3 47.3 45.7 31.3 41.6 
Total Number 93,954 79,015 63,253 38,482 28,958 9,297 5,484 2,970 321,413 
 Per cent 31.2 34.0 32.2 36.2 38.1 37.4 37.0 24.8 33.4 
Notes 
1. Participants in the program were defined as members of the eligible population who returned a completed FOBT kit, regardless of whether it 
was correctly completed.  
2. Percentages equal people participating as a proportion of the total number of the eligible population who were invited to screen. This includes 
people who suspended or opted off. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A1.1: Participation, by weeks since invitation using Kaplan–Meier estimates,  
by state and territory, 2012–13 
 
 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A1.2: Participation, by weeks since invitation using Kaplan–Meier estimates,  
by age, 2012–13 
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Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A1.3: Participation, by weeks since invitation using Kaplan–Meier estimates,  
by sex, 2012–13 
2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52
Weeks following invitation
0
10
20
30
40
50
FemalesMales
People participating (per cent)
 50 National Bowel Cancer Screening Program monitoring report: 2012–13 
Table A1.3: Crude participation, by remoteness area, 2012–13  
 Remoteness area  
 Major cities Inner regional Outer regional Remote Very remote Unknown Total 
Males 
50 years Number 28,929 7,841 4,259 558 217 519 42,324 
 Per cent 25.9 25.4 24.7 21.9 16.9 24.8 25.5 
55 years Number 38,946 12,152 6,304 792 304 710 59,208 
 Per cent 30.2 31.7 31.0 27.4 22.6 30.4 30.5 
65 years Number 30,178 11,217 5,572 607 228 653 48,454 
 Per cent 38.5 42.6 40.7 36.0 28.1 36.2 39.5 
Total Number 98,052 31,210 16,136 1,958 749 1,882 149,986 
 Per cent 30.7 32.7 31.5 27.5 21.8 30.2 31.1 
Females 
50 years Number 32,405 9,452 4,711 627 228 515 47,937 
 Per cent 29.4 30.3 29.0 26.5 18.2 28.1 29.4 
55 years Number 46,485 14,782 7,132 874 287 711 70,271 
 Per cent 35.2 38.2 37.5 34.8 23.6 34.4 35.9 
65 years Number 33,481 12,543 5,856 571 194 574 53,219 
 Per cent 42.1 47.8 46.6 40.6 31.4 43.5 43.7 
Total Number 112,371 36,777 17,698 2,071 709 1,800 171,427 
 Per cent 34.9 38.3 37.0 33.0 23.0 34.5 35.7 
Persons 
50 years Number 61,334 17,293 8,970 1,185 445 1,034 90,261 
 Per cent 27.6 27.9 26.8 24.1 17.6 26.4 27.4 
55 years Number 85,431 26,934 13,436 1,666 591 1,421 129,479 
 Per cent 32.7 35.0 34.1 30.9 23.1 32.3 33.2 
65 years Number 63,659 23,759 11,428 1,178 422 1,227 101,673 
 Per cent 40.3 45.2 43.5 38.1 29.5 39.3 41.6 
Total Number 210,424 67,987 33,834 4,029 1,458 3,682 321,413 
 Per cent 32.8 35.5 34.1 30.0 22.3 32.2 33.4 
Notes  
1. Percentages equal the number of people returning a completed FOBT kit (regardless of whether it was correctly completed) as a proportion 
of the eligible population invited to screen. 
2. The residential postcodes of invitees and respondents were mapped to remoteness areas in the 2011 Australian Statistical Geography 
Standard remoteness structure through a postal area correspondence. Those that could not be mapped were included in the ‘Unknown’ 
column. 
3. Discrepancies may occur between totals and sums of the component items due to rounding—see ‘Geographical classification’, Appendix C. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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Notes 
1. Rate per remoteness area is an average of participation across that remoteness area. 
2. Participation rates rounded to integers. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A1.4a: Crude participation, by remoteness area, New South Wales, 2012–13 
 
 
Notes 
1. Rate per remoteness area is an average of participation across that remoteness area. 
2. Participation rates rounded to integers. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A1.4b: Crude participation, by remoteness area, Victoria, 2012–13 
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Notes 
1. Rate per remoteness area is an average of participation across that remoteness area. 
2. Participation rates rounded to integers. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A1.4c: Crude participation, by remoteness area, Queensland, 2012–13 
 
 
Notes 
1. Rate per remoteness area is an average of participation across that remoteness area. 
2. Participation rates rounded to integers. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A1.4d: Crude participation, by remoteness area, Western Australia, 2012–13 
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Notes 
1. Rate per remoteness area is an average of participation across that remoteness area. 
2. Participation rates rounded to integers. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A1.4e: Crude participation, by remoteness area, South Australia, 2012–13 
 
 
Notes 
1. Rate per remoteness area is an average of participation across that remoteness area. 
2. Participation rates rounded to integers. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A1.4f: Crude participation, by remoteness area, Tasmania, 2012–13 
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Notes 
1. Rate per remoteness area is an average of participation across that remoteness area. 
2. Participation rates rounded to integers. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A1.4g: Crude participation, by remoteness area, Australian Capital Territory, 2012–13 
 
 
Notes 
1. Rate per remoteness area is an average of participation across that remoteness area. 
2. Participation rates rounded to integers. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A1.4h: Crude participation, by remoteness area, Northern Territory, 2012–13 
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Table A1.4: Crude participation, by socioeconomic status area, 2012–13 
 Socioeconomic status area  
 1 (lowest) 2 3 4 5 (highest) Unknown Total 
Males 
50 years Number 7,286 7,932 8,288 8,952 9,235 631 42,324 
 Per cent 22.9 24.3 25.2 26.7 28.3 25.2 25.5 
55 years Number 10,791 11,802 11,567 11,764 12,407 877 59,208 
 Per cent 28.3 30.2 30.3 31.1 32.4 31.3 30.5 
65 years Number 9,189 10,417 9,341 9,096 9,620 791 48,454 
 Per cent 37.4 40.6 39.4 39.9 40.5 37.2 39.5 
Total Number 27,266 30,151 29,196 29,812 31,262 2,299 149,986 
 Per cent 28.8 30.9 30.8 31.7 33.1 31.0 31.1 
Females 
50 years Number 7,945 9,230 9,240 10,048 10,843 631 47,937 
 Per cent 26.4 28.6 28.8 30.5 32.4 28.3 29.4 
55 years Number 12,485 13,911 13,678 14,218 15,120 859 70,271 
 Per cent 33.4 35.7 35.4 37.0 38.0 35.3 35.9 
65 years Number 10,255 11,333 10,285 10,052 10,566 728 53,219 
 Per cent 41.9 44.8 43.2 44.4 44.0 44.9 43.7 
Total Number 30,685 34,474 33,203 34,318 36,529 2,218 171,427 
 Per cent 33.4 35.7 35.2 36.5 37.6 35.3 35.7 
Persons 
50 years Number 15,231 17,162 17,528 19,000 20,078 1,262 90,261 
 Per cent 24.6 26.4 27.0 28.6 30.4 26.7 27.4 
55 years Number 23,276 25,713 25,245 25,982 27,527 1,736 129,479 
 Per cent 30.8 33.0 32.9 34.0 35.3 33.2 33.2 
65 years Number 19,444 21,750 19,626 19,148 20,186 1,519 101,673 
 Per cent 39.7 42.7 41.3 42.1 42.3 40.6 41.6 
Total Number 57,951 64,625 62,399 64,130 67,791 4,517 321,413 
 Per cent 31.1 33.3 33.0 34.1 35.3 33.0 33.4 
Notes  
1. Percentages equal the number of people returning a completed FOBT kit as a proportion of the total number of the eligible population who 
were invited to screen. 
2. An invitee’s socioeconomic status area was classified by mapping their residential postcode (through a postal area) to the Australian Bureau 
of Statistics (ABS) Index of Relative Socio-economic Disadvantage (IRSD) for 2011. Those that could not be mapped were included in the 
‘Unknown’ column.  
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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Table A1.5: Proportion of participants who indicated Aboriginal and Torres Strait Islander status, 2012–13 
 NBCSP participants  2011 Census 
 Indigenous Non-Indigenous Not stated Total 
Number  
 Indigenous Non-Indigenous Not stated 
 Number Per cent Number Per cent Number Per cent  Per cent 
Males            
50 years 301 0.7 40,172 94.9 1,851 4.4 42,324  1.7 93.1 5.2 
55 years 429 0.7 56,802 95.9 1,977 3.3 59,208  1.5 93.4 5.1 
65 years 236 0.5 46,346 95.6 1,872 3.9 48,454  1.0 94.2 4.9 
Total 966 0.6 143,320 95.6 5,700 3.8 149,986  1.5 93.5 5.1 
Females              
50 years 351 0.7 46,106 96.2 1,480 3.1 47,937  1.9 94.2 3.9 
55 years 462 0.7 68,162 97.0 1,647 2.3 70,271  1.6 94.5 4.0 
65 years 239 0.4 51,383 96.6 1,597 3.0 53,219  1.1 94.7 4.2 
Total 1,052 0.6 165,651 96.6 4,724 2.8 171,427  1.6 94.4 4.0 
Persons            
50 years 652 0.7 86,278 95.6 3,331 3.7 90,261  1.8 93.7 4.5 
55 years 891 0.7 124,964 96.5 3,624 2.8 129,479  1.5 93.9 4.5 
65 years 475 0.5 97,729 96.1 3,469 3.4 101,673  1.0 94.4 4.5 
Total 2,018 0.6 308,971 96.1 10,424 3.2 321,413  1.5 93.9 4.5 
Notes  
1. National Bowel Cancer Screening Program (NBCSP) percentages equal the number of people returning a completed FOBT who indicated their Aboriginal and Torres Strait Islander status as a proportion of all people 
returning an FOBT (regardless of whether they were correctly completed).  
2. NBCSP Aboriginal and Torres Strait Islander status was reported by the participant on the returned participant details form. Participants who did not indicate Aboriginal and Torres Strait Islander status were included in 
the ‘Not stated’ column. 
3. Indigenous status proportions as recorded at the 2011 Australian Census of Population and Housing are included for comparative purposes. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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Table A1.6: Proportion of participants who indicated preferred language spoken at home, 2012–13 
 NBCSP participants  2011 Census 
 
Language other than 
English English Total 
Number  
 Language other than 
English English Not stated 
 Number Per cent Number Per cent  Per cent 
Males          
50 years 5,799 13.7 36,525 86.3 42,324  16.4 78.3 5.3 
55 years 7,952 13.4 51,256 86.6 59,208  15.8 79.1 5.1 
65 years 5,182 10.7 43,272 89.3 48,454  14.5 80.8 4.7 
Total 18,933 12.6 131,053 87.4 149,986  15.7 79.2 5.1 
Females            
50 years 6,959 14.5 40,978 85.5 47,937  17.4 78.9 3.7 
55 years 10,044 14.3 60,227 85.7 70,271  17.6 78.6 3.8 
65 years 5,749 10.8 47,470 89.2 53,219  15.5 80.6 3.9 
Total 22,752 13.3 148,675 86.7 171,427  17.0 79.2 3.8 
Persons          
50 years 12,758 14.1 77,503 85.9 90,261  16.9 78.6 4.5 
55 years 17,996 13.9 111,483 86.1 129,479  16.7 78.8 4.4 
65 years 10,931 10.8 90,742 89.2 101,673  15.0 80.7 4.3 
Total 41,685 13.0 279,728 87.0 321,413  16.3 79.2 4.4 
Notes  
1. NBCSP percentages equal the number of people returning a completed FOBT who indicated their preferred language spoken at home as a proportion of all people returning an FOBT 
(regardless of whether they were correctly completed).  
2. NBCSP preferred language spoken at home was reported by the participant on the returned participant details form. Participants who did not indicate preferred language spoken at home 
were assumed to speak English. 
3. Language spoken at home proportions as recorded at the 2011 Australian Census of Population and Housing are included for comparative purposes. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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Table A1.7: Proportion of participants who indicated disability status, 2012–13 
 NBCSP participants  2011 Census 
 
Severe or profound 
activity limitation 
No severe or profound 
activity limitation Not stated Total 
Number  
 
Severe or profound 
activity limitation 
No severe or 
profound activity 
limitation Not stated 
 Number Per cent Number Per cent Number Per cent  Per cent 
Males            
50 years 1,526 3.6 36,948 87.3 3,850 9.1 42,324  3.1 91.0 5.9 
55 years 2,319 3.9 52,013 87.8 4,876 8.2 59,208  3.9 90.5 5.6 
65 years 3,197 6.6 41,410 85.5 3,847 7.9 48,454  8.1 86.7 5.2 
Total 7,042 4.7 130,371 86.9 12,573 8.4 149,986  4.7 89.7 5.6 
Females              
50 years 2,066 4.3 42,449 88.6 3,422 7.1 47,937  3.3 92.4 4.3 
55 years 3,367 4.8 62,272 88.6 4,632 6.6 70,271  4.3 91.4 4.3 
65 years 2,949 5.5 46,774 87.9 3,496 6.6 53,219  6.2 89.5 4.4 
Total 8,382 4.9 151,495 88.4 11,550 6.7 171,427  4.4 91.3 4.3 
Persons            
50 years 3,592 4.0 79,397 88.0 7,272 8.1 90,261  3.2 91.7 5.1 
55 years 5,686 4.4 114,285 88.3 9,508 7.3 129,479  4.1 91.0 4.9 
65 years 6,146 6.0 88,184 86.7 7,343 7.2 101,673  7.1 88.1 4.8 
Total 15,424 4.8 281,866 87.7 24,123 7.5 321,413  4.6 90.5 4.9 
Notes  
1. NBCSP percentages equal the number of people returning a completed FOBT who indicated their disability status as a proportion of all people returning an FOBT (regardless of whether they were correctly completed).  
2. NBCSP disability status was reported by the participant on the participant details form. Participants who did not indicate disability status are included in the ‘Not stated’ column. 
3. A ‘profound’ activity limitation indicates that a person always needs assistance with self-care, movement and/or communications activities. A ‘severe’ activity limitation indicates that a person sometimes needs assistance 
with these activities.  
4. Activity limitation status proportions as recorded at the 2011 Australian Census of Population and Housing are included for comparative purposes. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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A2 Faecal occult blood test outcome tables 
Table A2.1: FOBT results for correctly completed kits, by age and sex, 2012–13 
 
FOBT positive FOBT negative FOBT inconclusive Total 
Number Per cent Number Per cent Number Per cent Number 
Males        
50 years 2,852 6.9 38,720 93.1 22 0.1 41,594 
55 years 4,369 7.5 53,940 92.5 32 0.1 58,341 
65 years 5,051 10.6 42,687 89.4 15 — 47,753 
Total 12,272 8.3 135,347 91.6 69 — 147,688 
Females        
50 years 2,891 6.1 44,216 93.8 39 0.1 47,146 
55 years 4,309 6.2 64,956 93.7 34 — 69,299 
65 years 4,199 8.0 48,228 92.0 12 — 52,439 
Total 11,399 6.7 157,400 93.2 85 0.1 168,884 
Persons        
50 years 5,743 6.5 82,936 93.5 61 0.1 88,740 
55 years 8,678 6.8 118,896 93.1 66 0.1 127,640 
65 years 9,250 9.2 90,915 90.7 27 — 100,192 
Total 23,671 7.5 292,747 92.5 154 — 316,572 
Notes 
1. Percentages equal the number of participants with FOBT results in each category in terms of ‘positive’, ‘negative’ and ‘inconclusive’ as a 
proportion of the total number of participants with correctly completed FOBTs. 
2. For participants who returned more than 1 FOBT kit, a positive result was selected over any other result, and a negative result was selected 
over an inconclusive result. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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Table A2.2: FOBT positivity rates, by age and sex, 2012–13  
 Positive tests (number) Valid results (number) Positivity rate (per cent) 
Males    
50 years 2,852 41,572 6.9 
55 years 4,369 58,309 7.5 
65 years 5,051 47,738 10.6 
Total 12,272 147,619 8.3 
Females    
50 years 2,891 47,107 6.1 
55 years 4,309 69,265 6.2 
65 years 4,199 52,427 8.0 
Total 11,399 168,799 6.8 
Persons    
50 years 5,743 88,679 6.5 
55 years 8,678 127,574 6.8 
65 years 9,250 100,165 9.2 
Total 23,671 316,418 7.5 
Note: Positivity rate equals the number of participants with positive FOBT results as a percentage of the total number of participants with valid 
results. A valid result was either positive or negative; inconclusive results were excluded. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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Table A2.3: FOBT positivity rates, by state and territory, 2012–13  
 NSW Vic Qld WA SA Tas ACT NT Australia 
Males 
50 years Positive tests 832 689 585 339 251 63 50 43 2,852 
 Positivity rate 7.0 6.7 7.2 6.4 6.9 6.1 6.7 8.4 6.9 
55 years Positive tests 1,257 1,126 815 529 415 126 61 40 4,369 
 Positivity rate 7.2 7.8 7.2 7.6 8.3 7.7 6.0 7.7 7.5 
65 years Positive tests 1,462 1,155 1,042 594 478 180 78 62 5,051 
 Positivity rate 10.5 10.4 10.7 10.4 10.7 11.6 10.0 14.2 10.6 
Total Positive tests 3,551 2,970 2,442 1,462 1,144 369 189 145 12,272 
 Positivity rate 8.2 8.3 8.4 8.2 8.7 8.8 7.4 9.9 8.3 
Females 
50 years Positive tests 804 771 567 344 255 72 42 36 2,891 
 Positivity rate 6.1 6.4 6.2 5.9 6.2 5.4 5.4 6.7 6.1 
55 years Positive tests 1,312 1,128 783 458 411 109 73 35 4,309 
 Positivity rate 6.4 6.5 5.9 5.7 6.6 5.5 6.0 6.7 6.2 
65 years Positive tests 1,238 1,033 793 457 438 136 72 32 4,199 
 Positivity rate 8.1 8.2 7.4 7.7 8.5 8.2 8.2 8.7 8.0 
Total Positive tests 3,354 2,932 2,143 1,259 1,104 317 187 103 11,399 
 Positivity rate 6.8 7.0 6.5 6.4 7.2 6.4 6.5 7.2 6.8 
Persons 
50 years Positive tests 1,636 1,460 1,152 683 506 135 92 79 5,743 
 Positivity rate 6.5 6.5 6.7 6.2 6.5 5.7 6.0 7.5 6.5 
55 years Positive tests 2,569 2,254 1,598 987 826 235 134 75 8,678 
 Positivity rate 6.8 7.1 6.5 6.6 7.4 6.5 6.0 7.2 6.8 
65 years Positive tests 2,700 2,188 1,835 1,051 916 316 150 94 9,250 
 Positivity rate 9.2 9.3 9.0 9.0 9.5 9.9 9.0 11.7 9.2 
Total Positive tests 6,905 5,902 4,585 2,721 2,248 686 376 248 23,671 
 Positivity rate 7.5 7.6 7.4 7.2 7.9 7.5 6.9 8.6 7.5 
Notes 
1. Positive tests equal the number of FOBTs that returned a positive result. 
2. Positivity rate equals the number of participants with positive FOBT results as a percentage of the total number of participants with valid 
results. A valid result was either positive or negative; inconclusive results were excluded. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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Table A2.4: FOBT positivity rates, by geographical region, 2012–13  
 Remoteness area  
 Major cities Inner regional Outer regional Remote Very remote Unknown Total 
Males 
50 years Positive tests 1,922 520 308 48 18 35 2,852 
 Positivity rate 6.8 6.7 7.4 8.9 8.9 6.9 6.9 
55 years Positive tests 2,806 922 506 56 25 53 4,369 
 Positivity rate 7.3 7.7 8.2 7.2 8.8 7.6 7.5 
65 years Positive tests 3,088 1,150 628 80 31 73 5,051 
 Positivity rate 10.4 10.4 11.4 13.5 14.1 11.4 10.6 
Total Positive tests 7,817 2,592 1,443 184 75 161 12,272 
 Positivity rate 8.1 8.4 9.1 9.6 10.4 8.7 8.3 
Females 
50 years Positive tests 1,990 540 283 33 18 26 2,891 
 Positivity rate 6.3 5.8 6.1 5.5 8.4 5.2 6.1 
55 years Positive tests 2,811 924 454 57 20 43 4,309 
 Positivity rate 6.1 6.3 6.5 6.7 7.0 6.1 6.2 
65 years Positive tests 2,618 1,009 464 42 16 50 4,199 
 Positivity rate 7.9 8.1 8.0 7.6 8.3 8.8 8.0 
Total Positive tests 7,419 2,473 1,201 133 54 119 11,399 
 Positivity rate 6.7 6.8 6.9 6.6 7.8 6.7 6.8 
Persons 
50 years Positive tests 3,912 1,060 591 81 37 61 5,743 
 Positivity rate 6.5 6.2 6.7 7.1 8.6 6.0 6.5 
55 years Positive tests 5,618 1,846 961 113 45 96 8,678 
 Positivity rate 6.7 6.9 7.3 6.9 7.9 6.9 6.8 
65 years Positive tests 5,706 2,160 1,092 122 47 123 9,250 
 Positivity rate 9.1 9.2 9.7 10.6 11.4 10.2 9.2 
Total Positive tests 15,236 5,065 2,644 317 128 280 23,671 
 Positivity rate 7.4 7.6 7.9 8.0 9.1 7.7 7.5 
Notes  
1. Positive tests equal the number of FOBTs that returned a positive result. 
2. Positivity rate equals the number of participants with positive FOBT results as a percentage of the total number of participants with valid 
results. A valid result was either positive or negative; inconclusive results were excluded. 
3. The residential postcodes of participants were mapped to remoteness areas in the 2011 Australian Statistical Geography Standard 
remoteness structure through a postal area correspondence. Those that could not be mapped were included in the ‘Unknown’ column.  
4. Discrepancies may occur between totals and sums of the component items due to rounding—see ‘Geographical classification’, Appendix C. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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Notes 
1. Rate per remoteness area is an average of positivity across that remoteness area. 
2. Positivity rates rounded to 1 decimal place. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A2.1a: FOBT positivity, by remoteness area, New South Wales, 2012–13 
 
 
Notes 
1. Rate per remoteness area is an average of positivity across that remoteness area. 
2. Positivity rates rounded to 1 decimal place. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A2.1b: FOBT positivity, by remoteness area, Victoria, 2012–13 
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Notes 
1. Rate per remoteness area is an average of positivity across that remoteness area. 
2. Positivity rates rounded to 1 decimal place. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A2.1c: FOBT positivity, by remoteness area, Queensland, 2012–13 
 
 
Notes 
1. Rate per remoteness area is an average of positivity across that remoteness area. 
2. Positivity rates rounded to 1 decimal place. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A2.1d: FOBT positivity, by remoteness area, Western Australia, 2012–13 
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Notes 
1. Rate per remoteness area is an average of positivity across that remoteness area. 
2. Positivity rates rounded to 1 decimal place. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A2.1e: FOBT positivity, by remoteness area, South Australia, 2012–13 
 
 
Notes 
1. Rate per remoteness area is an average of positivity across that remoteness area. 
2. Positivity rates rounded to 1 decimal place. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A2.1f: FOBT positivity, by remoteness area, Tasmania, 2012–13 
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Notes 
1. Remoteness areas left unshaded contain data that are not publishable due to small numbers, confidentiality or other concerns.  
2. Rate per remoteness area is an average of positivity across that remoteness area. 
3. Positivity rates rounded to 1 decimal place. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A2.1g: FOBT positivity, by remoteness area, Australian Capital Territory, 2012–13 
 
 
Notes 
1. Rate per remoteness area is an average of positivity across that remoteness area. 
2. Positivity rates rounded to 1 decimal place. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A2.1h: FOBT positivity, by remoteness area, Northern Territory, 2012–13 
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Table A2.5: FOBT positivity rates, by socioeconomic status area, 2012–13  
 Socioeconomic status area  
 1 (lowest) 2 3 4 5 (highest) Unknown Total 
Males 
50 years Positive tests 559 572 556 578 546 41 2,852 
 Positivity rate 7.9 7.4 6.8 6.6 6.0 6.7 6.9 
55 years Positive tests 916 919 912 814 746 62 4,369 
 Positivity rate 8.6 7.9 8.0 7.0 6.1 7.2 7.5 
65 years Positive tests 1,102 1,181 1,001 870 813 84 5,051 
 Positivity rate 12.2 11.5 10.9 9.7 8.6 10.8 10.6 
Total Positive tests 2,577 2,672 2,469 2,262 2,105 187 12,272 
 Positivity rate 9.6 9.0 8.6 7.7 6.8 8.3 8.3 
Females 
50 years Positive tests 540 581 561 573 604 32 2,891 
 Positivity rate 6.9 6.4 6.2 5.8 5.7 5.2 6.1 
55 years Positive tests 869 909 828 847 805 51 4,309 
 Positivity rate 7.1 6.6 6.1 6.0 5.4 6.0 6.2 
65 years Positive tests 928 913 807 758 731 62 4,199 
 Positivity rate 9.2 8.2 8.0 7.6 7.0 8.7 8.0 
Total Positive tests 2,337 2,403 2,196 2,178 2,140 145 11,399 
 Positivity rate 7.8 7.1 6.7 6.4 5.9 6.7 6.8 
Persons 
50 years Positive tests 1,099 1,153 1,117 1,151 1,150 73 5,743 
 Positivity rate 7.4 6.8 6.5 6.2 5.8 6.0 6.5 
55 years Positive tests 1,785 1,828 1,740 1,661 1,551 113 8,678 
 Positivity rate 7.8 7.2 7.0 6.5 5.7 6.6 6.8 
65 years Positive tests 2,030 2,094 1,808 1,628 1,544 146 9,250 
 Positivity rate 10.6 9.8 9.3 8.6 7.8 9.8 9.2 
Total Positive tests 4,914 5,075 4,665 4,440 4,245 332 23,671 
 Positivity rate 8.6 8.0 7.6 7.0 6.3 7.5 7.5 
Notes  
1. Positive tests equal the number of FOBTs that returned a positive result. 
2. Positivity rate equals the number of participants with positive FOBT results as a percentage of the total number of participants with valid 
results. A valid result was either positive or negative; inconclusive results were excluded. 
3. A participant’s socioeconomic status area was classified by mapping their residential postcode (through a postal area) to the ABS IRSD for 
2011. Those that could not be mapped were included in the ‘Unknown’ column. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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Table A2.6: FOBT positivity rates, by Aboriginal and Torres Strait Islander status, 2012–13  
 Indigenous Non-Indigenous Not stated Total 
Males      
50 years Positive tests 22 2,673 157 2,852 
 Positivity rate 7.5 6.8 8.9 6.9 
55 years Positive tests 57 4,135 177 4,369 
 Positivity rate 14.0 7.4 9.4 7.5 
65 years Positive tests 32 4,795 224 5,051 
 Positivity rate 13.9 10.5 12.6 10.6 
Total Positive tests 111 11,603 558 12,272 
 Positivity rate 11.9 8.2 10.3 8.3 
Females 
50 years Positive tests 23 2,762 106 2,891 
 Positivity rate 6.8 6.1 7.5 6.1 
55 years Positive tests 43 4,150 116 4,309 
 Positivity rate 9.6 6.2 7.4 6.2 
65 years Positive tests 29 4,012 158 4,199 
 Positivity rate 12.5 7.9 10.6 8.0 
Total Positive tests 95 10,924 380 11,399 
 Positivity rate 9.3 6.7 8.5 6.8 
Persons 
50 years Positive tests 45 5,435 263 5,743 
 Positivity rate 7.2 6.4 8.3 6.5 
55 years Positive tests 100 8,285 293 8,678 
 Positivity rate 11.7 6.7 8.5 6.8 
65 years Positive tests 61 8,807 382 9,250 
 Positivity rate 13.2 9.1 11.7 9.2 
Total Positive tests 206 22,527 938 23,671 
 Positivity rate 10.6 7.4 9.5 7.5 
Notes 
1. Positive tests equal the number of FOBTs that returned a positive result. 
2. Positivity rate equals the number of participants with positive FOBT results as a percentage of the total number of participants with valid 
results. A valid result was either positive or negative; inconclusive results were excluded. 
3. NBCSP Aboriginal and Torres Strait Islander status was reported by the participant on the returned participant details form. Participants 
who did not indicate Aboriginal and Torres Strait Islander status were included in the ‘Not stated’ column. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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Table A2.7: FOBT positivity rates, by language spoken at home, 2012–13  
 Language other than English English Total 
Males 
50 years Positive tests 421 2,431 2,852 
 Positivity rate 7.4 6.8 6.9 
55 years Positive tests 630 3,739 4,369 
 Positivity rate 8.0 7.4 7.5 
65 years Positive tests 569 4,482 5,051 
 Positivity rate 11.2 10.5 10.6 
Total Positive tests 1,620 10,652 12,272 
 Positivity rate 8.7 8.3 8.3 
Females 
50 years Positive tests 470 2,421 2,891 
 Positivity rate 6.9 6.0 6.1 
55 years Positive tests 674 3,635 4,309 
 Positivity rate 6.8 6.1 6.2 
65 years Positive tests 484 3,715 4,199 
 Positivity rate 8.6 7.9 8.0 
Total Positive tests 1,628 9,771 11,399 
 Positivity rate 7.3 6.7 6.8 
Persons 
50 years Positive tests 891 4,852 5,743 
 Positivity rate 7.1 6.4 6.5 
55 years Positive tests 1,304 7,374 8,678 
 Positivity rate 7.4 6.7 6.8 
65 years Positive tests 1,053 8,197 9,250 
 Positivity rate 9.9 9.2 9.2 
Total Positive tests 3,248 20,423 23,671 
 Positivity rate 7.9 7.4 7.5 
Notes 
1. Positive tests equal the number of FOBTs that returned a positive result. 
2. Positivity rate equals the number of participants with positive FOBT results as a percentage of the total number of participants with valid 
results. A valid result was either positive or negative; inconclusive results were excluded. 
3. NBCSP preferred language spoken at home was reported by the participant on the returned participant details form. Participants who did not 
indicate preferred language spoken at home were assumed to speak English. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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Table A2.8: FOBT positivity rates, by disability status, 2012–13  
 
Severe or profound 
activity limitation 
No severe or profound 
activity limitation Not stated Total 
Males 
50 years Positive tests 161 2,444 247 2,852 
 Positivity rate 10.9 6.7 6.7 6.9 
55 years Positive tests 283 3,729 357 4,369 
 Positivity rate 12.5 7.3 7.6 7.5 
65 years Positive tests 490 4,201 360 5,051 
 Positivity rate 15.6 10.3 9.7 10.6 
Total Positive tests 934 10,374 964 12,272 
 Positivity rate 13.6 8.1 7.9 8.3 
Females 
50 years Positive tests 198 2,494 199 2,891 
 Positivity rate 9.8 6.0 6.1 6.1 
55 years Positive tests 299 3,739 271 4,309 
 Positivity rate 9.1 6.1 6.0 6.2 
65 years Positive tests 345 3,589 265 4,199 
 Positivity rate 12.1 7.8 7.9 8.0 
Total Positive tests 842 9,822 735 11,399 
 Positivity rate 10.3 6.6 6.6 6.8 
Persons 
50 years Positive tests 359 4,938 446 5,743 
 Positivity rate 10.3 6.3 6.4 6.5 
55 years Positive tests 582 7,468 628 8,678 
 Positivity rate 10.5 6.6 6.8 6.8 
65 years Positive tests 835 7,790 625 9,250 
 Positivity rate 14.0 8.9 8.8 9.2 
Total Positive tests 1,776 20,196 1,699 23,671 
 Positivity rate 11.8 7.3 7.3 7.5 
Notes 
1. Positive tests equal the number of FOBTs that returned a positive result. 
2. Positivity rate equals the number of participants with positive FOBT results as a percentage of the total number of participants with valid 
results. A valid result was either positive or negative; inconclusive results were excluded. 
3. NBCSP disability status was reported by the participant on the participant details form. Participants who did not indicate disability status are 
included in the ‘Not stated’ column. 
4. A ‘profound’ activity limitation indicates that a person always needs assistance with self-care, movement and/or communications activities. 
A ‘severe’ activity limitation indicates that a person sometimes needs assistance with these activities.  
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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A3 Primary health-care practitioner (PHCP) and 
colonoscopy follow-up tables and figures 
Table A3.1: Crude PHCP follow-up after a positive FOBT result, by state and territory, 2012–13  
 NSW Vic Qld WA SA Tas ACT NT Australia 
Males 
50 years Number 435 311 329 185 128 39 18 10 1,455 
 Per cent 52.3 45.1 56.2 54.6 51.0 61.9 n.p. n.p. 51.0 
55 years Number 748 546 452 309 257 72 40 18 2,442 
 Per cent 59.5 48.5 55.5 58.4 61.9 57.1 n.p. n.p. 55.9 
65 years Number 884 622 639 359 294 106 43 27 2,974 
 Per cent 60.5 53.9 61.3 60.4 61.5 58.9 n.p. n.p. 58.9 
Total Number 2,067 1,479 1,420 853 679 217 101 55 6,871 
 Per cent 58.2 49.8 58.1 58.3 59.4 58.8 53.4 37.9 56.0 
Females 
50 years Number 473 398 353 208 160 42 23 18 1,675 
 Per cent 58.8 51.6 62.3 60.5 62.7 n.p. n.p. n.p. 57.9 
55 years Number 826 581 484 301 257 66 33 17 2,565 
 Per cent 63.0 51.5 61.8 65.7 62.5 60.6 n.p. n.p. 59.5 
65 years Number 785 563 528 288 303 84 40 19 2,610 
 Per cent 63.4 54.5 66.6 63.0 69.2 61.8 n.p. n.p. 62.2 
Total Number 2,084 1,542 1,365 797 720 192 96 54 6,850 
 Per cent 62.1 52.6 63.7 63.3 65.2 60.6 51.3 52.4 60.1 
Persons 
50 years Number 908 709 682 393 288 81 41 28 3,130 
 Per cent 55.5 48.6 59.2 57.5 56.9 60.0 n.p. n.p. 54.5 
55 years Number 1,574 1,127 936 610 514 138 73 35 5,007 
 Per cent 61.3 50.0 58.6 61.8 62.2 58.7 54.5 n.p. 57.7 
65 years Number 1,669 1,185 1,167 647 597 190 83 46 5,584 
 Per cent 61.8 54.2 63.6 61.6 65.2 60.1 55.3 n.p. 60.4 
Total Number 4,151 3,021 2,785 1,650 1,399 409 197 109 13,721 
 Per cent 60.1 51.2 60.7 60.6 62.2 59.6 52.4 44.0 58.0 
Notes 
1. Percentages equal the number of people having consulted a primary health-care practitioner (PHCP) after a positive FOBT result as a 
proportion of the total number of people with positive FOBT results.  
2. Reporting of PHCP follow-up is not mandatory; actual numbers of participant consultations may be underestimated. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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Table A3.2: Kaplan–Meier PHCP follow-up at 26 and 52 weeks after a positive FOBT, by state and 
territory, 2012–13 
  NSW Vic Qld WA SA Tas ACT NT Australia 
26 weeks          
PHCP follow-
up (per cent) 59.5 51.1 60.7 60.5 61.7 59.2 51.3 44.5 57.7 
95% 
confidence 
interval 58.3–60.7 49.8–52.4 59.2–62.1 58.6–62.3 59.7–63.7 55.5–62.9 46.2–56.4 38.2–50.8 57.0–58.3 
52 weeks          
PHCP follow-
up (per cent) 61.0 52.0 61.1 61.5 62.7 60.1 53.2 45.3 58.7 
95% 
confidence 
interval 59.8–62.2 50.7–53.3 59.7–62.6 59.6–63.3 60.6–64.7 56.4–63.8 48.1–58.4 38.9–51.6 58.0–59.3 
Note: PHCP follow-up rates equal the estimated Kaplan–Meier follow-up rate of people who consulted a PHCP as a proportion of the total number 
of people with positive FOBT results. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
 
 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A3.1a: PHCP follow-up rate after positive FOBT using Kaplan–Meier estimates, Australia, 
2012–13 
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Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A3.1b: PHCP follow-up rate after positive FOBT using Kaplan–Meier estimates, New South 
Wales, Victoria, Queensland and Western Australia, 2012–13 
 
 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A3.1c: PHCP follow-up rate after positive FOBT using Kaplan–Meier estimates, South 
Australia, Tasmania, Australian Capital Territory and Northern Territory, 2012–13 
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Table A3.3: Crude PHCP follow-up after a positive FOBT result, by remoteness area, 2012–13  
 Remoteness area  
 Major cities Inner regional Outer regional Remote Very remote Unknown Total 
Males 
50 years Number 974 280 146 27 11 17 1,455 
 Per cent 50.7 53.9 47.3 n.p. n.p. n.p. 51.0 
55 years Number 1,546 540 291 23 10 32 2,442 
 Per cent 55.1 58.5 57.5 n.p. n.p. n.p. 55.9 
65 years Number 1,800 682 384 49 18 42 2,974 
 Per cent 58.3 59.3 61.0 n.p. n.p. n.p. 58.9 
Total Number 4,320 1,502 821 99 38 91 6,871 
 Per cent 55.3 57.9 56.9 53.9 n.p. 56.5 56.0 
Females 
50 years Number 1,132 320 184 17 7 15 1,675 
 Per cent 56.9 59.3 65.1 n.p. n.p. n.p. 57.9 
55 years Number 1,635 581 281 32 9 27 2,565 
 Per cent 58.2 62.9 61.9 n.p. n.p. n.p. 59.5 
65 years Number 1,611 635 298 25 10 31 2,610 
 Per cent 61.6 62.9 64.2 n.p. n.p. n.p. 62.2 
Total Number 4,379 1,536 763 74 26 73 6,850 
 Per cent 59.0 62.1 63.5 55.4 n.p. 61.3 60.1 
Persons 
50 years Number 2,106 601 330 44 17 32 3,130 
 Per cent 53.8 56.7 55.8 n.p. n.p. n.p. 54.5 
55 years Number 3,181 1,120 572 55 19 59 5,007 
 Per cent 56.6 60.7 59.6 48.4 n.p. n.p. 57.7 
65 years Number 3,411 1,317 681 75 27 73 5,584 
 Per cent 59.8 61.0 62.4 60.9 n.p. 59.3 60.4 
Total Number 8,699 3,038 1,584 173 64 164 13,721 
 Per cent 57.1 60.0 59.9 54.6 49.5 58.6 58.0 
Notes 
1. Percentages equal the number of people having consulted a PHCP after a positive FOBT result as a proportion of the total number of people 
with positive FOBT results.  
2. Reporting of PHCP follow-up is not mandatory; actual numbers of participant consultations may be underestimated. 
3. The residential postcodes of participants were mapped to remoteness areas in the 2011 Australian Statistical Geography Standard 
remoteness structure through a postal area correspondence. Those that could not be mapped were included in the ‘Unknown’ column. 
4. Discrepancies may occur between totals and sums of the component items due to rounding—see ‘Geographical classification’, Appendix C. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
  National Bowel Cancer Screening Program monitoring report: 2012–13 75 
 
Notes 
1. Remoteness areas left unshaded contain data that are not publishable due to small numbers, confidentiality or other concerns.  
2. Rate per remoteness area is an average of PHCP follow-up reported across that remoteness area. 
3. PHCP follow-up rates rounded to integers. 
4. Differences in PHCP follow-up rates across remoteness areas may involve differences in assessment form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A3.2a: PHCP follow-up, by remoteness area, New South Wales, 2012–13 
 
 
Notes 
1. Rate per remoteness area is an average of PHCP follow-up reported across that remoteness area. 
2. PHCP follow-up rates rounded to integers. 
3. Differences in PHCP follow-up rates across remoteness areas may involve differences in assessment form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A3.2b: PHCP follow-up, by remoteness area, Victoria, 2012–13 
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Notes 
1. Rate per remoteness area is an average of PHCP follow-up reported across that remoteness area. 
2. PHCP follow-up rates rounded to integers. 
3. Differences in PHCP follow-up rates across remoteness areas may involve differences in assessment form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A3.2c: PHCP follow-up, by remoteness area, Queensland, 2012–13 
 
 
Notes 
1. Rate per remoteness area is an average of PHCP follow-up reported across that remoteness area. 
2. PHCP follow-up rates rounded to integers. 
3. Differences in PHCP follow-up rates across remoteness areas may involve differences in assessment form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A3.2d: PHCP follow-up, by remoteness area, Western Australia, 2012–13 
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Notes 
1. Rate per remoteness area is an average of PHCP follow-up reported across that remoteness area. 
2. PHCP follow-up rates rounded to integers. 
3. Differences in PHCP follow-up rates across remoteness areas may involve differences in assessment form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A3.2e: PHCP follow-up, by remoteness area, South Australia, 2012–13 
 
 
Notes 
1. Rate per remoteness area is an average of PHCP follow-up reported across that remoteness area. 
2. PHCP follow-up rates rounded to integers. 
3. Differences in PHCP follow-up rates across remoteness areas may involve differences in assessment form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A3.2f: PHCP follow-up, by remoteness area, Tasmania, 2012–13 
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Notes 
1. Remoteness areas left unshaded contain data that are not publishable due to small numbers, confidentiality or other concerns.  
2. Rate per remoteness area is an average of PHCP follow-up reported across that remoteness area. 
3. PHCP follow-up rates rounded to integers. 
4. Differences in PHCP follow-up rates across remoteness areas may involve differences in assessment form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A3.2g: PHCP follow-up, by remoteness area, Australian Capital Territory, 2012–13 
 
 
Notes 
1. Remoteness areas left unshaded contain data that are not publishable due to small numbers, confidentiality or other concerns.  
2. Rate per remoteness area is an average of PHCP follow-up reported across that remoteness area. 
3. PHCP follow-up rates rounded to integers. 
4. Differences in PHCP follow-up rates across remoteness areas may involve differences in assessment form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A3.2h: PHCP follow-up, by remoteness area, Northern Territory, 2012–13 
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Table A3.4: Crude PHCP follow-up after a positive FOBT result, by socioeconomic status area, 
2012–13  
 Socioeconomic status area  
 1 (lowest) 2 3 4 5 (highest) Unknown Total 
Males 
50 years Number 299 298 285 293 258 22 1,455 
 Per cent 53.5 52.1 51.3 50.7 47.3 n.p. 51.0 
55 years Number 508 514 517 445 420 38 2,442 
 Per cent 55.5 55.9 56.7 54.7 56.3 n.p. 55.9 
65 years Number 653 690 594 512 477 48 2,974 
 Per cent 59.3 58.4 59.3 58.9 58.7 n.p. 58.9 
Total Number 1,460 1,502 1,396 1,250 1,155 108 6,871 
 Per cent 56.7 56.2 56.5 55.3 54.9 57.8 56.0 
Females 
50 years Number 306 329 312 336 373 19 1,675 
 Per cent 56.7 56.6 55.6 58.6 61.8 n.p. 57.9 
55 years Number 514 568 496 490 465 32 2,565 
 Per cent 59.1 62.5 59.9 57.9 57.8 n.p. 59.5 
65 years Number 580 575 492 465 462 36 2,610 
 Per cent 62.5 63.0 61.0 61.3 63.2 n.p. 62.2 
Total Number 1,400 1,472 1,300 1,291 1,300 87 6,850 
 Per cent 59.9 61.3 59.2 59.3 60.7 60.0 60.1 
Persons 
50 years Number 605 627 597 629 631 41 3,130 
 Per cent 55.1 54.4 53.4 54.6 54.9 n.p. 54.5 
55 years Number 1,022 1,082 1,013 935 885 70 5,007 
 Per cent 57.3 59.2 58.2 56.3 57.1 61.9 57.7 
65 years Number 1,233 1,265 1,086 977 939 84 5,584 
 Per cent 60.7 60.4 60.1 60.0 60.8 57.5 60.4 
Total Number 2,860 2,974 2,696 2,541 2,455 195 13,721 
 Per cent 58.2 58.6 57.8 57.2 57.8 58.7 58.0 
Notes  
1. Percentages equal the number of people having consulted a PHCP after a positive FOBT result as a proportion of the total number of people 
with positive FOBT results.  
2. Reporting of PHCP follow-up is not mandatory; actual numbers of participant consultations may be underestimated. 
3. A participant’s socioeconomic status area was classified by mapping their residential postcode (through a postal area) to the ABS IRSD for 
2011. Those that could not be mapped were included in the ‘Unknown’ column. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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Table A3.5: Crude PHCP follow-up after a positive FOBT result, by Aboriginal and Torres Strait 
Islander status, 2012–13  
 Indigenous Non-indigenous Not stated Total 
Males 
50 years Number 12 1,414 29 1,455 
 Per cent n.p. 52.9 18.5 51.0 
55 years Number 33 2,384 25 2,442 
 Per cent n.p. 57.7 14.1 55.9 
65 years Number 18 2,912 44 2,974 
 Per cent n.p. 60.7 19.6 58.9 
Total Number 63 6,710 98 6,871 
 Per cent 56.8 57.8 17.6 56.0 
Females 
50 years Number 17 1,635 23 1,675 
 Per cent n.p. 59.2 21.7 57.9 
55 years Number 21 2,516 28 2,565 
 Per cent n.p. 60.6 24.1 59.5 
65 years Number 15 2,539 56 2,610 
 Per cent n.p. 63.3 35.4 62.2 
Total Number 53 6,690 107 6,850 
 Per cent n.p. 61.2 28.2 60.1 
Persons 
50 years Number 29 3,049 52 3,130 
 Per cent n.p. 56.1 19.8 54.5 
55 years Number 54 4,900 53 5,007 
 Per cent 54.0 59.1 18.1 57.7 
65 years Number 33 5,451 100 5,584 
 Per cent n.p. 61.9 26.2 60.4 
Total Number 116 13,400 205 13,721 
 Per cent 56.3 59.5 21.9 58.0 
Notes  
1. Percentages equal the number of people having consulted a PHCP after a positive FOBT result as a proportion of the total number of 
people with positive FOBT results.  
2. Reporting of PHCP follow-up is not mandatory; actual numbers of participant consultations may be underestimated. 
3. NBCSP Aboriginal and Torres Strait Islander status was reported by the participant on the returned participant details form. Participants 
who did not indicate Aboriginal and Torres Strait Islander status were included in the ‘Not stated’ column. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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Table A3.6: Crude PHCP follow-up after a positive FOBT result, by language spoken at home, 
2012–13  
 
Language other than 
English English Total 
Males 
50 years Number 209 1,246 1,455 
 Per cent 49.6 51.3 51.0 
55 years Number 354 2,088 2,442 
 Per cent 56.2 55.8 55.9 
65 years Number 346 2,628 2,974 
 Per cent 60.8 58.6 58.9 
Total Number 909 5,962 6,871 
 Per cent 56.1 56.0 56.0 
Females 
50 years Number 269 1,406 1,675 
 Per cent 57.2 58.1 57.9 
55 years Number 380 2,185 2,565 
 Per cent 56.4 60.1 59.5 
65 years Number 268 2,342 2,610 
 Per cent 55.4 63.0 62.2 
Total Number 917 5,933 6,850 
 Per cent 56.3 60.7 60.1 
Persons 
50 years Number 478 2,652 3,130 
 Per cent 53.6 54.7 54.5 
55 years Number 734 4,273 5,007 
 Per cent 56.3 57.9 57.7 
65 years Number 614 4,970 5,584 
 Per cent 58.3 60.6 60.4 
Total Number 1,826 11,895 13,721 
 Per cent 56.2 58.2 58.0 
Notes 
1. Percentages equal the number of people having consulted a PHCP after a positive FOBT result as a proportion of the total number of 
people with positive FOBT results.  
2. Reporting of PHCP follow-up is not mandatory; actual numbers of participant consultations may be underestimated. 
3. NBCSP preferred language spoken at home was reported by the participant on the returned participant details form. Participants who did not 
indicate preferred language spoken at home were assumed to speak English. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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Table A3.7: Crude PHCP follow-up after a positive FOBT result, by disability status, 2012–13  
 
Severe or profound activity 
limitation 
No severe or profound 
activity limitation Not stated Total 
Males 
50 years Number 94 1,318 43 1,455 
 Per cent 58.4 53.9 17.4 51.0 
55 years Number 181 2,174 87 2,442 
 Per cent 64.0 58.3 24.4 55.9 
65 years Number 314 2,587 73 2,974 
 Per cent 64.1 61.6 20.3 58.9 
Total Number 589 6,079 203 6,871 
 Per cent 63.1 58.6 21.1 56.0 
Females 
50 years Number 107 1,517 51 1,675 
 Per cent 54.0 60.8 25.6 57.9 
55 years Number 175 2,309 81 2,565 
 Per cent 58.5 61.8 29.9 59.5 
65 years Number 198 2,325 87 2,610 
 Per cent 57.4 64.8 32.8 62.2 
Total Number 480 6,151 219 6,850 
 Per cent 57.0 62.6 29.8 60.1 
Persons 
50 years Number 201 2,835 94 3,130 
 Per cent 56.0 57.4 21.1 54.5 
55 years Number 356 4,483 168 5,007 
 Per cent 61.2 60.0 26.8 57.7 
65 years Number 512 4,912 160 5,584 
 Per cent 61.3 63.1 25.6 60.4 
Total Number 1,069 12,230 422 13,721 
 Per cent 60.2 60.6 24.8 58.0 
Notes  
1. Percentages equal the number of people having consulted a PHCP after a positive FOBT result as a proportion of the total number of 
people with positive FOBT results.  
2. Reporting of PHCP follow-up is not mandatory; actual numbers of participant consultations may be underestimated. 
3. NBCSP disability status was reported by the participant on the participant details form. Participants who did not indicate disability status are 
included in the ‘Not stated’ column. 
4. A ‘profound’ activity limitation indicates that a person always needs assistance with self-care, movement and/or communications activities. 
A ‘severe’ activity limitation indicates that a person sometimes needs assistance with these activities.  
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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Table A3.8: Symptoms reported to PHCPs after a positive FOBT result, 2012–13 
 
No 
symptoms 
Recent 
onset rectal 
bleeding 
 ≤6 months 
Longer- 
standing 
rectal 
bleeding  
>6 months 
Significant 
change in 
bowel 
habits 
Iron 
deficiency 
anaemia 
Abdominal 
pain 
All 
participants 
reporting 
symptom 
status 
Males 
50 years Number 1,088 91 107 34 6 24 1,329 
 Per cent 81.9 6.8 8.1 2.6 0.5 1.8  
55 years Number 1,835 144 168 60 11 55 2,225 
 Per cent 82.5 6.5 7.6 2.7 0.5 2.5  
65 years Number 2,295 148 171 72 22 58 2,728 
 Per cent 84.1 5.4 6.3 2.6 0.8 2.1  
Total Number 5,218 383 446 166 39 137 6,282 
 Per cent 83.1 6.1 7.1 2.6 0.6 2.2  
Females 
50 years Number 1,259 69 99 72 29 65 1,546 
 Per cent 81.4 4.5 6.4 4.7 1.9 4.2  
55 years Number 1,931 129 151 97 31 96 2,361 
 Per cent 81.8 5.5 6.4 4.1 1.3 4.1  
65 years Number 1,990 112 118 103 37 112 2,408 
 Per cent 82.6 4.7 4.9 4.3 1.5 4.7  
Total Number 5,180 310 368 272 97 273 6,315 
 Per cent 82.0 4.9 5.8 4.3 1.5 4.3  
Persons 
50 years Number 2,347 160 206 106 35 89 2,875 
 Per cent 81.6 5.6 7.2 3.7 1.2 3.1  
55 years Number 3,766 273 319 157 42 151 4,586 
 Per cent 82.1 6.0 7.0 3.4 0.9 3.3  
65 years Number 4,285 260 289 175 59 170 5,136 
 Per cent 83.4 5.1 5.6 3.4 1.1 3.3  
Total Number 10,398 693 814 438 136 410 12,597 
 Per cent 82.5 5.5 6.5 3.5 1.1 3.3  
Notes 
1. Percentages equal the number of people reporting specific symptoms after a positive FOBT as a proportion of the total number of people 
who reported any symptoms. 
2. Only participants who had a symptom status (including ‘no symptoms’) recorded in the assessment form question 2 were included in this 
analysis. There were 1,124 participants with missing data for this question excluded from the analysis. 
3. Percentages can add to more than 100, as respondents may have reported more than 1 symptom.  
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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Table A3.9: Referrals made by PHCPs after a positive FOBT result and subsequent consultation, 
2012–13 
 Colonoscopy 
Double 
contrast 
barium 
enema Sigmoidoscopy 
CT 
colonography Other  
No 
referral 
All PHCP 
visits 
Males 
50 years Number 1,356 — — 2 29 68 1,455 
 Per cent 93.2 — — 0.1 2.0 4.7  
55 years Number 2,278 2 2 3 34 123 2,442 
 Per cent 93.3 0.1 0.1 0.1 1.4 5.0  
65 years Number 2,703 3 3 8 58 199 2,974 
 Per cent 90.9 0.1 0.1 0.3 2.0 6.7  
Total Number 6,337 5 5 13 121 390 6,871 
 Per cent 92.2 0.1 0.1 0.2 1.8 5.7  
Females 
50 years Number 1,525 2 — 3 61 84 1,675 
 Per cent 91.0 0.1 — 0.2 3.6 5.0  
55 years Number 2,343 3 1 2 63 153 2,565 
 Per cent 91.3 0.1 — 0.1 2.5 6.0  
65 years Number 2,374 4 2 5 46 179 2,610 
 Per cent 91.0 0.2 0.1 0.2 1.8 6.9  
Total Number 6,242 9 3 10 170 416 6,850 
 Per cent 91.1 0.1 — 0.1 2.5 6.1  
Persons 
50 years Number 2,881 2 — 5 90 152 3,130 
 Per cent 92.0 0.1 — 0.2 2.9 4.9  
55 years Number 4,621 5 3 5 97 276 5,007 
 Per cent 92.3 0.1 0.1 0.1 1.9 5.5  
65 years Number 5,077 7 5 13 104 378 5,584 
 Per cent 90.9 0.1 0.1 0.2 1.9 6.8  
Total Number 12,579 14 8 23 291 806 13,721 
 Per cent 91.7 0.1 0.1 0.2 2.1 5.9  
Notes 
1. Percentages equal the number of people consulting a PHCP after a positive FOBT who received/did not receive referral for either 
colonoscopy or other examination as a proportion of the total number of follow-up consultations after a positive FOBT. 
2. Referrals may sum to more than all follow-up PHCP visits, as more than 1 referral may be given to a person. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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Table A3.10: PHCP referrals for colonoscopy or other examination after a positive FOBT result, by 
geographical location, 2012–13  
 
Colonoscopy 
 
Other 
 
No referral  
All 
PHCP 
visits 
Number Per cent  Number Per cent  Number Per cent  Number 
Major 
cities 
Males 3,983 92.2  87 2.0  250 5.8  4,320 
Females 4,007 91.5  114 2.6  258 5.9  4,379 
Persons 7,990 91.8  201 2.3  508 5.8  8,699 
Inner 
regional 
Males 1,374 91.5  37 2.4  91 6.1  1,502 
Females 1,409 91.7  42 2.7  86 5.6  1,536 
Persons 2,783 91.6  78 2.6  177 5.8  3,038 
Outer 
regional 
Males 767 93.5  13 1.6  40 4.9  821 
Females 677 88.7  29 3.9  56 7.4  763 
Persons 1,444 91.2  43 2.7  97 6.1  1,584 
Remote Males 91 n.p.  3 n.p.  4 n.p.  99 
Females 66 n.p.  2 n.p.  6 n.p.  74 
Persons 158 91.1  5 3.1  10 5.8  173 
Very 
remote 
Males 36 n.p.  1 n.p.  0 n.p.  38 
Females 21 n.p.  1 n.p.  3 n.p.  26 
Persons 58 n.p.  2 n.p.  3 n.p.  64 
Unknown Males 85 n.p.  2 n.p.  4 n.p.  91 
Females 62 n.p.  4 n.p.  7 n.p.  73 
Persons 147 89.6  6 3.7  11 6.7  164 
Notes  
1. Percentages equal the number of people consulting a PHCP after a positive FOBT who received/did not receive referral for either 
colonoscopy or other examination as a proportion of the total number of follow-up consultations after a positive FOBT. 
2. The residential postcodes of participants were mapped to remoteness areas in the 2011 Australian Statistical Geography Standard 
remoteness structure through a postal area correspondence. Those that could not be mapped were included in the ‘Unknown’ row. 
3. Discrepancies may occur between totals and sums of the component items due to rounding—see ‘Geographical classification’, Appendix C. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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Table A3.11: Reason for non-referrals for colonoscopy by PHCPs, 2012–13 
Bowel cancer 
 previously 
 diagnosed 
Limited life 
expectancy 
Recent 
colonoscopy 
(<18 months) 
Patient 
declines 
colonoscopy 
Significant 
comorbidity 
Other 
medical 
condition(s) 
All 
non-referred 
participants 
Males 
50 years Number 0 1 37 30 4 35 99 
 Per cent — n.p. n.p. n.p. n.p. n.p.  
55 years Number 2 1 85 32 10 48 164 
 Per cent 1.2 0.6 51.8 19.5 6.1 29.3  
65 years Number 0 5 132 67 15 84 271 
 Per cent — 1.8 48.7 24.7 5.5 31.0  
Total Number 2 7 254 129 29 167 534 
 Per cent 0.4 1.3 47.6 24.2 5.4 31.3  
Females 
50 years Number 1 1 62 51 2 49 150 
 Per cent 0.7 0.7 41.3 34.0 1.3 32.7  
55 years Number 2 3 105 65 7 61 222 
 Per cent 0.9 1.4 47.3 29.3 3.2 27.5  
65 years Number 6 4 126 52 22 65 236 
 Per cent 2.5 1.7 53.4 22.0 9.3 27.5  
Total Number 9 8 293 168 31 175 608 
 Per cent 1.5 1.3 48.2 27.6 5.1 28.8  
Persons 
50 years Number 1 2 99 81 6 84 249 
 Per cent 0.4 0.8 39.8 32.5 2.4 33.7  
55 years Number 4 4 190 97 17 109 386 
 Per cent 1.0 1.0 49.2 25.1 4.4 28.2  
65 years Number 6 9 258 119 37 149 507 
 Per cent 1.2 1.8 50.9 23.5 7.3 29.4  
Total Number 11 15 547 297 60 342 1,142 
 Per cent 1.0 1.3 47.9 26.0 5.3 29.9  
Notes 
1. Percentages equal the number of consultations for each reason (after a positive FOBT) that did not refer for colonoscopy as a proportion of 
the total number of positive FOBT consultations that did not refer for colonoscopy. 
2. A participant may have multiple reasons for non-referral for colonoscopy indicated. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
  
  National Bowel Cancer Screening Program monitoring report: 2012–13 87 
Table A3.12: Crude colonoscopy follow-up after a positive FOBT result, by state and territory,  
2012–13  
 NSW Vic Qld WA SA Tas ACT NT Australia 
Males 
50 years Number 553 452 480 201 172 43 36 15 1,952 
 Per cent 66.5 65.6 82.1 59.3 68.5 n.p. n.p. n.p. 68.4 
55 years Number 820 749 651 334 291 104 42 19 3,010 
 Per cent 65.2 66.5 79.9 63.1 70.1 82.5 n.p. n.p. 68.9 
65 years Number 957 805 868 395 366 134 54 20 3,599 
 Per cent 65.5 69.7 83.3 66.5 76.6 74.4 n.p. n.p. 71.3 
Total Number 2,330 2,006 1,999 930 829 281 132 54 8,561 
 Per cent 65.6 67.5 81.9 63.6 72.5 76.2 69.8 37.2 69.8 
Females 
50 years Number 530 510 458 227 182 52 26 14 1,999 
 Per cent 65.9 66.1 80.8 66.0 71.4 n.p. n.p. n.p. 69.1 
55 years Number 849 790 635 304 307 86 50 18 3,039 
 Per cent 64.7 70.0 81.1 66.4 74.7 78.9 n.p. n.p. 70.5 
65 years Number 844 730 668 312 334 111 55 17 3,071 
 Per cent 68.2 70.7 84.2 68.3 76.3 81.6 n.p. n.p. 73.1 
Total Number 2,223 2,030 1,761 843 823 249 131 49 8,109 
 Per cent 66.3 69.2 82.2 67.0 74.5 78.5 70.1 47.6 71.1 
Persons 
50 years Number 1,083 962 938 428 354 95 62 29 3,951 
 Per cent 66.2 65.9 81.4 62.7 70.0 70.4 n.p. n.p. 68.8 
55 years Number 1,669 1,539 1,286 638 598 190 92 37 6,049 
 Per cent 65.0 68.3 80.5 64.6 72.4 80.9 68.7 n.p. 69.7 
65 years Number 1,801 1,535 1,536 707 700 245 109 37 6,670 
 Per cent 66.7 70.2 83.7 67.3 76.4 77.5 72.7 n.p. 72.1 
Total Number 4,553 4,036 3,760 1,773 1,652 530 263 103 16,670 
 Per cent 65.9 68.4 82.0 65.2 73.5 77.3 69.9 41.5 70.4 
Notes 
1. Percentages of colonoscopies performed equal the number of people who have had a colonoscopy recorded after a positive FOBT as a 
proportion of the total number of people with positive FOBT results. 
2. Record of a colonoscopy as part of the NBCSP is identified from colonoscopy report forms, histopathology report forms and/or Medicare 
claims. 
3. As progression through the pathway to the colonoscopy stage may take some time, some participants may not have had sufficient time to 
have had a colonoscopy. Additionally, reporting of colonoscopy follow-up is not mandatory. Therefore, actual numbers of participant 
colonoscopies may be underestimated. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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Table A3.13: Kaplan–Meier estimated colonoscopy follow-up per 100 people with positive FOBTs 
at 26 and 52 weeks since positive FOBT, by state and territory, 2012–13 
  NSW Vic Qld WA SA Tas ACT NT Australia 
26 weeks          
Colonoscopy 
follow-up  
(per cent) 63.7 66.3 79.6 62.7 69.7 73.6 69.4 40.6 68.0 
95% 
confidence 
interval 62.6–64.9 65.0–67.5 78.4–80.8 60.9–64.6 67.8–71.6 70.2–76.9 64.6–74.2 34.2–46.9 67.4–68.6 
52 weeks          
Colonoscopy 
follow-up  
(per cent) 68.2 69.0 84.3 66.3 75.4 77.3(a) 72.1 46.0 72.1 
95% 
confidence 
interval 67.1–69.4 67.8–70.2 83.2–85.5 64.4–68.2 73.5–77.3 73.8–80.4 67.3–76.9 38.6–53.3 71.5–72.7 
(a) The crude rate was substituted as the estimated Kaplan–Meier rate was lower than the actual crude rate. 
Note: Colonoscopy follow-up rates equal the estimated Kaplan–Meier follow-up rate of people who have had a colonoscopy as a proportion of the 
total number of people with positive FOBT results, including people who suspended or opted off the program. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
 
 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A3.3a: Colonoscopy follow-up after a positive FOBT using Kaplan–Meier estimates, 
Australia, 2012–13 
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Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A3.3b: Colonoscopy follow-up after a positive FOBT using Kaplan–Meier estimates,  
New South Wales, Victoria, Queensland and Western Australia, 2012–13 
 
 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A3.3c: Colonoscopy follow-up after a positive FOBT using Kaplan–Meier estimates,  
South Australia, Tasmania, Australian Capital Territory and Northern Territory, 2012–13 
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Table A3.14: Crude colonoscopy follow-up after a positive FOBT result, by remoteness area,  
2012–13  
 Remoteness area  
 Major cities 
Inner 
regional 
Outer 
regional Remote Very remote Unknown Total 
Males 
50 years Number 1,381 325 190 23 7 26 1,952 
 Per cent 71.8 62.5 61.7 n.p. n.p. n.p. 68.4 
55 years Number 2,019 592 317 30 16 35 3,010 
 Per cent 72.0 64.2 62.6 n.p. n.p. n.p. 68.9 
65 years Number 2,280 812 401 47 20 39 3,599 
 Per cent 73.8 70.5 63.9 n.p. n.p. n.p. 71.3 
Total Number 5,680 1,729 909 100 43 100 8,561 
 Per cent 72.7 66.7 63.0 54.6 n.p. 62.1 69.8 
Females 
50 years Number 1,429 352 170 20 12 16 1,999 
 Per cent 71.8 65.2 60.0 n.p. n.p. n.p. 69.1 
55 years Number 2,067 631 269 36 14 23 3,039 
 Per cent 73.5 68.3 59.1 n.p. n.p. n.p. 70.5 
65 years Number 2,020 681 306 24 10 30 3,071 
 Per cent 77.2 67.4 66.1 n.p. n.p. n.p. 73.1 
Total Number 5,516 1,664 745 80 35 69 8,109 
 Per cent 74.4 67.3 62.0 59.8 n.p. 58.0 71.1 
Persons 
50 years Number 2,810 677 360 42 19 42 3,951 
 Per cent 71.8 63.9 60.9 n.p. n.p. n.p. 68.8 
55 years Number 4,086 1,223 586 66 29 58 6,049 
 Per cent 72.7 66.3 61.0 58.7 n.p. n.p. 69.7 
65 years Number 4,300 1,492 708 71 30 69 6,670 
 Per cent 75.4 69.1 64.8 58.0 n.p. 56.1 72.1 
Total Number 11,196 3,393 1,654 180 79 169 16,670 
 Per cent 73.5 67.0 62.5 56.7 61.2 60.4 70.4 
Notes 
1. Percentages of colonoscopies performed equal the number of people who have had a colonoscopy recorded after a positive FOBT as a 
proportion of the total number of people with positive FOBT results.  
2. Reporting of colonoscopy follow-up is not mandatory. Therefore, actual numbers of participant colonoscopies may be underestimated. 
3. The residential postcodes of participants were mapped to remoteness areas in the 2011 Australian Statistical Geography Standard 
remoteness structure through a postal area correspondence. Those that could not be mapped were included in the ‘Unknown’ column. 
4. Discrepancies may occur between totals and sums of the component items due to rounding—see ‘Geographical classification’, Appendix C. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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Notes 
1. Rate per remoteness area is an average of colonoscopy follow-up reported across that remoteness area. 
2. Colonoscopy follow-up rates rounded to integers. 
3. Differences in colonoscopy follow-up rates across remoteness areas may involve differences in form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A3.4a: Colonoscopy follow-up, by remoteness area, New South Wales, 2012–13 
 
 
Notes 
1. Rate per remoteness area is an average of colonoscopy follow-up reported across that remoteness area. 
2. Colonoscopy follow-up rates rounded to integers. 
3. Differences in colonoscopy follow-up rates across remoteness areas may involve differences in form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A3.4b: Colonoscopy follow-up, by remoteness area, Victoria, 2012–13 
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Notes 
1. Rate per remoteness area is an average of colonoscopy follow-up reported across that remoteness area. 
2. Colonoscopy follow-up rates rounded to integers. 
3. Differences in colonoscopy follow-up rates across remoteness areas may involve differences in form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A3.4c: Colonoscopy follow-up, by remoteness area, Queensland, 2012–13 
 
 
Notes 
1. Rate per remoteness area is an average of colonoscopy follow-up reported across that remoteness area. 
2. Colonoscopy follow-up rates rounded to integers. 
3. Differences in colonoscopy follow-up rates across remoteness areas may involve differences in form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A3.4d: Colonoscopy follow-up, by remoteness area, Western Australia, 2012–13 
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Notes 
1. Rate per remoteness area is an average of colonoscopy follow-up reported across that remoteness area. 
2. Colonoscopy follow-up rates rounded to integers. 
3. Differences in colonoscopy follow-up rates across remoteness areas may involve differences in form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A3.4e: Colonoscopy follow-up, by remoteness area, South Australia, 2012–13 
 
 
Notes 
1. Rate per remoteness area is an average of colonoscopy follow-up reported across that remoteness area. 
2. Colonoscopy follow-up rates rounded to integers. 
3. Differences in colonoscopy follow-up rates across remoteness areas may involve differences in form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A3.4f: Colonoscopy follow-up, by remoteness area, Tasmania, 2012–13 
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Notes 
1. Remoteness areas left unshaded contain data that are not publishable due to small numbers, confidentiality or other concerns.  
2. Rate per remoteness area is an average of colonoscopy follow-up reported across that remoteness area. 
3. Colonoscopy follow-up rates rounded to integers. 
4. Differences in colonoscopy follow-up rates across remoteness areas may involve differences in form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A3.4g: Colonoscopy follow-up, by remoteness area, Australian Capital Territory, 2012–13 
 
 
Notes 
1. Rate per remoteness area is an average of colonoscopy follow-up reported across that remoteness area. 
2. Colonoscopy follow-up rates rounded to integers. 
3. Differences in colonoscopy follow-up rates across remoteness areas may involve differences in form return only. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A3.4h: Colonoscopy follow-up, by remoteness area, Northern Territory, 2012–13 
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Table A3.15: Crude colonoscopy follow-up after a positive FOBT result, by socioeconomic status 
area, 2012–13  
 Socioeconomic status area  
 1 (lowest) 2 3 4 5 (highest) Unknown Total 
Males 
50 years Number 370 359 372 423 397 31 1,952 
 Per cent 66.2 62.8 66.9 73.2 72.7 n.p. 68.4 
55 years Number 587 567 661 579 578 38 3,010 
 Per cent 64.1 61.7 72.5 71.1 77.5 n.p. 68.9 
65 years Number 733 817 744 624 636 45 3,599 
 Per cent 66.5 69.2 74.3 71.7 78.2 n.p. 71.3 
Total Number 1,690 1,743 1,777 1,626 1,611 114 8,561 
 Per cent 65.6 65.2 72.0 71.9 76.5 61.0 69.8 
Females 
50 years Number 339 373 388 424 455 20 1,999 
 Per cent 62.8 64.2 69.2 74.0 75.3 n.p. 69.1 
55 years Number 575 617 580 639 602 26 3,039 
 Per cent 66.2 67.9 70.0 75.4 74.8 n.p. 70.5 
65 years Number 628 636 595 581 596 35 3,071 
 Per cent 67.7 69.7 73.7 76.6 81.5 n.p. 73.1 
Total Number 1,542 1,626 1,563 1,644 1,653 81 8,109 
 Per cent 66.0 67.7 71.2 75.5 77.2 55.9 71.1 
Persons 
50 years Number 709 732 760 847 852 51 3,951 
 Per cent 64.5 63.5 68.0 73.6 74.1 n.p. 68.8 
55 years Number 1,162 1,184 1,241 1,218 1,180 64 6,049 
 Per cent 65.1 64.8 71.3 73.3 76.1 56.6 69.7 
65 years Number 1,361 1,453 1,339 1,205 1,232 80 6,670 
 Per cent 67.0 69.4 74.1 74.0 79.8 54.8 72.1 
Total Number 3,232 3,369 3,340 3,270 3,264 195 16,670 
 Per cent 65.8 66.4 71.6 73.6 76.9 58.7 70.4 
Notes 
1. Percentages of colonoscopies performed equal the number of people who have had a colonoscopy recorded after a positive FOBT as a 
proportion of the total number of people with positive FOBT results.  
2. Reporting of colonoscopy follow-up is not mandatory. Therefore, actual numbers of participant colonoscopies may be underestimated.  
3. A participant’s socioeconomic status area was classified by mapping their residential postcode (through a postal area) to the ABS IRSD for 
2011. Those that could not be mapped were included in the ‘Unknown’ column. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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Table A3.16: Crude colonoscopy follow-up after a positive FOBT result, by Aboriginal and Torres 
Strait Islander status, 2012–13  
 Indigenous Non-indigenous Not stated Total 
Males 
50 years Number 11 1,862 79 1,952 
 Per cent n.p. 69.7 50.3 68.4 
55 years Number 28 2,904 78 3,010 
 Per cent n.p. 70.2 44.1 68.9 
65 years Number 20 3,458 121 3,599 
 Per cent n.p. 72.1 54.0 71.3 
Total Number 59 8,224 278 8,561 
 Per cent 53.2 70.9 49.8 69.8 
Females 
50 years Number 11 1,947 41 1,999 
 Per cent n.p. 70.5 38.7 69.1 
55 years Number 30 2,950 59 3,039 
 Per cent n.p. 71.1 50.9 70.5 
65 years Number 21 2,954 96 3,071 
 Per cent n.p. 73.6 60.8 73.1 
Total Number 62 7,851 196 8,109 
 Per cent n.p. 71.9 51.6 71.1 
Persons 
50 years Number 22 3,809 120 3,951 
 Per cent n.p. 70.1 45.6 68.8 
55 years Number 58 5,854 137 6,049 
 Per cent 58.0 70.7 46.8 69.7 
65 years Number 41 6,412 217 6,670 
 Per cent n.p. 72.8 56.8 72.1 
Total Number 121 16,075 474 16,670 
 Per cent 58.7 71.4 50.5 70.4 
Notes 
1. Percentages of colonoscopies performed equal the number of people who have had a colonoscopy recorded after a positive FOBT as a 
proportion of the total number of people with positive FOBT results.  
2. Reporting of colonoscopy follow-up is not mandatory. Therefore, actual numbers of participant colonoscopies may be underestimated. 
3. NBCSP Aboriginal and Torres Strait Islander status was reported by the participant on the returned participant details form. Participants 
who did not indicate Aboriginal and Torres Strait Islander status were included in the ‘Not stated’ column. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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Table A3.17: Crude colonoscopy follow-up after a positive FOBT result, by language spoken at 
home, 2012–13  
 Language other than English English Total 
Males 
50 years Number 291 1,661 1,952 
 Per cent 69.1 68.3 68.4 
55 years Number 420 2,590 3,010 
 Per cent 66.7 69.3 68.9 
65 years Number 371 3,228 3,599 
 Per cent 65.2 72.0 71.3 
Total Number 1,082 7,479 8,561 
 Per cent 66.8 70.2 69.8 
Females 
50 years Number 308 1,691 1,999 
 Per cent 65.5 69.8 69.1 
55 years Number 448 2,591 3,039 
 Per cent 66.5 71.3 70.5 
65 years Number 344 2,727 3,071 
 Per cent 71.1 73.4 73.1 
Total Number 1,100 7,009 8,109 
 Per cent 67.6 71.7 71.1 
Persons 
50 years Number 599 3,352 3,951 
 Per cent 67.2 69.1 68.8 
55 years Number 868 5,181 6,049 
 Per cent 66.6 70.3 69.7 
65 years Number 715 5,955 6,670 
 Per cent 67.9 72.6 72.1 
Total Number 2,182 14,488 16,670 
 Per cent 67.2 70.9 70.4 
Notes 
1. Percentages of colonoscopies performed equal the number of people who have had a colonoscopy recorded after a positive FOBT as 
a proportion of the total number of people with positive FOBT results.  
2. Reporting of colonoscopy follow-up is not mandatory. Therefore, actual numbers of participant colonoscopies may be underestimated. 
3. NBCSP preferred language spoken at home was reported by the participant on the returned participant details form. Participants who did not 
indicate preferred language spoken at home were assumed to speak English. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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Table A3.18: Crude colonoscopy follow-up after a positive FOBT result, by disability status,  
2012–13  
 
Severe or profound 
activity limitation 
No severe or profound 
activity limitation Not stated Total 
Males 
50 years Number 97 1,729 126 1,952 
 Per cent 60.2 70.7 51.0 68.4 
55 years Number 161 2,667 182 3,010 
 Per cent 56.9 71.5 51.0 68.9 
65 years Number 311 3,076 212 3,599 
 Per cent 63.5 73.2 58.9 71.3 
Total Number 569 7,472 520 8,561 
 Per cent 60.9 72.0 53.9 69.8 
Females 
50 years Number 129 1,773 97 1,999 
 Per cent 65.2 71.1 48.7 69.1 
55 years Number 186 2,704 149 3,039 
 Per cent 62.2 72.3 55.0 70.5 
65 years Number 209 2,710 152 3,071 
 Per cent 60.6 75.5 57.4 73.1 
Total Number 524 7,187 398 8,109 
 Per cent 62.2 73.2 54.1 71.1 
Persons 
50 years Number 226 3,502 223 3,951 
 Per cent 63.0 70.9 50.0 68.8 
55 years Number 347 5,371 331 6,049 
 Per cent 59.6 71.9 52.7 69.7 
65 years Number 520 5,786 364 6,670 
 Per cent 62.3 74.3 58.2 72.1 
Total Number 1,093 14,659 918 16,670 
 Per cent 61.5 72.6 54.0 70.4 
Notes 
1. Percentages of colonoscopies performed equal the number of people who have had a colonoscopy recorded after a positive FOBT as a 
proportion of the total number of people with positive FOBT results.  
2. Reporting of colonoscopy follow-up is not mandatory. Therefore, actual numbers of participant colonoscopies may be underestimated. 
3. NBCSP disability status was reported by the participant on the participant details form. Participants who did not indicate disability status are 
included in the ‘Not stated’ column. 
4. A ‘profound’ activity limitation indicates that a person always needs assistance with self-care, movement and/or communications activities. 
A ‘severe’ activity limitation indicates that a person sometimes needs assistance with these activities.  
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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A4 Bowel abnormality detection tables 
Table A4.1: Colonoscopy outcomes (excludes histopathology), 2012–13 
 Colonoscopy outcome  
 
Suspected 
cancer 
Polyp(s) 
>10 mm 
Polyp(s) 
≤10 mm 
Other 
diagnoses(a) 
No 
abnormality 
Outcome not 
specified 
All 
colonoscopy 
report forms 
Males 
  50 years Number 41 235 634 294 263 1 1,468 
 Per cent 2.8 16.0 43.2 20.0 17.9 0.1  
55 years Number 77 391 978 477 329 2 2,254 
 Per cent 3.4 17.3 43.4 21.2 14.6 0.1  
65 years Number 146 498 1,265 528 299 2 2,738 
 Per cent 5.3 18.2 46.2 19.3 10.9 0.1  
Total Number 264 1,124 2,877 1,299 891 5 6,460 
 Per cent 4.1 17.4 44.5 20.1 13.8 0.1  
Females 
  
  
  
  
  
50 years Number 20 127 449 424 437 3 1,460 
 Per cent 1.4 8.7 30.8 29.0 29.9 0.2  
55 years Number 57 192 764 648 591 6 2,258 
 Per cent 2.5 8.5 33.8 28.7 26.2 0.3  
65 years Number 86 267 914 664 428 4 2,363 
 Per cent 3.6 11.3 38.7 28.1 18.1 0.2  
Total Number 163 586 2,127 1,736 1,456 13 6,081 
 Per cent 2.7 9.6 35.0 28.5 23.9 0.2  
Persons 
50 years Number 61 362 1,083 718 700 4 2,928 
 Per cent 2.1 12.4 37.0 24.5 23.9 0.1  
55 years Number 134 583 1,742 1,125 920 8 4,512 
 Per cent 3.0 12.9 38.6 24.9 20.4 0.2  
65 years Number 232 765 2,179 1,192 727 6 5,101 
 Per cent 4.5 15.0 42.7 23.4 14.3 0.1  
Total Number 427 1,710 5,004 3,035 2,347 18 12,541 
 Per cent 3.4 13.6 39.9 24.2 18.7 0.1  
(a) Other diagnoses include haemorrhoids, diverticular disease and inflammatory bowel disease. 
Note: Only colonoscopies with an associated colonoscopy report form were included in this analysis; colonoscopies identified from histopathology 
report forms or Medicare claims only were not included.  
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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Table A4.2: Overall diagnostic outcomes (including histopathology), by state and territory, 2012–13 
State/ 
territory  
Invitations 
issued(a) 
Number 
screened(b) 
Total 
positive 
FOBT 
FOBT positive 
Colonoscopy 
recorded(c) 
No  
cancer or 
adenoma(d) 
Polyps 
awaiting 
histo-
pathology(e) 
Confirmed 
diminutive 
adenoma(f) 
Confirmed 
small 
adenoma(f) 
Confirmed 
advanced 
adenoma(f) 
Suspected 
cancer(g)  
Confirmed 
cancer(h) 
NSW Number 300,742 93,954 6,905 3,190 1,515 1,489 28 9 42 97 10 
 Per cent     47.5 46.7 0.9 0.3 1.3 3.0 0.3 
Vic Number 232,439 79,015 5,902 3,114 1,635 1,248 30 27 90 77 7 
 Per cent     52.5 40.1 1.0 0.9 2.9 2.5 0.2 
Qld Number 196,472 63,253 4,585 3,199 1,292 1,140 128 114 417 90 18 
 Per cent     40.4 35.6 4.0 3.6 13.0 2.8 0.6 
WA Number 106,249 38,482 2,721 1,151 404 621 56 — 45 23 2 
 Per cent     35.1 54.0 4.9 — 3.9 2.0 0.2 
SA Number 75,978 28,958 2,248 1,340 659 516 22 25 77 37 4 
 Per cent     49.2 38.5 1.6 1.9 5.7 2.8 0.3 
Tas Number 24,837 9,297 686 461 242 120 12 25 40 15 7 
 Per cent     52.5 26.0 2.6 5.4 8.7 3.3 1.5 
ACT  Number 14,840 5,484 376 204 83 70 26 — 15 6 4 
 Per cent     40.7 34.3 12.7 — 7.4 2.9 2.0 
NT Number 11,961 2,970 248 79 27 42 1 — 2 7 — 
 Per cent     34.2 53.2 1.3 — 2.5 8.9 — 
Australia Number 963,518 321,413 23,671 12,738 5,857 5,246 303 200 728 352 52 
 Per cent         46.0 41.2 2.4 1.6 5.7 2.8 0.4 
(a) ‘Invitations issued’ equals the number of eligible people who were issued an invitation to screen in the NBCSP. 
(b) ‘Number screened’ equals the number of people who completed an FOBT kit and had results forwarded to the Register. 
(c) ‘Colonoscopy recorded’ includes colonoscopies recorded via the colonoscopy report and/or histopathology report forms. It does not include colonoscopies identified through Medicare claims. 
(d) No cancers were suspected at colonoscopy or confirmed non-cancerous by histopathology; no polyps identified at colonoscopy, or polyps confirmed as non-adenomatous at histopathology. 
(e) Polyps detected at colonoscopy and sent to histopathology for analysis. No histopathology report form received by Register. 
(f) Confirmed adenoma figures were based on a combination of the colonoscopy and histopathology report forms for a person received by the Register.  
(g) Cancer suspected at colonoscopy but not yet confirmed by histopathology.  
(h) Cancer confirmed by histopathology.  
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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Table A4.3: Overall diagnostic outcomes (including histopathology), by age and sex, 2012–13 
  
Invitations 
issued(a) 
Number 
screened(b) 
Total 
positive 
FOBT 
FOBT positive 
Colonoscopy 
recorded(c) 
No  
cancer or 
adenoma(d) 
Polyps awaiting 
histopathology(e) 
Confirmed 
diminutive 
adenoma(f) 
Confirmed 
small 
adenoma(f) 
Confirmed 
advanced 
adenoma(f) 
Suspected 
cancer(g)  
Confirmed 
cancer(h) 
Males  
50 years Number 165,963 42,324 2,852 1,489 603 681 41 24 105 29 6 
 Per cent     40.5 45.7 2.8 1.6 7.1 1.9 0.4 
55 years Number 194,412 59,208 4,369 2,293 888 1,073 54 39 166 60 13 
 Per cent     38.7 46.8 2.4 1.7 7.2 2.6 0.6 
65 years Number 122,632 48,454 5,051 2,786 947 1,378 78 50 196 122 15 
 Per cent     34.0 49.5 2.8 1.8 7.0 4.4 0.5 
Total Number 483,007 149,986 12,272 6,568 2,438 3,132 173 113 467 211 34 
 Per cent     37.1 47.7 2.6 1.7 7.1 3.2 0.5 
Females  
50 years Number 163,145 47,937 2,891 1,484 915 448 23 19 56 20 3 
 Per cent     61.7 30.2 1.5 1.3 3.8 1.3 0.2 
55 years Number 195,573 70,271 4,309 2,286 1,311 760 46 25 91 48 5 
 Per cent     57.3 33.2 2.0 1.1 4.0 2.1 0.2 
65 years Number 121,793 53,219 4,199 2,400 1,193 906 61 43 114 73 10 
 Per cent     49.7 37.8 2.5 1.8 4.8 3.0 0.4 
Total Number 480,511 171,427 11,399 6,170 3,419 2,114 130 87 261 141 18 
 Per cent         55.4 34.3 2.1 1.4 4.2 2.3 0.3 
(continued) 
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Table A4.3 (continued): Overall diagnostic outcomes (including histopathology), by age and sex, 2012–13 
  
Invitations 
issued(a) 
Number 
screened(b) 
Total 
positive 
FOBT 
FOBT positive 
Colonoscopy 
recorded(c) 
No  
cancer or 
adenoma(d) 
Polyps awaiting 
histopathology(e) 
Confirmed 
diminutive 
adenoma(f) 
Confirmed 
small 
adenoma(f) 
Confirmed 
advanced 
adenoma(f) 
Suspected 
cancer(g)  
Confirmed 
cancer(h) 
Persons  
50 years Number 329,108 90,261 5,743 2,973 1,518 1,129 64 43 161 49 9 
 Per cent     51.1 38.0 2.2 1.4 5.4 1.6 0.3 
55 years Number 389,985 129,479 8,678 4,579 2,199 1,833 100 64 257 108 18 
 Per cent     48.0 40.0 2.2 1.4 5.6 2.4 0.4 
65 years Number 244,425 101,673 9,250 5,186 2,140 2,284 139 93 310 195 25 
 Per cent     41.3 44.0 2.7 1.8 6.0 3.8 0.5 
Total Number 963,518 321,413 23,671 12,738 5,857 5,246 303 200 728 352 52 
 Per cent         46.0 41.2 2.4 1.6 5.7 2.8 0.4 
(a) ‘Invitations issued’ equals the number of eligible people who were issued an invitation to screen in the NBCSP. 
(b) ‘Number screened’ equals the number of people who completed an FOBT kit and had results forwarded to the Register. 
(c) ‘Colonoscopy recorded’ includes colonoscopies recorded via the colonoscopy report and/or histopathology report forms. It does not include colonoscopies identified through Medicare claims. 
(d) No cancers were suspected at colonoscopy or confirmed non-cancerous by histopathology; no polyps identified at colonoscopy, or polyps confirmed as non-adenomatous at histopathology. 
(e) Polyps detected at colonoscopy and sent to histopathology for analysis. No histopathology report form received by Register. 
(f) Confirmed adenoma figures were based on a combination of the colonoscopy and histopathology report forms for a person received by the Register.  
(g) Cancer suspected at colonoscopy but not yet confirmed by histopathology.  
(h) Cancer confirmed by histopathology. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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A5 Adverse event tables 
Table A5.1: Adverse outcomes after investigation of positive FOBT by colonoscopy, 2012–13 
  Adverse outcomes  
Unplanned 
hospital 
admission 
within 30 days 
 
Colonoscopies Bleeding 
Infection/ 
sepsis Perforation 
Reaction to 
sedation/ 
anaesthesia Death Other 
Delayed 
discharge 
Surgery 
required 
Males Number 8,561 22 — 2 4 — 7 14 28 — 
 Per cent  0.3 — — — — 0.1 0.2 0.3 — 
Females Number 8,109 5 1 2 2 — 5 7 12 4 
 Per cent  0.1 — — — — 0.1 0.1 0.1 — 
Persons Number 16,670 27 1 4 6 — 12 21 40 4 
 Per cent  0.2 — — — — 0.1 0.1 0.2 — 
Notes 
1. All participants known to have had a colonoscopy are included, including those only recorded through Medicare claim or histopathology data. 
2. A colonoscopy may have more than 1 adverse event. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
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A6 Additional NBCSP outcome data 
Overall outcomes (August 2006–June 2013) 
Overall data on invitees, and their progression through the pathway, have been applied to 
the Population based screening framework (APHDPCSS 2008) stages (Figure A6.1). 
 
 
Recruitment
4,691,681 invitations sent
Screening
1,803,893 participants returned 
an FOBT for screening
(38.4%)
Assessment
137,882 positive FOBTs
(7.8%)(a)
Diagnosis(b)
91,085 recorded 
colonoscopies
(66.1%)
Recorded colonoscopy outcomes
No cancer or adenoma 43,056 (47.3%)
Polyp awaiting histopathology29,341  (32.2%)
Diminutive adenoma 3,967 (4.4%)
Small adenoma 2,156 (2.4%)
Advanced adenoma 9,429 (10.4%)
Suspected cancer 2,234 (2.5%)
Confirmed cancer 902 (1.0%)
 
(a) Based on the 1,778,526 participants who returned a valid FOBT. 
(b) Additionally, 16,320 participants underwent colonoscopic diagnostic assessment as identified through a Medicare claim. However, these 
were not included as there were no associated outcome data available for analysis. 
Notes 
1. Invitees aged 50, 55 and 65 were included; other aged invitees (for example, pilot invitees from phase 1) were excluded. 
2. Adenoma classifications are described in Appendix B. 
3. Figure is not to scale. 
Source: National Bowel Cancer Screening Program Register as at 31 December 2013. 
Figure A6.1: Overall NBCSP outcomes for all invitees aged 50, 55 and 65, August 2006 – June 2013  
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The current overall screening rate of 38.4% is lower than the 45.4% rate achieved in the pilot 
program, while the overall crude colonoscopy follow-up (diagnosis) rate of 66.1% is higher 
than that achieved in the pilot program (55.0%) (DoHA 2005).  
Since the inception of the NBCSP in 2006, 3,136 participants have been found with suspected 
or confirmed cancers and 9,429 more have been diagnosed with advanced adenomas. 
Additionally, 6,123 participants have been diagnosed with earlier-stage adenomas.  
While the NBCSP only follows participants up to the point of definite diagnosis, and 
outcomes of treatment for these participants are unknown, it would be expected that the 
earlier treatment the NBCSP afforded these participants should improve their treatment 
outcomes. This may eventually be shown as reductions in colorectal cancer incidence and 
mortality in the coming years.  
Lastly, an increase in the rate of return of colonoscopy and histopathology report forms, 
would improve monitoring of the NBCSP and its invitees. 
Updated outcomes for 2011–12 invitees 
The previous monitoring report, National Bowel Cancer Screening Program monitoring report: 
July 2011–June 2012 (AIHW 2013), presented national statistics on key program activity, 
performance and outcome indicators for people invited from 1 July 2011 to 30 June 2012. The 
report used outcome data up until 31 December 2012, and those results are shown in the 
comparison table provided after the summary of this report (Table 1).  
For many participants invited late in the period reported, limited follow-up data were 
available. The latest program data, to 31 December 2013, provide an extra 12 months of 
participation and documented follow-up outcomes for this cohort. Table A6.1 provides a 
comparison of the initial and updated statistics for these people invited from 1 July 2011 to 
30 June 2012.  
The changes reflected in the final column show slight increases in participation rates, as well 
as increases in outcome data related to additional follow-up outcome form return. It is 
important to note, however, that while the values in this table are based on a larger amount 
of outcome data and may be considered final, follow-up information remains incomplete 
due to an unknown number of follow-up outcome forms—particularly those relating to 
histopathology—never being returned to the NBCSP Register. 
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Table A6.1: Initially reported and final performance measure outcomes, people aged 50, 55 and 65, 
2011–12  
Performance measure Initial (per cent)(a) Final (per cent)(b) 
Participation rate 35.0 35.8 
 50 years 29.2 30.0 
 55 years 34.1 34.8 
 65 years 44.0 44.8 
FOBT positivity rate 7.0 7.0 
PHCP follow-up rate 63.4 64.5 
Colonoscopy follow-up rate 72.0 77.4 
Colonoscopy outcomes   
 Suspected/confirmed cancers 3.1 3.2 
 Advanced adenomas 6.7 7.9 
 Polyps awaiting histopathology 39.6 36.2 
 No abnormality 46.3 47.1 
(a) Initial values relate to those known for the 2011–12 invitees using data as reported in the previous monitoring report (AIHW 2013).  
(b) Final values relate to those known for the 2011–12 invitees using data as at 31 December 2013.  
Notes 
1. Participation is the percentage of eligible invitees who returned a completed FOBT kit, regardless of whether they later suspended 
their participation or opted off. 
2. FOBT positivity equals the percentage of valid FOBT results that were positive, with valid results being either positive or negative; 
inconclusive results were excluded. 
3. PHCP follow-up rate equals the percentage of people with a positive FOBT result who then consulted a PHCP and had an assessment 
form returned to the NBCSP Register.  
4. Colonoscopy follow-up rate equals the percentage of people with a positive FOBT result who then had a colonoscopy recorded in the 
register.  
5. Colonoscopy outcomes relate to the most accurate outcome data available for recorded colonoscopies. 
Source: National Bowel Cancer Screening Program Register. 
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Appendix B National Bowel Cancer 
Screening Program (NBCSP) information 
NBCSP resources 
 
© Commonwealth of Australia 2013.  
Source: DoHA (2013b). 
Reproduced with permission of the copyright owner. 
Figure B.1: The NBCSP participant’s screening pathway  
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NBCSP definitions 
Target population 
The NBCSP has been phased in gradually to ensure demand for services such as colonoscopy 
can be met. Table B.1 outlines the start dates of each phase, and the target age groups. 
Table B.1: NBCSP phases and target populations 
Phase Start date End date Target ages 
1 7 August 2006 30 June 2008 55 and 65 
2 1 July 2008 30 June 2011(a) 50, 55 and 65 
2(b) 1 July 2011 30 June 2013 50, 55 and 65 
3 1 July 2013 Ongoing 50, 55, 60 and 65 
3 1 July 2015  50, 55, 60, 65, 70 and 74 
3 1 July 2016  50, 55, 60, 64, 65, 70, 72 and 74 
3 1 July 2017  50, 54, 55, 58, 60, 64, 68, 70, 72 and 74 
3 1 July 2018  50, 54, 58, 60, 62, 64, 66, 68, 70, 72 and 74 
3 1 July 2019  50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72 and 74 
(a) Eligible birthdates, and thus invitations, ended on 31 December 2010. 
(b) Ongoing NBCSP funding began. 
Note: The eligible population for all Phase 2 and 3 start dates incorporates all those turning the target ages from 1 January of that  
year, onwards. 
Eligible population 
The eligible population invited included those in the target population, as defined above, 
who were registered as an Australian citizen or migrant in the Medicare enrolment file, or 
were registered with a Department of Veterans’ Affairs gold card. Invitees who were outside 
the target ages or had a current address outside Australia were excluded from this report. 
People who chose to opt off or suspend participation were included in the eligible 
population.  
Polyps 
Colorectal polyps are small growths of colon tissue that protrude into the colonic or rectal 
lumen. They are usually asymptomatic, but sometimes cause visible rectal bleeding and, 
rarely, other symptoms. Polyps may occur individually but it is common for a person to have 
multiple polyps. They occur more commonly in later life, and hereditary and dietary 
(lifestyle) factors may play a part. Polyps may become cancerous and are generally defined 
as 2 main types: 
• hyperplastic—a type of polyp that has a low risk, if any, of developing into a cancer; 
however, people with multiple hyperplastic polyps are associated with an increased risk 
of bowel cancer 
• adenoma (adenomatous)—a polyp that has a higher chance of becoming cancerous, as it 
contains molecular characteristics that are common with adenocarcinoma (see ‘Adenoma 
classifications’ below). 
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Polyp number, size and microscopic features may also predict the likelihood of a polyp 
becoming cancerous, with larger and flatter (non-stalked) polyps having the higher risk. 
During a colonoscopy, polyps are removed, thus lowering the risk of bowel cancer 
developing in the person. 
Adenoma classifications 
An adenoma (adenomatous polyp) is a benign tumour that arises from epithelial cells. All 
adenomas have malignant potential. Adenomas in the rectum or colon have a higher chance 
of developing into cancer (adenocarcinoma) than adenomas in most other organs.  
Although nearly all cancers in the colon (adenocarcinomas) arise from adenomas, only a 
small minority of adenomas (1 in 20 or fewer) progress to cancer (Ahnen & Macrae 2008). 
While most small tubular adenomas have a low risk of progressing to cancer, the risk is 
much higher in advanced adenomas.  
Adenoma classifications were derived from information reported by colonoscopists and 
histopathologists, and were classified from highest risk (advanced) to lowest risk 
(diminutive), as listed below. Where a person had multiple adenomas, they were classified 
according to the adenoma having the highest risk. 
Advanced adenoma 
If any of the indicators of higher risk were present, the adenoma was classified as advanced: 
• adenoma multiplicity—3 or more adenomas present at examination, regardless of 
histopathology or size 
• adenoma size—a size of 10 millimetres or greater. The measurement is subject to certain 
problems with accuracy. Where colonoscopy and pathology reports differ in their 
recording of size, the larger size was used 
• high-grade dysplasia 
• significant villous change or serrated—adenomas recorded as serrated, tubulovillous or 
villous on pathology reports. 
Small adenoma 
A tubular or mixed adenoma between 5 millimetres and 9 millimetres. 
Diminutive adenoma 
A tubular or mixed adenoma smaller than 5 millimetres, or with no size recorded.  
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Appendix C Data sources and 
classifications 
Data sources 
Multiple data sources were analysed to produce this report. These are summarised in 
Table C.1. All data used in this report were based on calendar years. 
Table C.1: Sources for data presented in this report 
Description Data source 
Participation National Bowel Cancer Screening Program Register 
Cancer detection National Bowel Cancer Screening Program Register 
Population data Australian June 2001 standard population; Estimated resident 
populations, Australian Bureau of Statistics (ABS); 2011 Census of 
Population and Housing, ABS 
Incidence (ICD-10 C18–20) Australian Cancer Database (ACD), Australian Institute of Health and 
Welfare (AIHW) 
Mortality (ICD-9 153, 154.0–154.1, ICD-10 C18–20) National Mortality Database (NMD), AIHW 
National Bowel Cancer Screening Program (NBCSP) Register data 
This report uses NBCSP Register data to presents statistics on the progression of eligible 
participants through the screening pathway, for those invited into the NBCSP from 
1 July 2012 to 30 June 2013. It covers measures of participation, faecal occult blood test 
(FOBT) results, and follow-up investigations and outcomes. Analyses are presented by age, 
sex, state and territory, geographical region, socioeconomic status, Aboriginal and Torres 
Strait Islander status, language spoken at home and disability status. 
Data Quality Statement: NBCSP screening data: 2012–13 
Summary of key issues 
• The NBCSP is managed by the Australian Government Department of Health in 
partnership with state and territory governments. The NBCSP is monitored annually by 
the Australian Institute of Health and Welfare (AIHW). Results are compiled and 
reported at the national level by the AIHW in an annual NBCSP monitoring report.  
• NBCSP data depend on the return of data forms from participants, general practitioners, 
colonoscopists and pathologists to the NBCSP Register. The register is maintained by the 
Department of Human Services (formerly Medicare Australia). Data from the register are 
provided to the AIHW 6-monthly as de-identified unit record data.  
• Analysis of remoteness and socioeconomic status are based on postcode of residential 
address of NBCSP invitees at the time of screening. Correspondences for these 
disaggregations may be unavoidably older than the year(s) of screening data being 
reported, potentially leading to inaccuracies.  
• Aboriginal and Torres Strait Islander, language and disability status are self-reported by 
participating individuals.  
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• Exclusion of people screened outside the NBCSP will result in an underestimation of 
population screening rates in the target ages.  
• Data return for later stages in the NBCSP screening pathway (GP, colonoscopy and 
pathology follow-up, as required) is not mandatory. Further, not all people who received 
a positive (abnormal) screening result may have had time to complete follow-up steps at 
the time of reporting. These factors may result in under-reporting of outcome data.  
• Data may be suppressed for confidentiality and reliability reasons (for example, if the 
denominator is less than 100, or the rate could not be sensibly estimated). 
Description 
The NBCSP is managed by the Australian Government Department of Health in partnership 
with state and territory governments. The NBCSP started in 2006 and uses national 
invitation and screening analysis processes. A ‘usual care’ model is then used for follow-up 
functions for those with a positive (abnormal) screening result; that is, these people are 
encouraged to see their doctor to discuss the test result and seek further diagnostic testing 
(such as colonoscopy) as required. Data from these follow-up functions are returned to the 
national NBCSP Register via non-mandatory form return. 
Currently, people that are registered as Australian citizens or migrants in the Medicare 
enrolment file, or are registered with a Department of Veterans’ Affairs gold card receive a 
screening invitation at, or around, their 50th, 55th and 65th birthdays. From July 2013 the 
program will also include people aged 60, and from July 2015, it will be expanded to 
implement a biennial screening interval for those aged 50–74 by 2020. 
NBCSP data depend on the return of data forms from participants, general practitioners, 
colonoscopists and pathologists to the NBCSP Register. The register is maintained by the 
Department of Human Services (formerly Medicare Australia). Data from the register are 
provided to the AIHW 6-monthly as de-identified unit record data.  
The NBCSP is monitored annually by the AIHW. Results are compiled and reported at the 
national level by the AIHW in an annual NBCSP monitoring report. 
Institutional environment 
The AIHW is a major national agency set up by the Australian Government under the 
Australian Institute of Health and Welfare Act 1987 to provide reliable, regular and relevant 
information and statistics on Australia’s health and welfare. It is an independent statutory 
authority established in 1987, governed by a management Board, and accountable to the 
Australian Parliament through the Health portfolio. 
The AIHW aims to improve the health and wellbeing of Australians through better health 
and welfare information and statistics. It collects and reports information on a wide range of 
topics and issues, ranging from health and welfare expenditure, hospitals, disease and 
injury, and mental health, to ageing, homelessness, disability and child protection. 
The AIHW also plays a role in developing and maintaining national metadata standards. 
This work contributes to improving the quality and consistency of national health and 
welfare statistics. The AIHW works closely with governments and non-government 
organisations to achieve greater adherence to these standards in administrative data 
collections to promote national consistency and comparability of data and reporting. 
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The Australian Institute of Health and Welfare Act 1987, in conjunction with compliance to the 
Privacy Act 1988 (Cwlth), ensures that the data collections managed by the AIHW are kept 
securely and under the strictest conditions with respect to privacy and confidentiality. 
For further information see the AIHW website, <www.aihw.gov.au>. 
The AIHW has been receiving NBCSP screening data since 2006. 
Relevance 
NBCSP screening data are highly relevant for monitoring trends and outcomes from NBCSP 
screening participation. It is important to note that additional bowel cancer screening is 
undertaken outside of the NBCSP. Data on people screened outside the program are not 
routinely collected; therefore, the level of underestimation of overall bowel cancer screening 
in Australia is unknown.  
Socioeconomic status Index of Relative Socio-economic Disadvantage (IRSD) rankings are 
calculated by postal area (POA) using a population-based method at the Australia-wide 
level. These ranked socioeconomic status POAs are then allocated to their relevant 
jurisdiction, meaning quintiles should contain similar socioeconomic groups across 
jurisdictions. 
Timeliness 
The data discussed in this data quality statement are for the period July 2012 – June 2013. 
A snapshot of all NBCSP activity is made available to the AIHW regularly at 6-month 
intervals for analysis. However, as there is a time lag between issuing invitations and 
confirmed diagnosis of bowel cancer, the monitoring reports are based on outcomes of a 
cohort of people sent invitations in a given period—this is usually cut off about 6 months 
before the date of the data supply to allow for sufficient follow-up data for analysis. 
Therefore, the NBCSP data held at the AIHW at any given time is about 6 months behind the 
current date. 
Accuracy 
Self-reporting of Aboriginal and Torres Strait Islander, language spoken at home and 
disability status within the program means these data are dependent on accurate, and 
complete, information. 
IRSD rankings are measured only at the time of the Australian Census of Population and 
Housing and are not available for about 18 months from the census date. Consequently, 
socioeconomic status for a geographical area may be up to 6 years out of date and not an 
accurate representation of the status of residents at the time the data are analysed.  
An Australian Bureau of Statistics POA to remoteness correspondence and a POA to 
socioeconomic status correspondence are used to allocate persons screened to remoteness 
and socioeconomic status areas based on their postcode of residence. POAs are defined to 
match Australia Post postcodes as closely as possible, but for various reasons, they do not 
match identically. Socioeconomic status is calculated using a population-based method at the 
Australia-wide level. 
The remoteness (and socioeconomic status) to POA correspondences are based on postal 
areas, boundaries and classifications as at the year of the last Australian census, which may 
have been up to 5 years earlier, and boundaries, socioeconomic status and remoteness 
regions may have changed over time, creating inaccuracies. New postal areas defined since 
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the previous census will not have valid remoteness or socioeconomic status correspondence 
data available as they will not match the old postal areas. 
NBCSP outcome data are via non-mandatory form return from GP visits, colonoscopies, 
histopathology, adverse events and surgical resection. The level of form return is unknown; 
therefore, there is an unknown amount of missing outcome data. This needs to be taken into 
consideration when reviewing NBCSP outcome analyses.  
The data used in NBCSP monitoring reports allow for 6 months of follow-up time 
post-invitation. However, this may not be enough time for all people who had a positive 
screening result to have completed the screening pathway and had outcomes returned to the 
NBCSP Register. This may also result in some under-reporting of outcome data.  
Some data cells have been suppressed for confidentiality and reliability reasons (for example, 
if the denominator is less than 100, or the rate could not be sensibly estimated). 
Coherence 
NBCSP screening data are reported and published annually by the AIHW. Changes in 
reporting practices over time are clearly noted throughout the monitoring reports. In future, 
the addition of extra screening ages and biennial rescreening are expected to affect results in 
most areas of the screening pathway. 
Interpretability 
While the concept of participation in the NBCSP is easy to interpret, the NBCSP screening 
pathway and other concepts and statistical calculations are more complex and may be 
confusing to some users. All concepts are explained within the body of the reports 
presenting these data, along with footnotes to provide further details and caveats. The 
appendixes provide additional detail on the data sources and classifications, and on the 
statistical methods used. 
Accessibility 
The NBCSP annual monitoring reports, and any supplementary data, are available via the 
AIHW website where they can be downloaded free of charge. Users can request data not 
available online or in reports via the Cancer and Screening Unit of the AIHW on 02 6244 1000 
or via email to <screening@aihw.gov.au>. Requests that take longer than half an hour to 
compile are charged for on a cost-recovery basis. General enquiries about AIHW 
publications can be made to the Communications, Media and Marketing Unit on 
02 6244 1032 or via email to <info@aihw.gov.au>. 
General enquiries about AIHW publications can be made to the Communications, Media and 
Marketing Unit on 02 6244 1032 or via email to <info@aihw.gov.au>. 
This Data Quality Statement can be found on AIHW website at 
<http://meteor.aihw.gov.au/content/index.phtml/itemId/569056>. 
Incidence data 
Incidence data came from the Australian Cancer Database (ACD)—a national collection of 
cancer statistics held and operated by the AIHW. The AIHW receives data from individual 
state and territory cancer registries on cancers diagnosed in residents of Australia, and 
produces reports on national incidence. 
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The Data Quality Statement for the ACD 2010 can be found on the AIHW website at 
<http://meteor.aihw.gov.au/content/index.phtml/itemId/565218>. 
Incidence of bowel cancer in this report was for 1996 to 2010, the latest year for which 
national incidence data are available. Note that 2010 data for New South Wales (NSW) and 
the Australian Capital Territory (ACT) were not available for inclusion in the 2010 version of 
the ACD. Therefore, the 2010 incidence data for NSW and the ACT were estimated by the 
AIHW in consultation with the NSW and ACT cancer registries. The estimates were 
combined with the actual data supplied by other state and territory cancer registries to form 
the 2010 national cancer data set. 
Mortality data 
Deaths data are provided to the AIHW by the Registrars of Births, Deaths and Marriages and 
the National Coronial Information System and coded by the ABS. The data are maintained 
by the AIHW in the National Mortality Database (NMD). 
The NMD contains information on the cause of death supplied by the medical practitioner 
certifying the death or by a coroner from 1964 to 2011.  
The Data Quality Statement for NMD data can be found on the ABS website at 
<http://www.abs.gov.au/Ausstats/abs@.nsf/0/D4A300EE1E04AA43CA2576E800156A24?
OpenDocument>. 
Mortality data in this report were for 1997 to 2011. Causes of death from 1997 onwards were 
coded automatically to ICD-10.  
In the NMD, both the year of occurrence of the death and the year in which the death was 
registered are provided. For this report, mortality data are shown based on the year of death, 
except for the most recent year (namely, 2011) where the number of people whose death was 
registered is used. This is because there is a consistent annual lag in the registration of deaths 
and a small proportion are not registered until the following year. 
All states and territories have provision for the identification of Aboriginal and Torres Strait 
Islander deaths on their death registration forms. However, the coverage of deaths identified 
as Indigenous varies across states and territories and over time. While the identification of 
Indigenous deaths is incomplete in all state and territory registration systems, the ABS and 
AIHW assessed the adequacy of identification for analysis and: 
• Western Australia, South Australia and the Northern Territory were found to have had 
adequate identification from 1991 onwards,  
• Queensland was added as having adequate identification from 1998 onwards, and 
• New South Wales was also deemed as having adequate identification from 2001 
onwards (meaning five jurisdictions can be reported from 2001 onwards).  
Data for Aboriginal and Torres Strait Islander deaths, state and territory and geographical 
location have been combined for the 5 years from 2007–2011 due to the small number of 
deaths from bowel cancer in each year.  
Population data 
The ABS estimated (mid-year) resident population data were used to calculate incidence and 
mortality rates in this report. These data were sourced from ABS Australian demographic 
statistics (ABS cat. no. 3101.0) (ABS 2013) as at 20 June 2013. 
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Classifications 
Geographical classification 
The ability to access and provide a wide range of services is influenced by the distance 
between clients and providers, be it for the clients to travel to the service providers or for the 
providers to travel to deliver services close to a person’s home. The geographical location of 
areas is therefore an important concept in planning and analysing the provision of services.  
Geographical location was classified according to the ABS Australian Statistical Geography 
Standard (ASGS) 2011 Remoteness Structure, which groups geographical areas into 6 
categories. These categories, called Remoteness Areas, are based on ASGS Statistical Area 
level 1 units and defined using the Accessibility/Remoteness Index for Australia (ARIA). 
ARIA is a measure of the remoteness of a location from the services provided by large towns 
or cities. Accessibility is judged purely on distance to one of the metropolitan centres. A 
higher ARIA score denotes a more remote location. The 6 Remoteness Areas are listed in 
Table C.2; the sixth, Migratory, is not used in this publication. The category Major cities 
includes Australia’s capital cities, with the exceptions of Hobart and Darwin, which are 
classified as Inner regional. Further information is available on the ABS website at 
<http://www.abs.gov.au/websitedbs/D3310114.nsf/home/geography>. 
Table C.2: Remoteness Areas of the Australian Statistical Geography Standard 2011 
Region  Collection districts (CDs) within region 
Major cities of Australia  CDs with an average ARIA index value of 0 to 0.2 
Inner regional Australia  CDs with an average ARIA index value greater than 0.2 and less than or equal to 2.4 
Outer regional Australia CDs with an average ARIA index value greater than 2.4 and less than or equal to 5.92 
Remote Australia  CDs with an average ARIA index value greater than 5.92 and less than or equal to 10.53 
Very remote Australia  CDs with an average ARIA index value greater than 10.53 
Migratory  Areas composed of offshore, shipping and migratory CDs 
Residential address postcodes of participants were mapped to 2011 ASGS Remoteness Areas, 
ranging from Major cities to Very remote areas. As some postcodes can span different 
Remoteness Areas, a weighting for each Remoteness Area is attributed to the postcode. This 
can result in non-integer counts for remoteness classifications. For example, the Northern 
Territory postal area 0822 is classified as 69.3% Very remote, 15.9% Remote and 14.8% Outer 
regional. Participants with postcode 0822 have their counts apportioned accordingly. 
Tables in this report based on geographical location were rounded to integer values. Where 
figures were rounded, discrepancies may occur between totals and sums of the component 
items. Participants whose postcode was not available in the remoteness correspondence were 
included in an ‘Unknown’ column in the relevant tables. 
Socioeconomic classification 
A person’s health, and their ability to access and provide a wide range of services, is also 
influenced by the relative socioeconomic advantage and disadvantage of the area in which 
they live. 
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Socioeconomic classifications were based on the 2011 ABS Index of Relative Socio-economic 
Disadvantage (IRSD). Geographical areas are assigned a score based on attributes such as 
low income, low educational attainment, high unemployment and jobs in relatively 
unskilled occupations. It does not refer to the socioeconomic situation of a particular 
individual, but instead refers to the area in which a person lives. A low score on this index 
means an area has more low-income families, people with little training and high 
unemployment, and may be considered disadvantaged relative to other areas with higher 
scores. However, such an area is also likely to contain some people who are relatively 
advantaged. When area-level indexes are used as proxy measures of individual-level 
socioeconomic advantage and disadvantage, many people are likely to be misclassified. 
Geographical areas may be excluded where no score is determined due to low populations 
or high levels of non-response in the underlying census.  
In this report, socioeconomic status of a participant’s area of residence was classified using 
the participant’s residential postcode according to the IRSD for 2011. Socioeconomic status 
(based on IRSD rankings) were calculated with a postal area (POA) correspondence 
(previously called a concordance) using a population-based method at the Australia-wide 
level. Five socioeconomic groups, based on the level of the index, were used for analysis, 
where group 1 represents the most disadvantaged fifth of the population and group 5 the 
least disadvantaged. Participants whose postcode was not available in the socioeconomic 
status correspondence were included in an ‘Unknown’ column in the relevant tables. 
Caution should always be taken when analysing the results of data that have been converted 
using correspondences, and the potential limitations of the data taken into account. 
NBCSP classifications 
See Appendix B for classifications specific to the NBCSP. 
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Appendix D Statistical methods 
Comparisons and tests of statistical significance 
This report includes statistical tests of the significance of comparisons of rates between 
population groups. Any statistical comparison applied to one variable must take account of 
any other potentially relevant variables. For example, any comparison of participation by 
state and territory must also take account of differences in the distribution of age and sex 
between the states and territories. These other variables are known as confounding variables. 
Crude rates 
A crude rate is defined as the number of events over a specified period divided by the total 
population. The crude rate (for participation, attendance and follow-up) is the proportion of 
people who have proceeded to a key point on the screening pathway (at the date of the data 
extraction) out of those eligible to proceed to that point. For example, the crude participation 
rate is the proportion of the eligible people invited in 2012–13 who return a completed faecal 
occult blood test (FOBT) kit by 31 December 2013. The crude colonoscopy follow-up is the 
proportion of people invited in 2012–13 with a positive FOBT result who proceeded to 
colonoscopy by 31 December 2013.  
The crude proportions will generally underestimate the true proportions of the population 
who participated in the National Bowel Cancer Screening Program (NBCSP). This is because 
at any point in time there are members of the population who are eligible to proceed to the 
next point on the screening pathway, but who have not yet had time to do so. For example, a 
person who has just received an invitation to screen may intend to participate in screening 
but may not have had time to do so. They will be counted in the denominator of the crude 
participation but not in the numerator. Similarly, there is a time lag between when a person 
with a positive FOBT result is referred for a colonoscopy and when they can actually have 
the colonoscopy. A colonoscopy follow-up calculated during this lag includes them in the 
denominator but not in the numerator. 
Age-specific rates 
Age-specific rates were calculated by dividing the number of cases occurring in each 
specified age group by the corresponding population in the same age group, expressed as 
per 100,000 persons.  
Age-standardised rates  
Rates are adjusted for age to help comparisons between populations that have different age 
structures—for example, between youthful and ageing communities. Two different methods 
are commonly used to adjust for age. In this publication, direct standardisation was used, in 
which age-specific rates were multiplied against a constant population (the Australian 2001 
population). This effectively removes the influence of age structure on the summary rate, 
and is described as the age-standardised rate. The method used for this calculation 
comprises 3 steps:  
• Calculate the age-specific rate for each age group. 
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• Calculate the expected number of cases in each 5-year age group by multiplying the 
age-specific rates by the corresponding standard population, and dividing by 100,000, 
giving the expected number of cases. 
• Calculate the age-standardised rate by summing the expected number of cases in each 
age group, and dividing this sum by the total of the standard population used in the 
calculation and multiplying by 100,000. 
The results of age standardisation depend directly on the constant population chosen. Care 
must be taken when comparing the reported age-standardised rates between countries 
because different constant populations may have been used in each case. 
Confidence intervals 
Confidence intervals are a range determined by variability in data, within which there is a 
specified (usually 95%) chance that the true value of a calculated parameter lies.  
This report uses data that are based on administrative data sets that contain ‘complete 
counts’, not sample survey data. While confidence intervals could be used to describe 
variability that is due to non-sample errors in the data, practically it is not easy to do so 
accurately. Therefore, as the size of this error is difficult to determine, and instead of 
providing confidence intervals that could be misleading, the AIHW instead recommends 
caution be exercised when interpreting small differences between rates. This is especially 
true where counts are small, and rates based on small counts will be noted (see ‘Small 
counts’ below).  
In this report, 95% confidence intervals are only used in ‘Chapter 3 Follow-up of positive 
FOBT results’, Section 2 to determine if a statistically significant difference exists between 
compared Kaplan–Meier estimates. Where the confidence intervals do not overlap, the 
difference between values is greater than that which could be explained by chance and is 
regarded as statistically significant.  
Kaplan–Meier estimates of participation and follow-up 
Kaplan–Meier estimates are statistical methods that calculate a modelled rate based on the 
time it takes each individual invited for screening to move between points on the screening 
pathway. For example, participation is calculated by following each invited person and, for 
those who respond (by returning a completed FOBT kit), recording the time (in weeks) it 
took them to do so. This allows the calculation of an overall response rate over time from the 
date of invitation, calculated as if all invitations sent throughout a particular period were 
sent on the same date. Such Kaplan–Meier estimates represent valid estimates of the true 
FOBT participation. The Bowel Cancer Screening Pilot Program used Kaplan–Meier 
estimates of participation, attendance and follow-up. The use of Kaplan–Meier estimates in 
the NBCSP was endorsed by the Implementation Advisory Group, and allows direct 
comparison of participation, attendance and follow-up rates with the Bowel Cancer 
Screening Pilot Program.  
In principle, the Kaplan–Meier estimate gives a result only at a specific point in time. The 
estimate is likely to grow for later points in time. However, inspection of these estimates 
shows that they reach a plateau, after which they have only a negligible increase.  
Kaplan–Meier estimates in this report were calculated at 26 weeks and 52 weeks for 
participation, and PHCP and colonoscopy follow-up.  
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The Kaplan–Meier estimates require that classifying variables be known for the population. 
Hence, they can be calculated for participation classified by age, sex and jurisdiction. 
However, they cannot be used for participation classified by Aboriginal and Torres Strait 
Islander status, language group or disability status, which are not known for all the invited 
population. These variables are only known for those participants who identify themselves 
as a member of these groups on their returned participant details form. Therefore, the 
Kaplan–Meier estimates cannot be applied.  
Aboriginal and Torres Strait Islander status, language group status and disability status will 
be known for all people completing FOBT kits (at least to the extent that people self-identify 
as members of these groups). Hence, in principle, Kaplan–Meier estimates can be calculated 
for these groups for participation at subsequent points on the screening pathway. In practice, 
these calculations depend on sufficient numbers of people identifying as group members to 
allow the calculation of reliable estimates. 
Confidentiality and reliability of data 
The AIHW operates under a strict privacy regime which has its basis in section 29 of the 
Australian Institute of Health and Welfare Act 1987 (AIHW Act) and the Privacy Act 1988 
(Privacy Act). 
Section 29 of the AIHW Act requires that confidentiality of data relating to persons (living 
and deceased) and organisations be maintained. The Privacy Act governs confidentiality of 
information about living individuals. 
As well as the protection offered by AIHW Act and the Privacy Act, personal information 
held by the AIHW is covered by a range of other Commonwealth, state and territory 
legislation. 
The AIHW is committed to reporting that maximises the value of information released for 
users while being statistically reliable and meeting legislative requirements described above. 
To ensure the confidentiality of its data, the AIHW has a range of policies, protocols and 
processes in place—the AIHW Policy on reporting to manage confidentiality and reliability 
(AIHW Confidentiality Policy) is one important example, as it deals with how data should be 
reported to ensure confidentiality. 
AIHW Confidentiality Policy, a summary 
The AIHW Confidentiality Policy contains 7 guidelines to assist those working with data to 
apply it to their outputs. 
Guideline 1 
It is AIHW policy that if the data being considered have already been released publicly at the 
granularity AIHW intends to release, further confidentialisation is not required. 
Guideline 2 
Cells in tables where the value of the cell is the same as a row/column/wafer total (that is, 
all other cells in the row, column or wafer are zero) generally lead to disclosure of an 
additional attribute. It is AIHW policy that these cells need to be confidentialised unless the 
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attribute that would be disclosed is deemed to be non-sensitive in the context of the data 
being published.  
Guideline 3 
It is AIHW policy that data on organisations must be confidentialised if 1 organisation 
contributes more than 85% of the total, or 2 organisations more than 90%, unless the attribute 
that would be disclosed is deemed to be non-sensitive in the context of the data being 
published or the organisation(s) have given consent to release.  
Guideline 4 
It is AIHW policy that guidelines 2 and 3 need to be applied so as to ensure that attribute 
confidentiality is maintained within tables and across tables within the same release. That is, 
when assessing whether a cell needs to be confidentialised, consideration needs to be given 
to whether there are other cells in that table, or other tables in the release, which may require 
consequential confidentialisation. 
Guideline 5 
Rates, averages and other statistics based on denominators of less than 100 are usually not 
reliable and it is AIHW policy that they should generally not be reported.  
Guideline 6 
It is AIHW policy that if data suppliers or clients require additional suppression rules be 
applied to an AIHW release in order to manage confidentiality or reliability, then these 
should be applied. Where such additional rules are applied they should be described in the 
release, and it should be noted that this approach is required by the data supplier. 
Guideline 7 
It is AIHW policy that, if a client wishes to be provided with data output (for example, 
tables) at a more detailed level than any of the above guidelines would allow, then they may 
apply to be provided output against which some or all of the above guidelines are not 
applied. Provision of this more detailed output would be subject to the client signing a 
confidentiality undertaking and agreeing that any publication of information (including in 
online data cubes) based on output released to them will comply with this policy. 
Jurisdictional bowel cancer incidence data 
Further to the AIHW Confidentiality Policy guideline 6, tables specifically showing bowel 
cancer incidence by state and territory had numbers fewer than 5 suppressed. The Australian 
Capital Territory and Northern Territory incidence data also had rates based on fewer than 5 
cases suppressed. Suppressed values are marked with n.p. 
Mortality data 
Further to the AIHW confidentiality policy guideline 6, tables specifically showing bowel 
cancer mortality counts of 1 or 2 had these values, and rates based on them, suppressed. 
Suppressed values are marked with n.p. 
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Glossary 
age standardisation: A method of removing the influence of age when comparing 
populations with different age structures. This is usually necessary because the rates of many 
diseases vary strongly (usually increasing) with age. The age structures of the different 
populations are converted to the same ‘standard’ structure, then the disease rates that would 
have occurred with that structure are calculated and compared (AIHW 2012a). 
asymptomatic: Without symptoms. 
benign: Not malignant. 
bowel cancer: Comprises cancer of the colon and cancer of the rectum, collectively known as 
colorectal cancer. 
cancer death: A death where the underlying cause of death is indicated as cancer. Persons 
with cancer who die of other causes are not counted in the mortality statistics in this 
publication. 
cancer (malignant neoplasm): A large range of diseases whose common feature is that some 
of the body’s cells become defective, begin to multiply out of control, can invade and 
damage the area around them, and can also spread to other parts of the body to cause further 
damage (AIHW 2012a). 
confidence interval: A range determined by variability in data, within which there is a 
specified (usually 95%) chance that the true value of a calculated parameter lies. 
colonoscopy: A procedure to examine the bowel using a special scope (colonoscope) usually 
carried out in a hospital or day clinic. 
colonoscopy follow-up rate: The proportion of people with a positive FOBT who 
subsequently had a colonoscopy. 
CT colonography: A procedure that produces computed tomography (CT) pictures of the 
bowel by X-raying from many different angles. 
double contrast barium enema: A type of bowel X-ray in which barium sulphate and air are 
added into the bowel to assist in detecting abnormal growths. 
eligible population: For this report monitoring people invited in 2012–13, Australians 
registered as Australian citizens or migrants in the Medicare enrolment file, or are registered 
with a Department of Veterans’ Affairs gold card who turned 50, 55 and 65 from 1 January 
2012 to 30 June 2013, even if they had opted off or suspended their participation in the 
program. 
epithelium: The tissue lining the outer layer of the body, the digestive tract, and other 
hollow organs and structures. 
false negative: A screening test result that incorrectly indicates a person does not have a 
marker for the condition being tested when they do have the condition. Not all screening 
tests are completely accurate, so false negative results cannot be discounted. Further, with an 
FOBT test for bowel cancer, if a polyp, adenoma or cancer is not bleeding at the time of the 
test, it may be missed by the screening test. 
false positive: A screening test result that incorrectly indicates a person has the condition 
being tested when they do not have the condition. As FOBT tests detect blood in stool (which 
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may be caused by a number of conditions), a false positive finding regarding bowel cancer 
may still detect other non-bowel cancer conditions, or precancerous polyps or adenomas. 
FOBT: Faecal occult blood test. A test used to detect tiny traces of blood in a person’s faeces 
that may be a sign of bowel cancer. The immunochemical FOBT is a central part of 
Australia’s National Bowel Cancer Screening Program (NBCSP). 
Pathologists categorise completed NBCSP FOBTs into 1 of 3 groups:  
1. correctly completed  
2. incorrectly completed  
3. unsatisfactory.  
Participants are provided with specific instructions on how to complete the FOBT. Any tests 
not completed according to these instructions are classified as incorrectly completed. 
Unsatisfactory tests refer to those tests that could not be processed due to a problem with the 
kit (for example, an expired kit, kit samples that have been taken more than 2 weeks apart, or 
a kit that has taken more than 1 month in transit to arrive). Participants with FOBTs that are 
not correctly completed are requested to complete another FOBT. See Appendix B for details 
of the participant screening pathway. 
FOBT result: FOBT results are classified by pathologists into 1 of 3 groups: 
1. positive (blood is detected in at least 1 of 2 samples)  
2. negative (blood is not detected)  
3. inconclusive (the participant is asked to complete another kit). 
histopathology: The microscopic study of the structure and composition of tissues and 
associated disease. 
incidence: The number of new cases (of an illness or event, and so on) occurring during a 
given period. Compare with prevalence (AIHW 2012a). 
Indigenous: A person of Aboriginal and/or Torres Strait Islander descent who identifies as 
Aboriginal and/or Torres Strait Islander. 
International Statistical Classification of Diseases and Related Health Problems: The 
World Health Organization’s internationally accepted classification of death and disease. The 
tenth revision (ICD-10) is currently in use. 
invitee: A person who has been invited to participate in the National Bowel Cancer 
Screening Program. 
lymph node: A mass of lymphatic tissue, often bean-shaped, that produces adaptive 
immune system cells and through which lymph filters. These nodes are located throughout 
the body. 
malignant: Abnormal changes consistent with cancer. 
metastasis: The process by which cancerous cells are transferred from one part of the body to 
another to form a secondary cancer; for example, via the lymphatic system or the 
bloodstream. 
mortality: Death. For this publication specifically, see cancer death. 
neoplasm: An abnormal (‘neo’, new) growth of tissue. Can be benign (not a cancer) or 
malignant (a cancer). Same as tumour (AIHW 2012a). 
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opt off: Invitees who do not wish to participate in the National Bowel Cancer Screening 
Program now or in the future may opt off the program. Invitees will not be contacted again. 
Invitees may elect to opt back on at a later date. 
participant: A person who has agreed to participate in the National Bowel Cancer Screening 
Program by returning a completed FOBT kit and participant details form. 
positive predictive value: Proportion of people with a positive FOBT screen who have 
adenomas or cancer detected at colonoscopy and confirmed by histopathology. 
positivity rate: Number of positive FOBT results as a percentage of the total number of valid 
FOBT results. 
prevalence: The number or proportion (of cases, instances, and so forth) in a population at a 
given time. Compare with incidence (AIHW 2012a). 
primary health-care practitioner (PHCP): Classified by the Department of Human Services 
(DHS) as a general practitioner or other primary health-care provider. This may include 
remote health clinics or specialists providing general practitioner services. 
primary health-care practitioner follow-up rate: The proportion of people who were sent a 
positive FOBT result and who subsequently visit a primary health-care practitioner. 
prognosis: The likely outcome of an illness. 
radiation therapy: The treatment of disease with any type of radiation, most commonly with 
ionising radiation, such as X-rays, beta rays and gamma rays. 
screening: Repeated testing, at regular intervals, of apparently well people to detect a 
medical condition at an earlier stage than would otherwise be the case. Screening tests are 
not diagnostic (for example, see false positive, false negative and positive predictive value); 
therefore, people who receive a positive screening result require further assessment and 
diagnosis to determine whether or not they have the disease or risk marker being screened.  
sigmoidoscopy: Inspection of last portion of the bowel through either a rigid or flexible 
hollow tube. 
significant difference: Where rates are referred to as significantly different, or one rate is 
deemed significantly higher or lower than another, these differences are considered 
statistically significant. Rates are deemed statistically significantly different when their 
confidence intervals do not overlap, since their difference is greater than what could be 
explained by chance. See ‘Confidence intervals’ in Appendix D for more information. 
socioeconomic status: See Appendix C for details. 
suspend: Invitees who would like to participate in the National Bowel Cancer Screening 
Program but are unable to do so at this time. Invitees will be contacted once the nominated 
suspension period has elapsed. 
target population: See Table B.1 (in Appendix B). 
tumour: See neoplasm. 
underlying cause of death: The condition, disease or injury initiating the sequence of events 
leading directly to death; that is, the primary, or main, cause (AIHW 2012a). 
valid results: Only FOBT results that are either positive or negative are classified as valid 
results. Inconclusive results are excluded. 
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